


10/5/6 505
Rec'd PCT/PTO 01 APR 2005

REC'D 07 JUL 2003
WIPO PCT

PI 1032531



THE UNITED STATES OF AMERICA

TO ALL TO WHOM THESE PRESENTS SHALL COME:

**UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office**


June 30, 2003

**THIS IS TO CERTIFY THAT ANNEXED HERETO IS A TRUE COPY FROM
THE RECORDS OF THE UNITED STATES PATENT AND TRADEMARK
OFFICE OF THOSE PAPERS OF THE BELOW IDENTIFIED PATENT
APPLICATION THAT MET THE REQUIREMENTS TO BE GRANTED A
FILING DATE.**

**APPLICATION NUMBER: 10/348,431
FILING DATE: January 17, 2003
RELATED PCT APPLICATION NUMBER: PCT/US03/16214**

BEST AVAILABLE COPY

**By Authority of the
COMMISSIONER OF PATENTS AND TRADEMARKS**



H. Phillips
**H. PHILLIPS
Certifying Officer**

**PRIORITY
DOCUMENT**
SUBMITTED OR TRANSMITTED IN
COMPLIANCE WITH RULE 17.1(a) OR (b)

01-22-03 10348431.011703

BOX-5

01/17/03

10348431 U.S. PTO

UTILITY PATENT APPLICATION TRANSMITTAL
(Large Entity)

(Only for new nonprovisional applications under 37 CFR 1.53(b))

Docket No.
ISPH-0728

Total Pages in this Submission

TO THE ASSISTANT COMMISSIONER FOR PATENTSBox Patent Application
Washington, D.C. 20231

Transmitted herewith for filing under 35 U.S.C. 111(a) and 37 C.F.R. 1.53(b) is a new utility patent application for an invention entitled:

EXTRACELLULAR-SIGNAL-REGULATED KINASE-6 INHIBITORS FOR INHIBITING ANGIOGENESIS10348431 U.S. PTO
10/31/03

and invented by:

Marcusson et al.

If a **CONTINUATION APPLICATION**, check appropriate box and supply the requisite information:☐ Continuation ☐ Divisional ☒ Continuation-in-part (CIP) of prior application No.: 10/174,465

Which is a:

☐ Continuation ☐ Divisional ☐ Continuation-in-part (CIP) of prior application No.:

Which is a:

☐ Continuation ☐ Divisional ☐ Continuation-in-part (CIP) of prior application No.:

Enclosed are:

Application Elements

1. ☒ Filing fee as calculated and transmitted as described below
2. ☒ Specification having 113 pages and including the following:
 - a. ☒ Descriptive Title of the Invention
 - b. ☒ Cross References to Related Applications (if applicable)
 - c. ☐ Statement Regarding Federally-sponsored Research/Development (if applicable)
 - d. ☒ Reference to Sequence Listing, a Table, or a Computer Program Listing Appendix
 - e. ☒ Background of the Invention
 - f. ☒ Brief Summary of the Invention
 - g. ☐ Brief Description of the Drawings (if filed)
 - h. ☒ Detailed Description
 - i. ☒ Claim(s) as Classified Below
 - j. ☒ Abstract of the Disclosure

UTILITY PATENT APPLICATION TRANSMITTAL (Large Entity)

(Only for new nonprovisional applications under 37 CFR 1.53(b))

Docket No.
ISPH-0728

Total Pages in this Submission

Application Elements (Continued)

3. ☐ Drawing(s) (when necessary as prescribed by 35 USC 113)
 - a. ☐ Formal Number of Sheets _____
 - b. ☐ Informal Number of Sheets _____
4. ☒ Oath or Declaration
 - a. ☐ Newly executed (original or copy) ☒ Unexecuted
 - b. ☐ Copy from a prior application (37 CFR 1.63(d)) (for continuation/divisional application only)
 - c. ☒ With Power of Attorney ☐ Without Power of Attorney
 - d. ☐ DELETION OF INVENTOR(S)
Signed statement attached deleting inventor(s) named in the prior application, see 37 C.F.R. 1.63(d)(2) and 1.33(b).
5. ☐ Incorporation By Reference (usable if Box 4b is checked)
The entire disclosure of the prior application, from which a copy of the oath or declaration is supplied under Box 4b, is considered as being part of the disclosure of the accompanying application and is hereby incorporated by reference therein.
6. ☐ CD ROM or CD-R in duplicate, large table or Computer Program (Appendix)
7. ☐ Application Data Sheet (See 37 CFR 1.76)
8. ☒ Nucleotide and/or Amino Acid Sequence Submission (if applicable, all must be included)
 - a. ☒ Computer Readable Form (CRF)
 - b. ☒ Specification Sequence Listing on:
 - i. ☐ CD-ROM or CD-R (2 copies); or
 - ii. ☒ Paper
 - c. ☒ Statement(s) Verifying Identical Paper and Computer Readable Copy

Accompanying Application Parts

9. ☐ Assignment Papers (cover sheet & document(s))
10. ☐ 37 CFR 3.73(B) Statement (when there is an assignee)
11. ☐ English Translation Document (if applicable)
12. ☐ Information Disclosure Statement/PTO-1449 ☐ Copies of IDS Citations
13. ☐ Preliminary Amendment
14. ☒ Return Receipt Postcard (MPEP 503) (Should be specifically itemized)
15. ☐ Certified Copy of Priority Document(s) (if foreign priority is claimed)
16. ☒ Certificate of Mailing

☐ First Class ☒ Express Mail (Specify Label No.): EV215113931US

**UTILITY PATENT APPLICATION TRANSMITTAL
(Large Entity)***(Only for new nonprovisional applications under 37 CFR 1.53(b))*Docket No.
ISPH-0728

Total Pages in this Submission

Accompanying Application Parts (Continued)

17. ☒ Additional Enclosures *(please identify below):*

USPTO Credit Card Payment form

Request That Application Not Be Published Pursuant To 35 U.S.C. 122(b)(2)

18. ☐ Pursuant to 35 U.S.C. 122(b)(2), Applicant hereby requests that this patent application not be published pursuant to 35 U.S.C. 122(b)(1). Applicant hereby certifies that the invention disclosed in this application has not and will not be the subject of an application filed in another country, or under a multilateral international agreement, that requires publication of applications 18 months after filing of the application.

Warning

An applicant who makes a request not to publish, but who subsequently files in a foreign country or under a multilateral international agreement specified in 35 U.S.C. 122(b)(2)(B)(i), must notify the Director of such filing not later than 45 days after the date of the filing of such foreign or international application. A failure of the applicant to provide such notice within the prescribed period shall result in the application being regarded as abandoned, unless it is shown to the satisfaction of the Director that the delay in submitting the notice was unintentional.

UTILITY PATENT APPLICATION TRANSMITTAL (Large Entity)

(Only for new nonprovisional applications under 37 CFR 1.53(b))

Docket No.
ISPH-0728

Total Pages in this Submission

Fee Calculation and Transmittal

CLAIMS AS FILED

For	#Filed	#Allowed	#Extra	Rate	Fee
Total Claims	26	- 20 =	6	x \$18.00	\$108.00
Indep. Claims	2	- 3 =	0	x \$84.00	\$0.00
Multiple Dependent Claims (check if applicable) <input type="checkbox"/>					\$0.00
BASIC FEE					\$750.00
OTHER FEE (specify purpose)					\$0.00
TOTAL FILING FEE					\$858.00

- ☐ A check in the amount of _____ to cover the filing fee is enclosed.
- ☒ The Commissioner is hereby authorized to charge and credit Deposit Account No. 50-1619 as described below. A duplicate copy of this sheet is enclosed.
- ☐ Charge the amount of _____ as filing fee.
- ☒ Credit any overpayment.
- ☒ Charge any additional filing fees required under 37 C.F.R. 1.16 and 1.17.
- ☐ Charge the issue fee set in 37 C.F.R. 1.18 at the mailing of the Notice of Allowance, pursuant to 37 C.F.R. 1.311(b).

Dated: January 17, 2003

cc:

Jane Massey Licata
Signature
Jane Massey Licata
Reg. No. 32,257
Licata & Tyrrell P.C.
66 E. Main Street
Marlton, NJ 08053
Tel: 856-810-1515
Fax: 856-810-1454

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Attorney Docket No.: ISPH-0728

Inventors: Marcusson et al.

Serial No.: Not yet assigned

Filing Date: Herewith

Examiner: Not yet assigned

Group Art Unit: Not yet assigned

Title: Extracellular-Signal-Regulated Kinase-6
Inhibitors for Inhibiting Angiogenesis

"Express Mail" Label No. EV215113931US
Date of Deposit January 17, 2003

I hereby certify that this paper is being deposited
with the United States Postal Service "Express Mail
Post Office to Addressee" service under 37 CFR 1.10
on the date indicated above and is addressed to the
U.S. Patent & Trademark Office, Box Sequence,
P.O. Box 2327, Arlington, VA 22202.

By Jane Massey Licata
Typed Name: Jane Massey Licata, Reg. No. 32,257

U.S. Patent and Trademark Office
Box Sequence, P.O. Box 2327
Arlington, VA 22202

Sir:

STATEMENT TO SUPPORT FILING AND SUBMISSION IN ACCORDANCE
WITH 37 CFR §§ 1.821 THROUGH 1.825

- (XX) I hereby state, in accordance with the requirements of 37
C.F.R. §1.821(f), that the contents of the paper and
computer readable copies of the Sequence Listing, submitted
in accordance with 37 CFR §1.821(c) and (e), respectively
are the same.
- () I hereby state that the submission filed in accordance with
37 CFR §1.821(g) does not include new matter.

- () I hereby state that the submission filed in accordance with 37 CFR §1.821(h) does not include new matter or go beyond the disclosure in the international application as filed.
- () I hereby state that the amendments, made in accordance with 37 CFR §1.825(a), included in the substitute sheet(s) of the Sequence Listing were made to conform to the current Sequence Listing Rules. I hereby state that the substitute sheet(s) of the Sequence Listing does not include new matter.
- () I hereby state that the substitute copy of the computer readable form, submitted in accordance with 37 CFR §1.825(b), is the same as the amended Sequence Listing.
- () I hereby state that the substitute copy of the computer readable form, submitted in accordance with 37 CFR §1.825(d), contains identical data to that originally filed.

Respectfully submitted,

Jane Massey Licata

Jane Massey Licata
Registration No. 32,257

Date: January 17, 2003

Licata & Tyrrell P.C.
66 E. Main Street
Marlton, New Jersey 08053

(856) 810-1515

ISPH-0728

CERTIFICATE OF EXPRESS MAILING

"Express Mail" Label No. EV215113931US
Date of Deposit January 17, 2003

I hereby certify that this paper is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 C.F.R. 1.10 on the date indicated above and is addressed to the "BOX SEQUENCE", U.S. Patent & Trademark Office, P.O. Box 2327, Arlington, VA 22202.

- 1) Patent Application Transmittal Letter (2 copies);
- 2) Application consisting of 113 pages of Specification, including three (3) pages of Claims and one (1) page of Abstract;
- 3) Return Post Card;
- 4) Credit Card Payment Form in the amount of \$858.00;
- 5) Unexecuted Declaration and Power of Attorney;
- 6) Statement to Support Filing and Submission in Accordance with 37 C.F.R. §§1.821-1.825;
- 7) Sequence listing; and
- 8) Diskette containing computer readable copy of Sequence Listing.

JANE MASSEY LICATA
JANE MASSEY LICATA

5 **EXTRACELLULAR-SIGNAL-REGULATED KINASE-6 INHIBITORS FOR**
 INHIBITING ANGIOGENESIS

INTRODUCTION

 This application is a continuation-in-part of U.S.
10 Application No. 10/174,465 filed on June 17, 2002.

FIELD OF THE INVENTION

 The present invention provides compositions and methods
for modulating the expression of extracellular-signal-
15 regulated kinase-6. In particular, this invention relates
to compounds, particularly oligonucleotides, specifically
hybridizable with nucleic acids encoding extracellular-
signal-regulated kinase-6. Such compounds have been shown
to modulate the expression of extracellular-signal-regulated
20 kinase-6.

BACKGROUND OF THE INVENTION

 Mitogen-activated protein kinases (MAPKs) are a family
of serine/threonine protein kinases that play a crucial role
25 in relaying extracellular signals transduced through the
plasma membrane to the nucleus. MAPKs respond to cues such
as cellular stresses and pro-inflammatory cytokines,
mitogens and tumour-promoting phorbol esters, and hormones
or polypeptide growth factors, and they response by
30 promoting changes in gene expression, cell proliferation,
and cell survival during embryogenesis, growth and
differentiation. The MAPK pathway includes three major
families: the extracellular-signal-regulated kinases (ERKs),
the c-Jun NH₂-terminal kinases (JNKs)/stress-activated
35 protein kinases (SAPKs), and the p38 kinases (English and
Cobb, *Trends Pharm. Sci.*, 2002, 23, 40-45).

ISPH-0728

-2-

PATENT

Interest in MAPKs as therapeutic targets has soared since the identification of potential pharmacological inhibitors of the MAPKs ERK1, ERK2, two p38 isoforms, three JNK/SAPKs, and ERK5. In particular, pyridinyl imidazole
5 anti-inflammatory drugs have been shown to target p38 MAPK and demonstrate efficacy in treatment of arthritis and psoriasis, reaffirming the idea that intracellular enzymes with multiple functions are valuable therapeutic targets for specific applications. Thus, most extensive activity in
10 MAPK inhibitor development has revolved around p38 MAPKs (English and Cobb, *Trends Pharm. Sci.*, 2002, 23, 40-45).

In mammals, four major p38 MAPK isoforms have been identified: p38 α (SAPK2a), p38 β 2 (SAPK2b), p38 δ (SAPK4), and extracellular-signal-regulated kinase-6 (also known as p38 γ ,
15 ERK-6, ERK6, ERK5, ERK3, p38gamma, stress-activated protein kinase 3, SAPK3, mitogen-activated protein kinase 3, mitogen-activated protein kinase 12, MAPK12 and PRKM12). These isoforms appear to mediate distinct functions *in vivo* due, in part, to differences in their activation by the
20 selective formation of functional complexes with a particular MAPK kinase, as well as to phosphorylation of p38-specific substrates (Enslen et al., *EMBO J.*, 2000, 19, 1301-1311).

As the third member of the p38 group of MAP kinases,
25 the extracellular-signal-regulated kinase-6 gene was identified from two overlapping expressed sequence tag (EST) clones in the GenBank database. While other p38 family members are expressed in multiple tissues, extracellular-signal-regulated kinase-6 mRNA was expressed primarily in
30 skeletal muscle; thus, extracellular-signal-regulated kinase-6 is predicted to have unique functions and substrate preferences (Li et al., *Biochem. Biophys. Res. Commun.*, 1996, 228, 334-340). By fluorescence *in situ* hybridization, the extracellular-signal-regulated kinase-6 gene was mapped
35 to human chromosomal locus 22q13.3. Two cDNAs representing

ISPH-0728

-3-

PATENT

human extracellular-signal-regulated kinase-6 were identified, suggesting the existence of alternative splice forms that produce at least two protein isoforms, 357 and 367 amino acids in length. Although mRNA levels were found to be highest in skeletal muscle, extracellular-signal-regulated kinase-6 mRNA was also detected in other tissues (Goedert et al., *Genomics*, 1997, 41, 501-502).

Independently, the human extracellular-signal-regulated kinase-6 gene was isolated and the encoded protein reported to be a tissue-specific, signal-transducing factor connected to phosphotyrosine-mediated signaling pathways active during myogenic differentiation. Overexpression of extracellular-signal-regulated kinase-6 was found to enhance differentiation of myoblasts to myotubes, and inactivation inhibited this differentiation, maintaining cells in a proliferative state (Lechner et al., *Proc. Natl. Acad. Sci. U. S. A.*, 1996, 93, 4355-4359).

Prolonged strenuous exercise, for example marathon running, results in a robust but transient increase in phosphorylation and activation of JNK and extracellular-signal-regulated kinase-6, suggesting that stress-activated protein kinases may be responsible for skeletal muscle adaptations to exercise (Boppart et al., *J. Physiol.*, 2000, 526 Pt 3, 663-669). Hypoxia is a common physiological stress involved in a variety of pathological processes including angiogenesis, tumor progression and apoptosis. Extracellular-signal-regulated kinase-6 has is activated by hypoxia. Two D2-dopamine receptor antagonists have been shown to enhance hypoxia-induced phosphorylation of extracellular-signal-regulated kinase-6 in neural-like pheochromocytoma (PC12) cells derived from rat adrenal medullary tumors. Removal of extracellular calcium blocked the hypoxia-induced increase in extracellular-signal-regulated kinase-6 activity. Thus, the D2 receptor and calcium regulate extracellular-signal-regulated kinase-6

following hypoxic exposure (Conrad et al., *Cell Signal.*, 2000, 12, 463-467).

A large family of G protein-coupled receptors related to the m1 class of human muscarinic acetylcholine receptors
5 can activate the c-Jun promoter via elevation of the activity of extracellular-signal-regulated kinase-6. Moreover, activation of extracellular-signal-regulated kinase-6 is necessary for full activation of the c-Jun promoter, apparently stimulating distinct regulatory
10 elements within the promoter (Marinissen et al., *Mol. Cell. Biol.*, 1999, 19, 4289-4301).

Small GTP-binding proteins of the Rho family can also initiate a cascade of signaling events that lead to the activation of extracellular-signal-regulated kinase-6. An
15 activated form of the RhoA GTPase was found to potently stimulate activating phosphorylation of extracellular-signal-regulated kinase-6 by the lipid-activated protein serine/threonine kinase PRK1/PKN, leading to increased gene expression in NIH 3T3 murine fibroblasts (Marinissen et al.,
20 *Genes Dev.*, 2001, 15, 535-553). Recently, the GTP-binding protein Rit was identified as a novel branch of the Ras family of G proteins. When overexpressed, an activated Rit mutant can efficiently transform NIH 3T3 cells and stimulate extracellular-signal-regulated kinase-6. Furthermore,
25 extracellular-signal-regulated kinase-6 activation is required for the ability of Rit to stimulate gene expression and cellular transformation (Sakabe et al., *FEBS Lett.*, 2002, 511, 15-20). Thus, the MKK3/MKK6-extracellular-signal-regulated kinase-6 pathway appears to regulate the gene
30 expression and transforming abilities of the Rho and Rit Ras-like GTPases.

Extracellular-signal-regulated kinase-6 has been implicated in the cellular response to genotoxic agents such as cisplatin or etoposide, widely used in the treatment of
35 cancer. In human melanoma cells, extracellular-signal-regulated kinase-6 is activated in response to cisplatin

ISPH-0728

-5-

PATENT

exposure or UV treatment, while etoposide causes a much more discrete phosphorylation than either of the other DNA-damaging agents. Genotoxic stresses appear to differentially activate several p38 isoforms, and the cellular response is
5 believed to depend on cell type as well as the type of DNA damage (Pillaire et al., *Biochem. Biophys. Res. Commun.*, 2000, 278, 724-728).

The MAPK pathway and extracellular-signal-regulated kinase-6 participate in the DNA-damage checkpoint.
10 Activation of extracellular-signal-regulated kinase-6 is required for γ -irradiation-induced G2 arrest of the cell cycle. Human fibroblasts expressing a dominant negative allele of extracellular-signal-regulated kinase-6 display an attenuated arrest which allows cells to escape the DNA-
15 damage-induced checkpoint-mediated G2 delay; interfering with the extracellular-signal-regulated kinase-6 pathway dramatically enhances γ -irradiation-mediated cell killing. Extracellular-signal-regulated kinase-6 is, therefore, a potential target for improving cancer treatments by
20 inactivating the G2/M arrest correlated with radioresistance often acquired by tumor cells during cancer treatment (Wang et al., *Mol. Cell. Biol.*, 2000, 20, 4543-4552).

In Alzheimer's disease, paired helical filaments (PHFs), consisting of the hyperphosphorylated form of the
25 microtubule-associated protein tau, are the major fibrous element of neurofibrillary lesions. Extracellular-signal-regulated kinase-6 phosphorylates the tau protein at many sites known to be hyperphosphorylated in PHF-tau. Phosphorylation of tau resulted in a marked reduction in its
30 ability to promote microtubule assembly, suggesting a possible role for extracellular-signal-regulated kinase-6 in Alzheimer's disease and other neurodegenerative disorders (Goedert et al., *FEBS Lett.*, 1997, 409, 57-62).

Interestingly, extracellular-signal-regulated kinase-6
35 was found to be widely expressed at high levels in adult mouse brain. In subcellular localization studies,

ISPH-0728

-6-

PATENT

extracellular-signal-regulated kinase-6 was detected mainly in the cytoplasm and dendrites of neurons. Extraordinarily high basal activity in brain (as compared to peripheral organs), of all SAPK proteins, including extracellular-signal-regulated kinase-6, indicated that the SAPK pathway
5 may be involved in normal brain physiology, as well as synaptic plasticity or synaptic remodeling (Lee et al., *Brain Res. Mol. Brain Res.*, 1999, 70, 116-124).

Disclosed and claimed in US Patent 5,459,036 is an
10 isolated nucleic acid molecule encoding the extracellular-signal-regulated kinase-6 polypeptide, a nucleic acid probe able to detect the presence of extracellular-signal-regulated kinase-6 nucleic acid in a sample comprising an isolated nucleic acid molecule having at least 27 contiguous
15 nucleotides of said nucleic acid, a method of and a kit for detecting the presence of extracellular-signal-regulated kinase-6 RNA, an isolated nucleic acid molecule comprising a promoter effective to initiate transcription in a host cell and a nucleic acid encoding at least 9 contiguous amino
20 acids of said polypeptide, an isolated nucleic acid molecule consisting of a promoter region and a sequence complimentary to said RNA and a transcription termination region functional in said cell, and a transformed cell that contains said isolated nucleic acid molecule. Antisense
25 extracellular-signal-regulated kinase-6 nucleic acid constructs are generally disclosed (Lechner et al., 1995).

Disclosed and claimed in European Patent EP 1174129 is the use of an active agent for influencing, particularly inhibiting the expression of matrix-metalloproteases in
30 eukaryotic cells, for the preparation of a medicament or a pharmaceutical composition for the treatment of cancer; a method for the treatment of cancer, characterized in that eukaryotic cells are treated by an active agent which influences, particularly inhibits the expression of matrix-
35 metalloproteases; said use or method characterized in that said active agent is targeted against at least one member of the matrix-metalloprotease signal transduction pathway and

ISPH-0728

-7-

PATENT

that said member is a member of the p38 protein family, and that said member is extracellular-signal-regulated kinase-6; and a pharmaceutical composition, wherein said active agent is influencing, preferably inhibiting the expression of
5 matrix-metalloproteases in eukaryotic cells, and optionally further comprising a pharmaceutically acceptable carrier (Zenner and Simon, 2000).

Currently, there are no known therapeutic agents which effectively inhibit the synthesis of extracellular-signal-
10 regulated kinase-6 and to date, investigative strategies aimed at modulating extracellular-signal-regulated kinase-6 function have involved the use of a small molecule inhibitor.

A potential anti-inflammatory small-molecule inhibitor
15 of MAPK, VX-745, is under development for the treatment of rheumatoid arthritis (RA). VX-745 was reported to be active against several isotypes of p38 MAPK, including p38alpha, p38beta and extracellular-signal-regulated kinase-6, and was associated with the suppression of the release of
20 inflammatory mediators, including interleukin (IL)-1beta and tumor necrosis factor (TNF)alpha, known to be implicated in exacerbating the pathophysiology of RA (Haddad, *Curr. Opin. Investig. Drugs*, 2001, 2, 1070-1076). However, high concentrations of VX-745 must be used to inhibit
25 extracellular-signal-regulated kinase-6, and this inhibition is not specific for extracellular-signal-regulated kinase-6, as it has effects on other kinases not in the MAPK family (English and Cobb, *Trends Pharm. Sci.*, 2002, 23, 40-45).

Consequently, there remains a long felt need for
30 additional agents capable of effectively inhibiting extracellular-signal-regulated kinase-6 function.

Antisense technology is emerging as an effective means for reducing the expression of specific gene products and may therefore prove to be uniquely useful in a number of
35 therapeutic, diagnostic, and research applications for the

ISPH-0728

-8-

PATENT

modulation of extracellular-signal-regulated kinase-6 expression.

The present invention provides compositions and methods for modulating extracellular-signal-regulated kinase-6
5 expression.

SUMMARY OF THE INVENTION

The present invention is directed to compounds, particularly antisense oligonucleotides, which are targeted
10 to a nucleic acid encoding extracellular-signal-regulated kinase-6, and which modulate the expression of extracellular-signal-regulated kinase-6. Pharmaceutical and other compositions comprising the compounds of the invention are also provided. Further provided are methods of
15 modulating the expression of extracellular-signal-regulated kinase-6 in cells or tissues comprising contacting said cells or tissues with one or more of the antisense compounds or compositions of the invention. Further provided are methods of treating an animal, particularly a human,
20 suspected of having or being prone to a disease or condition associated with expression of extracellular-signal-regulated kinase-6 by administering a therapeutically or prophylactically effective amount of one or more of the antisense compounds or compositions of the invention.

25

DETAILED DESCRIPTION OF THE INVENTION

The present invention employs oligomeric compounds, particularly antisense oligonucleotides, for use in modulating the function of nucleic acid molecules encoding
30 extracellular-signal-regulated kinase-6, ultimately modulating the amount of extracellular-signal-regulated kinase-6 produced. This is accomplished by providing antisense compounds which specifically hybridize with one or more nucleic acids encoding extracellular-signal-regulated
35 kinase-6. As used herein, the terms "target nucleic acid" and "nucleic acid encoding extracellular-signal-regulated

ISPH-0728

-9-

PATENT

kinase-6" encompass DNA encoding extracellular-signal-regulated kinase-6, RNA (including pre-mRNA and mRNA) transcribed from such DNA, and also cDNA derived from such RNA. The specific hybridization of an oligomeric compound
5 with its target nucleic acid interferes with the normal function of the nucleic acid. This modulation of function of a target nucleic acid by compounds which specifically hybridize to it is generally referred to as "antisense". The functions of DNA to be interfered with include
10 replication and transcription. The functions of RNA to be interfered with include all vital functions such as, for example, translocation of the RNA to the site of protein translation, translocation of the RNA to sites within the cell which are distant from the site of RNA synthesis,
15 translation of protein from the RNA, splicing of the RNA to yield one or more mRNA species, and catalytic activity which may be engaged in or facilitated by the RNA. The overall effect of such interference with target nucleic acid function is modulation of the expression of extracellular-signal-regulated kinase-6. In the context of the present
20 invention, "modulation" means either an increase (stimulation) or a decrease (inhibition) in the expression of a gene. In the context of the present invention, inhibition is the preferred form of modulation of gene
25 expression and mRNA is a preferred target.

It is preferred to target specific nucleic acids for antisense. "Targeting" an antisense compound to a particular nucleic acid, in the context of this invention, is a multistep process. The process usually begins with the
30 identification of a nucleic acid sequence whose function is to be modulated. This may be, for example, a cellular gene (or mRNA transcribed from the gene) whose expression is associated with a particular disorder or disease state, or a nucleic acid molecule from an infectious agent. In the
35 present invention, the target is a nucleic acid molecule encoding extracellular-signal-regulated kinase-6. The targeting process also includes determination of a site or

ISPH-0728

-10-

PATENT

sites within this gene for the antisense interaction to occur such that the desired effect, e.g., detection or modulation of expression of the protein, will result. Within the context of the present invention, a preferred
5 intragenic site is the region encompassing the translation initiation or termination codon of the open reading frame (ORF) of the gene. Since, as is known in the art, the translation initiation codon is typically 5'-AUG (in transcribed mRNA molecules; 5'-ATG in the corresponding DNA
10 molecule), the translation initiation codon is also referred to as the "AUG codon," the "start codon" or the "AUG start codon". A minority of genes have a translation initiation codon having the RNA sequence 5'-GUG, 5'-UUG or 5'-CUG, and 5'-AUA, 5'-ACG and 5'-CUG have been shown to function *in*
15 *vivo*. Thus, the terms "translation initiation codon" and "start codon" can encompass many codon sequences, even though the initiator amino acid in each instance is typically methionine (in eukaryotes) or formylmethionine (in prokaryotes). It is also known in the art that eukaryotic
20 and prokaryotic genes may have two or more alternative start codons, any one of which may be preferentially utilized for translation initiation in a particular cell type or tissue, or under a particular set of conditions. In the context of the invention, "start codon" and "translation initiation
25 codon" refer to the codon or codons that are used *in vivo* to initiate translation of an mRNA molecule transcribed from a gene encoding extracellular-signal-regulated kinase-6, regardless of the sequence(s) of such codons.

It is also known in the art that a translation
30 termination codon (or "stop codon") of a gene may have one of three sequences, i.e., 5'-UAA, 5'-UAG and 5'-UGA (the corresponding DNA sequences are 5'-TAA, 5'-TAG and 5'-TGA, respectively). The terms "start codon region" and "translation initiation codon region" refer to a portion of
35 such an mRNA or gene that encompasses from about 25 to about 50 contiguous nucleotides in either direction (i.e., 5' or

ISPH-0728

-11-

PATENT

3') from a translation initiation codon. Similarly, the terms "stop codon region" and "translation termination codon region" refer to a portion of such an mRNA or gene that encompasses from about 25 to about 50 contiguous nucleotides in either direction (i.e., 5' or 3') from a translation termination codon.

The open reading frame (ORF) or "coding region," which is known in the art to refer to the region between the translation initiation codon and the translation termination codon, is also a region which may be targeted effectively. Other target regions include the 5' untranslated region (5'UTR), known in the art to refer to the portion of an mRNA in the 5' direction from the translation initiation codon, and thus including nucleotides between the 5' cap site and the translation initiation codon of an mRNA or corresponding nucleotides on the gene, and the 3' untranslated region (3'UTR), known in the art to refer to the portion of an mRNA in the 3' direction from the translation termination codon, and thus including nucleotides between the translation termination codon and 3' end of an mRNA or corresponding nucleotides on the gene. The 5' cap of an mRNA comprises an N7-methylated guanosine residue joined to the 5'-most residue of the mRNA via a 5'-5' triphosphate linkage. The 5' cap region of an mRNA is considered to include the 5' cap structure itself as well as the first 50 nucleotides adjacent to the cap. The 5' cap region may also be a preferred target region.

Although some eukaryotic mRNA transcripts are directly translated, many contain one or more regions, known as "introns," which are excised from a transcript before it is translated. The remaining (and therefore translated) regions are known as "exons" and are spliced together to form a continuous mRNA sequence. mRNA splice sites, i.e., intron-exon junctions, may also be preferred target regions, and are particularly useful in situations where aberrant splicing is implicated in disease, or where an overproduction of a particular mRNA splice product is

ISPH-0728

-12-

PATENT

implicated in disease. Aberrant fusion junctions due to rearrangements or deletions are also preferred targets. mRNA transcripts produced via the process of splicing of two (or more) mRNAs from different gene sources are known as

5 "fusion transcripts". It has also been found that introns can be effective, and therefore preferred, target regions for antisense compounds targeted, for example, to DNA or pre-mRNA.

It is also known in the art that alternative RNA

10 transcripts can be produced from the same genomic region of DNA. These alternative transcripts are generally known as "variants". More specifically, "pre-mRNA variants" are transcripts produced from the same genomic DNA that differ from other transcripts produced from the same genomic DNA in

15 either their start or stop position and contain both intronic and extronic regions.

Upon excision of one or more exon or intron regions or portions thereof during splicing, pre-mRNA variants produce smaller "mRNA variants". Consequently, mRNA variants are

20 processed pre-mRNA variants and each unique pre-mRNA variant must always produce a unique mRNA variant as a result of splicing. These mRNA variants are also known as "alternative splice variants". If no splicing of the pre-mRNA variant occurs then the pre-mRNA variant is identical

25 to the mRNA variant.

It is also known in the art that variants can be produced through the use of alternative signals to start or stop transcription and that pre-mRNAs and mRNAs can possess more than one start codon or stop codon. Variants that

30 originate from a pre-mRNA or mRNA that use alternative start codons are known as "alternative start variants" of that pre-mRNA or mRNA. Those transcripts that use an alternative stop codon are known as "alternative stop variants" of that pre-mRNA or mRNA. One specific type of alternative stop

35 variant is the "polyA variant" in which the multiple transcripts produced result from the alternative selection of one of the "polyA stop signals" by the transcription

ISPH-0728

-13-

PATENT

machinery, thereby producing transcripts that terminate at unique polyA sites.

Once one or more target sites have been identified, oligonucleotides are chosen which are sufficiently
5 complementary to the target, i.e., hybridize sufficiently well and with sufficient specificity, to give the desired effect.

In the context of this invention, "hybridization" means hydrogen bonding, which may be Watson-Crick, Hoogsteen or
10 reversed Hoogsteen hydrogen bonding, between complementary nucleoside or nucleotide bases. For example, adenine and thymine are complementary nucleobases which pair through the formation of hydrogen bonds. "Complementary," as used
15 herein, refers to the capacity for precise pairing between two nucleotides. For example, if a nucleotide at a certain position of an oligonucleotide is capable of hydrogen bonding with a nucleotide at the same position of a DNA or RNA molecule, then the oligonucleotide and the DNA or RNA are considered to be complementary to each other at that
20 position. The oligonucleotide and the DNA or RNA are complementary to each other when a sufficient number of corresponding positions in each molecule are occupied by nucleotides which can hydrogen bond with each other. Thus, "specifically hybridizable" and "complementary" are terms
25 which are used to indicate a sufficient degree of complementarity or precise pairing such that stable and specific binding occurs between the oligonucleotide and the DNA or RNA target. It is understood in the art that the sequence of an antisense compound need not be 100%
30 complementary to that of its target nucleic acid to be specifically hybridizable.

An antisense compound is specifically hybridizable when binding of the compound to the target DNA or RNA molecule interferes with the normal function of the target DNA or RNA
35 to cause a loss of activity, and there is a sufficient degree of complementarity to avoid non-specific binding of the antisense compound to non-target sequences under

ISPH-0728

-14-

PATENT

conditions in which specific binding is desired, i.e., under physiological conditions in the case of in vivo assays or therapeutic treatment, and in the case of in vitro assays, under conditions in which the assays are performed. It is preferred that the antisense compounds of the present invention comprise at least 80% sequence complementarity to a target region within the target nucleic acid, moreover that they comprise 90% sequence complementarity and even more comprise 95% sequence complementarity to the target region within the target nucleic acid sequence to which they are targeted. For example, an antisense compound in which 18 of 20 nucleobases of the antisense compound are complementary, and would therefore specifically hybridize, to a target region would represent 90 percent complementarity. Percent complementarity of an antisense compound with a region of a target nucleic acid can be determined routinely using basic local alignment search tools (BLAST programs) (Altschul et al., *J. Mol. Biol.*, 1990, 215, 403-410; Zhang and Madden, *Genome Res.*, 1997, 7, 649-656).

Antisense and other compounds of the invention, which hybridize to the target and inhibit expression of the target, are identified through experimentation, and representative sequences of these compounds are hereinbelow identified as preferred embodiments of the invention. The sites to which these preferred antisense compounds are specifically hybridizable are hereinbelow referred to as "preferred target regions" and are therefore preferred sites for targeting. As used herein the term "preferred target region" is defined as at least an 8-nucleobase portion of a target region to which an active antisense compound is targeted. While not wishing to be bound by theory, it is presently believed that these target regions represent regions of the target nucleic acid which are accessible for hybridization.

While the specific sequences of particular preferred target regions are set forth below, one of skill in the art

ISPH-0728

-15-

PATENT

will recognize that these serve to illustrate and describe particular embodiments within the scope of the present invention. Additional preferred target regions may be identified by one having ordinary skill.

5 Target regions 8-80 nucleobases in length comprising a stretch of at least eight (8) consecutive nucleobases selected from within the illustrative preferred target regions are considered to be suitable preferred target regions as well.

10 Exemplary good preferred target regions include DNA or RNA sequences that comprise at least the 8 consecutive nucleobases from the 5'-terminus of one of the illustrative preferred target regions (the remaining nucleobases being a consecutive stretch of the same DNA or RNA beginning
15 immediately upstream of the 5'-terminus of the target region and continuing until the DNA or RNA contains about 8 to about 80 nucleobases). Similarly good preferred target regions are represented by DNA or RNA sequences that comprise at least the 8 consecutive nucleobases from the 3'-
20 terminus of one of the illustrative preferred target regions (the remaining nucleobases being a consecutive stretch of the same DNA or RNA beginning immediately downstream of the 3'-terminus of the target region and continuing until the DNA or RNA contains about 8 to about 80 nucleobases). One
25 having skill in the art, once armed with the empirically-derived preferred target regions illustrated herein will be able, without undue experimentation, to identify further preferred target regions. In addition, one having ordinary skill in the art will also be able to identify additional
30 compounds, including oligonucleotide probes and primers, that specifically hybridize to these preferred target regions using techniques available to the ordinary practitioner in the art.

Antisense compounds are commonly used as research
35 reagents and diagnostics. For example, antisense oligonucleotides, which are able to inhibit gene expression with exquisite specificity, are often used by those of

ISPH-0728

-16-

PATENT

ordinary skill to elucidate the function of particular genes. Antisense compounds are also used, for example, to distinguish between functions of various members of a biological pathway. Antisense modulation has, therefore,
5 been harnessed for research use.

For use in kits and diagnostics, the antisense compounds of the present invention, either alone or in combination with other antisense compounds or therapeutics, can be used as tools in differential and/or combinatorial
10 analyses to elucidate expression patterns of a portion or the entire complement of genes expressed within cells and tissues.

Expression patterns within cells or tissues treated with one or more antisense compounds are compared to control
15 cells or tissues not treated with antisense compounds and the patterns produced are analyzed for differential levels of gene expression as they pertain, for example, to disease association, signaling pathway, cellular localization, expression level, size, structure or function of the genes
20 examined. These analyses can be performed on stimulated or unstimulated cells and in the presence or absence of other compounds which affect expression patterns.

Examples of methods of gene expression analysis known in the art include DNA arrays or microarrays (Brazma and
25 Vilo, *FEBS Lett.*, 2000, 480, 17-24; Celis, et al., *FEBS Lett.*, 2000, 480, 2-16), SAGE (serial analysis of gene expression) (Madden, et al., *Drug Discov. Today*, 2000, 5, 415-425), READS (restriction enzyme amplification of digested cDNAs) (Prashar and Weissman, *Methods Enzymol.*,
30 1999, 303, 258-72), TOGA (total gene expression analysis) (Sutcliffe, et al., *Proc. Natl. Acad. Sci. U. S. A.*, 2000, 97, 1976-81), protein arrays and proteomics (Celis, et al., *FEBS Lett.*, 2000, 480, 2-16; Jungblut, et al., *Electrophoresis*, 1999, 20, 2100-10), expressed sequence tag
35 (EST) sequencing (Celis, et al., *FEBS Lett.*, 2000, 480, 2-

ISPH-0728

-17-

PATENT

16; Larsson, et al., *J. Biotechnol.*, 2000, 80, 143-57),
subtractive RNA fingerprinting (SuRF) (Fuchs, et al., *Anal.*
Biochem., 2000, 286, 91-98; Larson, et al., *Cytometry*, 2000,
41, 203-208), subtractive cloning, differential display (DD)
5 (Jurecic and Belmont, *Curr. Opin. Microbiol.*, 2000, 3, 316-
21), comparative genomic hybridization (Carulli, et al., *J.*
Cell Biochem. Suppl., 1998, 31, 286-96), FISH (fluorescent
in situ hybridization) techniques (Going and Gusterson, *Eur.*
J. Cancer, 1999, 35, 1895-904) and mass spectrometry methods
10 (reviewed in To, *Comb. Chem. High Throughput Screen*, 2000,
3, 235-41).

The specificity and sensitivity of antisense is also
harnessed by those of skill in the art for therapeutic uses.
Antisense oligonucleotides have been employed as therapeutic
15 moieties in the treatment of disease states in animals and
man. Antisense oligonucleotide drugs, including ribozymes,
have been safely and effectively administered to humans and
numerous clinical trials are presently underway. It is thus
established that oligonucleotides can be useful therapeutic
20 modalities that can be configured to be useful in treatment
regimes for treatment of cells, tissues and animals,
especially humans.

In the context of this invention, the term
"oligonucleotide" refers to an oligomer or polymer of
25 ribonucleic acid (RNA) or deoxyribonucleic acid (DNA) or
mimetics thereof. This term includes oligonucleotides
composed of naturally-occurring nucleobases, sugars and
covalent internucleoside (backbone) linkages as well as
oligonucleotides having non-naturally-occurring portions
30 which function similarly. Such modified or substituted
oligonucleotides are often preferred over native forms
because of desirable properties such as, for example,
enhanced cellular uptake, enhanced affinity for nucleic acid
target and increased stability in the presence of nucleases.

While antisense oligonucleotides are a preferred form of antisense compound, the present invention comprehends other oligomeric antisense compounds, including but not limited to oligonucleotide mimetics such as are described below. The antisense compounds in accordance with this invention preferably comprise from about 8 to about 80 nucleobases (i.e. from about 8 to about 80 linked nucleosides). Particularly preferred antisense compounds are antisense oligonucleotides from about 8 to about 50 nucleobases, even more preferably those comprising from about 12 to about 30 nucleobases. Antisense compounds include ribozymes, external guide sequence (EGS) oligonucleotides (oligozymes), and other short catalytic RNAs or catalytic oligonucleotides which hybridize to the target nucleic acid and modulate its expression.

Antisense compounds 8-80 nucleobases in length comprising a stretch of at least eight (8) consecutive nucleobases selected from within the illustrative antisense compounds are considered to be suitable antisense compounds as well.

Exemplary preferred antisense compounds include DNA or RNA sequences that comprise at least the 8 consecutive nucleobases from the 5'-terminus of one of the illustrative preferred antisense compounds (the remaining nucleobases being a consecutive stretch of the same DNA or RNA beginning immediately upstream of the 5'-terminus of the antisense compound which is specifically hybridizable to the target nucleic acid and continuing until the DNA or RNA contains about 8 to about 80 nucleobases). Similarly preferred antisense compounds are represented by DNA or RNA sequences that comprise at least the 8 consecutive nucleobases from the 3'-terminus of one of the illustrative preferred antisense compounds (the remaining nucleobases being a consecutive stretch of the same DNA or RNA beginning immediately downstream of the 3'-terminus of the antisense compound which is specifically hybridizable to the target nucleic acid and continuing until the DNA or RNA contains

ISPH-0728

-19-

PATENT

about 8 to about 80 nucleobases). One having skill in the art, once armed with the empirically-derived preferred antisense compounds illustrated herein will be able, without undue experimentation, to identify further preferred
5 antisense compounds.

Antisense and other compounds of the invention, which hybridize to the target and inhibit expression of the target, are identified through experimentation, and representative sequences of these compounds are herein
10 identified as preferred embodiments of the invention. While specific sequences of the antisense compounds are set forth herein, one of skill in the art will recognize that these serve to illustrate and describe particular embodiments within the scope of the present invention. Additional
15 preferred antisense compounds may be identified by one having ordinary skill.

As is known in the art, a nucleoside is a base-sugar combination. The base portion of the nucleoside is normally a heterocyclic base. The two most common classes of such
20 heterocyclic bases are the purines and the pyrimidines. Nucleotides are nucleosides that further include a phosphate group covalently linked to the sugar portion of the nucleoside. For those nucleosides that include a pentofuranosyl sugar, the phosphate group can be linked to
25 either the 2', 3' or 5' hydroxyl moiety of the sugar. In forming oligonucleotides, the phosphate groups covalently link adjacent nucleosides to one another to form a linear polymeric compound. In turn, the respective ends of this linear polymeric structure can be further joined to form a
30 circular structure, however, open linear structures are generally preferred. In addition, linear structures may also have internal nucleobase complementarity and may therefore fold in a manner as to produce a double stranded structure. Within the oligonucleotide structure, the
35 phosphate groups are commonly referred to as forming the internucleoside backbone of the oligonucleotide. The normal

ISPH-0728

-20-

PATENT

linkage or backbone of RNA and DNA is a 3' to 5' phosphodiester linkage.

Specific examples of preferred antisense compounds useful in this invention include oligonucleotides containing
5 modified backbones or non-natural internucleoside linkages. As defined in this specification, oligonucleotides having modified backbones include those that retain a phosphorus atom in the backbone and those that do not have a phosphorus atom in the backbone. For the purposes of this
10 specification, and as sometimes referenced in the art, modified oligonucleotides that do not have a phosphorus atom in their internucleoside backbone can also be considered to be oligonucleosides.

Preferred modified oligonucleotide backbones include,
15 for example, phosphorothioates, chiral phosphorothioates, phosphorodithioates, phosphotriesters, aminoalkylphosphotriesters, methyl and other alkyl phosphonates including 3'-alkylene phosphonates, 5'-alkylene phosphonates and chiral phosphonates, phosphinates, phosphoramidates including 3'-
20 amino phosphoramidate and aminoalkylphosphoramidates, thionophosphoramidates, thionoalkylphosphonates, thionoalkylphosphotriesters, selenophosphates and boranophosphates having normal 3'-5' linkages, 2'-5' linked analogs of these, and those having inverted polarity wherein
25 one or more internucleotide linkages is a 3' to 3', 5' to 5' or 2' to 2' linkage. Preferred oligonucleotides having inverted polarity comprise a single 3' to 3' linkage at the 3'-most internucleotide linkage i.e. a single inverted nucleoside residue which may be abasic (the nucleobase is
30 missing or has a hydroxyl group in place thereof). Various salts, mixed salts and free acid forms are also included.

Representative United States patents that teach the preparation of the above phosphorus-containing linkages include, but are not limited to, U.S.: 3,687,808; 4,469,863;
35 4,476,301; 5,023,243; 5,177,196; 5,188,897; 5,264,423; 5,276,019; 5,278,302; 5,286,717; 5,321,131; 5,399,676; 5,405,939; 5,453,496; 5,455,233; 5,466,677; 5,476,925;

ISPH-0728

-21-

PATENT

5,519,126; 5,536,821; 5,541,306; 5,550,111; 5,563,253;
5,571,799; 5,587,361; 5,194,599; 5,565,555; 5,527,899;
5,721,218; 5,672,697 and 5,625,050, certain of which are
commonly owned with this application, and each of which is
5 herein incorporated by reference.

Preferred modified oligonucleotide backbones that do
not include a phosphorus atom therein have backbones that
are formed by short chain alkyl or cycloalkyl
internucleoside linkages, mixed heteroatom and alkyl or
10 cycloalkyl internucleoside linkages, or one or more short
chain heteroatomic or heterocyclic internucleoside linkages.
These include those having morpholino linkages (formed in
part from the sugar portion of a nucleoside); siloxane
backbones; sulfide, sulfoxide and sulfone backbones;
15 formacetyl and thioformacetyl backbones; methylene
formacetyl and thioformacetyl backbones; riboacetyl
backbones; alkene containing backbones; sulfamate backbones;
methyleneimino and methylenehydrazino backbones; sulfonate
and sulfonamide backbones; amide backbones; and others
20 having mixed N, O, S and CH₂ component parts.

Representative United States patents that teach the
preparation of the above oligonucleosides include, but are
not limited to, U.S.: 5,034,506; 5,166,315; 5,185,444;
5,214,134; 5,216,141; 5,235,033; 5,264,562; 5,264,564;
25 5,405,938; 5,434,257; 5,466,677; 5,470,967; 5,489,677;
5,541,307; 5,561,225; 5,596,086; 5,602,240; 5,610,289;
5,602,240; 5,608,046; 5,610,289; 5,618,704; 5,623,070;
5,663,312; 5,633,360; 5,677,437; 5,792,608; 5,646,269 and
5,677,439, certain of which are commonly owned with this
30 application, and each of which is herein incorporated by
reference.

In other preferred oligonucleotide mimetics, both the
sugar and the internucleoside linkage, i.e., the backbone,
of the nucleotide units are replaced with novel groups. The
35 base units are maintained for hybridization with an
appropriate nucleic acid target compound. One such
oligomeric compound, an oligonucleotide mimetic that has

ISPH-0728

-22-

PATENT

been shown to have excellent hybridization properties, is referred to as a peptide nucleic acid (PNA). In PNA compounds, the sugar-backbone of an oligonucleotide is replaced with an amide containing backbone, in particular an aminoethylglycine backbone. The nucleobases are retained and are bound directly or indirectly to aza nitrogen atoms of the amide portion of the backbone. Representative United States patents that teach the preparation of PNA compounds include, but are not limited to, U.S.: 5,539,082; 5,714,331; and 5,719,262, each of which is herein incorporated by reference. Further teaching of PNA compounds can be found in Nielsen et al., *Science*, 1991, 254, 1497-1500.

Most preferred embodiments of the invention are oligonucleotides with phosphorothioate backbones and oligonucleosides with heteroatom backbones, and in particular $-\text{CH}_2-\text{NH}-\text{O}-\text{CH}_2-$, $-\text{CH}_2-\text{N}(\text{CH}_3)-\text{O}-\text{CH}_2-$ [known as a methylene (methylinino) or MMI backbone], $-\text{CH}_2-\text{O}-\text{N}(\text{CH}_3)-\text{CH}_2-$, $-\text{CH}_2-\text{N}(\text{CH}_3)-\text{N}(\text{CH}_3)-\text{CH}_2-$ and $-\text{O}-\text{N}(\text{CH}_3)-\text{CH}_2-\text{CH}_2-$ [wherein the native phosphodiester backbone is represented as $-\text{O}-\text{P}-\text{O}-\text{CH}_2-$] of the above referenced U.S. patent 5,489,677, and the amide backbones of the above referenced U.S. patent 5,602,240. Also preferred are oligonucleotides having morpholino backbone structures of the above-referenced U.S. patent 5,034,506.

Modified oligonucleotides may also contain one or more substituted sugar moieties. Preferred oligonucleotides comprise one of the following at the 2' position: OH; F; O-, S-, or N-alkyl; O-, S-, or N-alkenyl; O-, S- or N-alkynyl; or O-alkyl-O-alkyl, wherein the alkyl, alkenyl and alkynyl may be substituted or unsubstituted C_1 to C_{10} alkyl or C_2 to C_{10} alkenyl and alkynyl. Particularly preferred are $\text{O}[(\text{CH}_2)_n\text{O}]_m\text{CH}_3$, $\text{O}(\text{CH}_2)_n\text{OCH}_3$, $\text{O}(\text{CH}_2)_n\text{NH}_2$, $\text{O}(\text{CH}_2)_n\text{CH}_3$, $\text{O}(\text{CH}_2)_n\text{ONH}_2$, and $\text{O}(\text{CH}_2)_n\text{ON}[(\text{CH}_2)_m\text{CH}_3]_2$, where n and m are from 1 to about 10. Other preferred oligonucleotides comprise one of the following at the 2' position: C_1 to C_{10} lower alkyl, substituted lower alkyl, alkenyl, alkynyl, alkaryl, aralkyl, O-alkaryl or O-aralkyl, SH, SCH_3 , OCN, Cl, Br, CN, CF_3 , OCF_3 ,

ISPH-0728

-23-

PATENT

SOCH₃, SO₂CH₃, ONO₂, NO₂, N₃, NH₂, heterocycloalkyl, heterocycloalkaryl, aminoalkylamino, polyalkylamino, substituted silyl, an RNA cleaving group, a reporter group, an intercalator, a group for improving the pharmacokinetic
5 properties of an oligonucleotide, or a group for improving the pharmacodynamic properties of an oligonucleotide, and other substituents having similar properties. A preferred modification includes 2'-methoxyethoxy (2'-O-CH₂CH₂OCH₃, also known as 2'-O-(2-methoxyethyl) or 2'-MOE) (Martin et al.,
10 *Helv. Chim. Acta*, 1995, 78, 486-504) i.e., an alkoxyalkoxy group. A further preferred modification includes 2'-dimethylaminoethoxy, i.e., a O(CH₂)₂ON(CH₃)₂ group, also known as 2'-DMAOE, as described in examples hereinbelow, and 2'-dimethylaminoethoxyethoxy (also known in the art as 2'-O-dimethyl-amino-ethoxy-ethyl or 2'-DMAEOE), i.e., 2'-O-CH₂-O-
15 CH₂-N(CH₃)₂, also described in examples hereinbelow.

Other preferred modifications include 2'-methoxy (2'-O-CH₃), 2'-aminopropoxy (2'-OCH₂CH₂CH₂NH₂), 2'-allyl (2'-CH₂-CH=CH₂), 2'-O-allyl (2'-O-CH₂-CH=CH₂) and 2'-fluoro (2'-F).
20 The 2'-modification may be in the arabino (up) position or ribo (down) position. A preferred 2'-arabino modification is 2'-F. Similar modifications may also be made at other positions on the oligonucleotide, particularly the 3' position of the sugar on the 3' terminal nucleotide or in
25 2'-5' linked oligonucleotides and the 5' position of 5' terminal nucleotide. Oligonucleotides may also have sugar mimetics such as cyclobutyl moieties in place of the pentofuranosyl sugar. Representative United States patents that teach the preparation of such modified sugar structures
30 include, but are not limited to, U.S.: 4,981,957; 5,118,800; 5,319,080; 5,359,044; 5,393,878; 5,446,137; 5,466,786; 5,514,785; 5,519,134; 5,567,811; 5,576,427; 5,591,722; 5,597,909; 5,610,300; 5,627,053; 5,639,873; 5,646,265; 5,658,873; 5,670,633; 5,792,747; and 5,700,920, certain of
35 which are commonly owned with the instant application, and each of which is herein incorporated by reference in its entirety.

ISPH-0728

-24-

PATENT

A further preferred modification includes Locked Nucleic Acids (LNAs) in which the 2'-hydroxyl group is linked to the 3' or 4' carbon atom of the sugar ring thereby forming a bicyclic sugar moiety. The linkage is preferably a methylene $(-\text{CH}_2-)_n$ group bridging the 2' oxygen atom and the 4' carbon atom wherein n is 1 or 2. LNAs and preparation thereof are described in WO 98/39352 and WO 99/14226.

Oligonucleotides may also include nucleobase (often referred to in the art simply as "base") modifications or substitutions. As used herein, "unmodified" or "natural" nucleobases include the purine bases adenine (A) and guanine (G), and the pyrimidine bases thymine (T), cytosine (C) and uracil (U). Modified nucleobases include other synthetic and natural nucleobases such as 5-methylcytosine (5-me-C), 5-hydroxymethyl cytosine, xanthine, hypoxanthine, 2-aminoadenine, 6-methyl and other alkyl derivatives of adenine and guanine, 2-propyl and other alkyl derivatives of adenine and guanine, 2-thiouracil, 2-thiothymine and 2-thiocytosine, 5-halouracil and cytosine, 5-propynyl $(-\text{C}\equiv\text{C}-\text{CH}_3)$ uracil and cytosine and other alkynyl derivatives of pyrimidine bases, 6-azo uracil, cytosine and thymine, 5-uracil (pseudouracil), 4-thiouracil, 8-halo, 8-amino, 8-thiol, 8-thioalkyl, 8-hydroxyl and other 8-substituted adenines and guanines, 5-halo particularly 5-bromo, 5-trifluoromethyl and other 5-substituted uracils and cytosines, 7-methylguanine and 7-methyladenine, 2-F-adenine, 2-amino-adenine, 8-azaguanine and 8-azaadenine, 7-deazaguanine and 7-deazaadenine and 3-deazaguanine and 3-deazaadenine. Further modified nucleobases include tricyclic pyrimidines such as phenoxazine cytidine (1H-pyrimido[5,4-b][1,4]benzoxazin-2(3H)-one), phenothiazine cytidine (1H-pyrimido[5,4-b][1,4]benzothiazin-2(3H)-one), G-clamps such as a substituted phenoxazine cytidine (e.g. 9-(2-aminoethoxy)-H-pyrimido[5,4-b][1,4]benzoxazin-2(3H)-one), carbazole cytidine (2H-pyrimido[4,5-b]indol-2-one), pyridoindole cytidine (H-pyrido[3',2':4,5]pyrrolo[2,3-d]pyrimidin-2-one). Modified nucleobases may also include

ISPH-0728

-25-

PATENT

those in which the purine or pyrimidine base is replaced with other heterocycles, for example 7-deaza-adenine, 7-deazaguanosine, 2-aminopyridine and 2-pyridone. Further nucleobases include those disclosed in United States Patent

5 No. 3,687,808, those disclosed in *The Concise Encyclopedia Of Polymer Science And Engineering*, pages 858-859, Kroschwitz, J.I., ed. John Wiley & Sons, 1990, those disclosed by Englisch et al., *Angewandte Chemie*, International Edition, 1991, 30, 613, and those disclosed by

10 Sanghvi, Y.S., Chapter 15, *Antisense Research and Applications*, pages 289-302, Crooke, S.T. and Lebleu, B., ed., CRC Press, 1993. Certain of these nucleobases are particularly useful for increasing the binding affinity of the oligomeric compounds of the invention. These include 5-

15 substituted pyrimidines, 6-azapyrimidines and N-2, N-6 and O-6 substituted purines, including 2-aminopropyladenine, 5-propynyluracil and 5-propynylcytosine. 5-methylcytosine substitutions have been shown to increase nucleic acid duplex stability by 0.6-1.2°C (Sanghvi, Y.S., Crooke, S.T.

20 and Lebleu, B., eds., *Antisense Research and Applications*, CRC Press, Boca Raton, 1993, pp. 276-278) and are presently preferred base substitutions, even more particularly when combined with 2'-O-methoxyethyl sugar modifications.

Representative United States patents that teach the

25 preparation of certain of the above noted modified nucleobases as well as other modified nucleobases include, but are not limited to, the above noted U.S. 3,687,808, as well as U.S.: 4,845,205; 5,130,302; 5,134,066; 5,175,273; 5,367,066; 5,432,272; 5,457,187; 5,459,255; 5,484,908;

30 5,502,177; 5,525,711; 5,552,540; 5,587,469; 5,594,121; 5,596,091; 5,614,617; 5,645,985; 5,830,653; 5,763,588; 6,005,096; and 5,681,941, certain of which are commonly owned with the instant application, and each of which is herein incorporated by reference, and United States patent

ISPH-0728

-26-

PATENT

5,750,692, which is commonly owned with the instant application and also herein incorporated by reference.

Another modification of the oligonucleotides of the invention involves chemically linking to the oligonucleotide one or more moieties or conjugates which enhance the activity, cellular distribution or cellular uptake of the oligonucleotide. The compounds of the invention can include conjugate groups covalently bound to functional groups such as primary or secondary hydroxyl groups. Conjugate groups of the invention include intercalators, reporter molecules, polyamines, polyamides, polyethylene glycols, polyethers, groups that enhance the pharmacodynamic properties of oligomers, and groups that enhance the pharmacokinetic properties of oligomers. Typical conjugate groups include cholesterols, lipids, phospholipids, biotin, phenazine, folate, phenanthridine, anthraquinone, acridine, fluoresceins, rhodamines, coumarins, and dyes. Groups that enhance the pharmacodynamic properties, in the context of this invention, include groups that improve oligomer uptake, enhance oligomer resistance to degradation, and/or strengthen sequence-specific hybridization with RNA. Groups that enhance the pharmacokinetic properties, in the context of this invention, include groups that improve oligomer uptake, distribution, metabolism or excretion. Representative conjugate groups are disclosed in International Patent Application PCT/US92/09196, filed October 23, 1992 the entire disclosure of which is incorporated herein by reference. Conjugate moieties include but are not limited to lipid moieties such as a cholesterol moiety (Letsinger et al., *Proc. Natl. Acad. Sci. USA*, 1989, 86, 6553-6556), cholic acid (Manoharan et al., *Bioorg. Med. Chem. Let.*, 1994, 4, 1053-1060), a thioether, e.g., hexyl-S-tritylthiol (Manoharan et al., *Ann. N.Y. Acad. Sci.*, 1992, 660, 306-309; Manoharan et al., *Bioorg. Med. Chem. Let.*, 1993, 3, 2765-2770), a thiocholesterol (Oberhauser et al., *Nucl. Acids Res.*, 1992, 20, 533-538), an aliphatic chain,

e.g., dodecandiol or undecyl residues (Saison-Behmoaras et al., *EMBO J.*, 1991, 10, 1111-1118; Kabanov et al., *FEBS Lett.*, 1990, 259, 327-330; Svinarchuk et al., *Biochimie*, 1993, 75, 49-54), a phospholipid, e.g., di-hexadecyl-rac-glycerol or triethylammonium 1,2-di-O-hexadecyl-rac-glycero-3-H-phosphonate (Manoharan et al., *Tetrahedron Lett.*, 1995, 36, 3651-3654; Shea et al., *Nucl. Acids Res.*, 1990, 18, 3777-3783), a polyamine or a polyethylene glycol chain (Manoharan et al., *Nucleosides & Nucleotides*, 1995, 14, 969-973), or adamantane acetic acid (Manoharan et al., *Tetrahedron Lett.*, 1995, 36, 3651-3654), a palmityl moiety (Mishra et al., *Biochim. Biophys. Acta*, 1995, 1264, 229-237), or an octadecylamine or hexylamino-carbonyl-oxycholesterol moiety (Crooke et al., *J. Pharmacol. Exp. Ther.*, 1996, 277, 923-937). Oligonucleotides of the invention may also be conjugated to active drug substances, for example, aspirin, warfarin, phenylbutazone, ibuprofen, suprofen, fenbufen, ketoprofen, (S)-(+)-pranoprofen, carprofen, dansylsarcosine, 2,3,5-triiodobenzoic acid, flufenamic acid, folinic acid, a benzothiadiazide, chlorothiazide, a diazepine, indomethacin, a barbiturate, a cephalosporin, a sulfa drug, an antidiabetic, an antibacterial or an antibiotic. Oligonucleotide-drug conjugates and their preparation are described in United States Patent Application 09/334,130 (filed June 15, 1999) which is incorporated herein by reference in its entirety.

Representative United States patents that teach the preparation of such oligonucleotide conjugates include, but are not limited to, U.S.: 4,828,979; 4,948,882; 5,218,105; 5,525,465; 5,541,313; 5,545,730; 5,552,538; 5,578,717; 5,580,731; 5,580,731; 5,591,584; 5,109,124; 5,118,802; 5,138,045; 5,414,077; 5,486,603; 5,512,439; 5,578,718; 5,608,046; 4,587,044; 4,605,735; 4,667,025; 4,762,779; 4,789,737; 4,824,941; 4,835,263; 4,876,335; 4,904,582;

ISPH-0728

-28-

PATENT

4,958,013; 5,082,830; 5,112,963; 5,214,136; 5,082,830;
5,112,963; 5,214,136; 5,245,022; 5,254,469; 5,258,506;
5,262,536; 5,272,250; 5,292,873; 5,317,098; 5,371,241,
5,391,723; 5,416,203, 5,451,463; 5,510,475; 5,512,667;
5 5,514,785; 5,565,552; 5,567,810; 5,574,142; 5,585,481;
5,587,371; 5,595,726; 5,597,696; 5,599,923; 5,599,928 and
5,688,941, certain of which are commonly owned with the
instant application, and each of which is herein
incorporated by reference.

10 It is not necessary for all positions in a given
compound to be uniformly modified, and in fact more than one
of the aforementioned modifications may be incorporated in a
single compound or even at a single nucleoside within an
oligonucleotide. The present invention also includes
15 antisense compounds which are chimeric compounds.
"Chimeric" antisense compounds or "chimeras," in the context
of this invention, are antisense compounds, particularly
oligonucleotides, which contain two or more chemically
distinct regions, each made up of at least one monomer unit,
20 i.e., a nucleotide in the case of an oligonucleotide
compound. These oligonucleotides typically contain at least
one region wherein the oligonucleotide is modified so as to
confer upon the oligonucleotide increased resistance to
nuclease degradation, increased cellular uptake, increased
25 stability and/or increased binding affinity for the target
nucleic acid. An additional region of the oligonucleotide
may serve as a substrate for enzymes capable of cleaving
RNA:DNA or RNA:RNA hybrids. By way of example, RNase H is a
cellular endonuclease which cleaves the RNA strand of an
30 RNA:DNA duplex. Activation of RNase H, therefore, results
in cleavage of the RNA target, thereby greatly enhancing the
efficiency of oligonucleotide inhibition of gene expression.
The cleavage of RNA:RNA hybrids can, in like fashion, be
accomplished through the actions of endoribonucleases, such
35 as interferon-induced RNaseL which cleaves both cellular and
viral RNA. Consequently, comparable results can often be
obtained with shorter oligonucleotides when chimeric

ISPH-0728

-29-

PATENT

oligonucleotides are used, compared to phosphorothioate deoxyoligonucleotides hybridizing to the same target region. Cleavage of the RNA target can be routinely detected by gel electrophoresis and, if necessary, associated nucleic acid hybridization techniques known in the art.

Chimeric antisense compounds of the invention may be formed as composite structures of two or more oligonucleotides, modified oligonucleotides, oligonucleosides and/or oligonucleotide mimetics as described above. Such compounds have also been referred to in the art as hybrids or gapmers. Representative United States patents that teach the preparation of such hybrid structures include, but are not limited to, U.S.: 5,013,830; 5,149,797; 5,220,007; 5,256,775; 5,366,878; 5,403,711; 5,491,133; 5,565,350; 5,623,065; 5,652,355; 5,652,356; and 5,700,922, certain of which are commonly owned with the instant application, and each of which is herein incorporated by reference in its entirety.

The antisense compounds used in accordance with this invention may be conveniently and routinely made through the well-known technique of solid phase synthesis. Equipment for such synthesis is sold by several vendors including, for example, Applied Biosystems (Foster City, CA). Any other means for such synthesis known in the art may additionally or alternatively be employed. It is well known to use similar techniques to prepare oligonucleotides such as the phosphorothioates and alkylated derivatives.

The compounds of the invention may also be admixed, encapsulated, conjugated or otherwise associated with other molecules, molecule structures or mixtures of compounds, as for example, liposomes, receptor-targeted molecules, oral, rectal, topical or other formulations, for assisting in uptake, distribution and/or absorption. Representative United States patents that teach the preparation of such uptake, distribution and/or absorption-assisting formulations include, but are not limited to, U.S.: 5,108,921; 5,354,844; 5,416,016; 5,459,127; 5,521,291;

ISPH-0728

-30-

PATENT

5,543,158; 5,547,932; 5,583,020; 5,591,721; 4,426,330;
4,534,899; 5,013,556; 5,108,921; 5,213,804; 5,227,170;
5,264,221; 5,356,633; 5,395,619; 5,416,016; 5,417,978;
5,462,854; 5,469,854; 5,512,295; 5,527,528; 5,534,259;
5 5,543,152; 5,556,948; 5,580,575; and 5,595,756, each of
which is herein incorporated by reference.

The antisense compounds of the invention encompass any
pharmaceutically acceptable salts, esters, or salts of such
esters, or any other compound which, upon administration to
10 an animal, including a human, is capable of providing
(directly or indirectly) the biologically active metabolite
or residue thereof. Accordingly, for example, the
disclosure is also drawn to prodrugs and pharmaceutically
acceptable salts of the compounds of the invention,
15 pharmaceutically acceptable salts of such prodrugs, and
other bioequivalents.

The term "prodrug" indicates a therapeutic agent that
is prepared in an inactive form that is converted to an
active form (i.e., drug) within the body or cells thereof by
20 the action of endogenous enzymes or other chemicals and/or
conditions. In particular, prodrug versions of the
oligonucleotides of the invention are prepared as SATE
[(S-acetyl-2-thioethyl) phosphate] derivatives according to
the methods disclosed in WO 93/24510 to Gosselin et al.,
25 published December 9, 1993 or in WO 94/26764 and U.S.
5,770,713 to Imbach et al.

The term "pharmaceutically acceptable salts" refers to
physiologically and pharmaceutically acceptable salts of the
compounds of the invention: i.e., salts that retain the
30 desired biological activity of the parent compound and do
not impart undesired toxicological effects thereto.

Pharmaceutically acceptable base addition salts are
formed with metals or amines, such as alkali and alkaline
earth metals or organic amines. Examples of metals used as
35 cations are sodium, potassium, magnesium, calcium, and the
like. Examples of suitable amines are
N,N'-dibenzylethylenediamine, chlorprocaine, choline,

ISPH-0728

-31-

PATENT

diethanolamine, dicyclohexylamine, ethylenediamine, N-methylglucamine, and procaine (see, for example, Berge et al., "Pharmaceutical Salts," *J. of Pharma Sci.*, 1977, 66, 1-19). The base addition salts of said acidic compounds are prepared by contacting the free acid form with a sufficient amount of the desired base to produce the salt in the conventional manner. The free acid form may be regenerated by contacting the salt form with an acid and isolating the free acid in the conventional manner. The free acid forms differ from their respective salt forms somewhat in certain physical properties such as solubility in polar solvents, but otherwise the salts are equivalent to their respective free acid for purposes of the present invention. As used herein, a "pharmaceutical addition salt" includes a pharmaceutically acceptable salt of an acid form of one of the components of the compositions of the invention. These include organic or inorganic acid salts of the amines. Preferred acid salts are the hydrochlorides, acetates, salicylates, nitrates and phosphates. Other suitable pharmaceutically acceptable salts are well known to those skilled in the art and include basic salts of a variety of inorganic and organic acids, such as, for example, with inorganic acids, such as for example hydrochloric acid, hydrobromic acid, sulfuric acid or phosphoric acid; with organic carboxylic, sulfonic, sulfo or phospho acids or N-substituted sulfamic acids, for example acetic acid, propionic acid, glycolic acid, succinic acid, maleic acid, hydroxymaleic acid, methylmaleic acid, fumaric acid, malic acid, tartaric acid, lactic acid, oxalic acid, gluconic acid, glucaric acid, glucuronic acid, citric acid, benzoic acid, cinnamic acid, mandelic acid, salicylic acid, 4-aminosalicylic acid, 2-phenoxybenzoic acid, 2-acetoxybenzoic acid, embonic acid, nicotinic acid or isonicotinic acid; and with amino acids, such as the 20 alpha-amino acids involved in the synthesis of proteins in nature, for example glutamic acid or aspartic acid, and also with phenylacetic acid, methanesulfonic acid, ethanesulfonic

ISPH-0728

-32-

PATENT

acid, 2-hydroxyethanesulfonic acid, ethane-1,2-disulfonic acid, benzenesulfonic acid, 4-methylbenzenesulfonic acid, naphthalene-2-sulfonic acid, naphthalene-1,5-disulfonic acid, 2- or 3-phosphoglycerate, glucose-6-phosphate, 5 N-cyclohexylsulfamic acid (with the formation of cyclamates), or with other acid organic compounds, such as ascorbic acid. Pharmaceutically acceptable salts of compounds may also be prepared with a pharmaceutically acceptable cation. Suitable pharmaceutically acceptable 10 cations are well known to those skilled in the art and include alkaline, alkaline earth, ammonium and quaternary ammonium cations. Carbonates or hydrogen carbonates are also possible.

For oligonucleotides, preferred examples of 15 pharmaceutically acceptable salts include but are not limited to (a) salts formed with cations such as sodium, potassium, ammonium, magnesium, calcium, polyamines such as spermine and spermidine, etc.; (b) acid addition salts formed with inorganic acids, for example hydrochloric acid, 20 hydrobromic acid, sulfuric acid, phosphoric acid, nitric acid and the like; (c) salts formed with organic acids such as, for example, acetic acid, oxalic acid, tartaric acid, succinic acid, maleic acid, fumaric acid, gluconic acid, citric acid, malic acid, ascorbic acid, benzoic acid, 25 tannic acid, palmitic acid, alginic acid, polyglutamic acid, naphthalenesulfonic acid, methanesulfonic acid, p-toluenesulfonic acid, naphthalenedisulfonic acid, polygalacturonic acid, and the like; and (d) salts formed from elemental anions such as chlorine, bromine, and iodine.

30 The antisense compounds of the present invention can be utilized for diagnostics, therapeutics, prophylaxis and as research reagents and kits. For therapeutics, an animal, preferably a human, suspected of having a disease or disorder which can be treated by modulating the expression 35 of extracellular-signal-regulated kinase-6 is treated by administering antisense compounds in accordance with this invention. The compounds of the invention can be utilized

ISPH-0728

-33-

PATENT

in pharmaceutical compositions by adding an effective amount of an antisense compound to a suitable pharmaceutically acceptable diluent or carrier. Use of the antisense compounds and methods of the invention may also be useful
5 prophylactically, e.g., to prevent or delay infection, inflammation or tumor formation, for example.

The antisense compounds of the invention are useful for research and diagnostics, because these compounds hybridize to nucleic acids encoding extracellular-signal-regulated
10 kinase-6, enabling sandwich and other assays to easily be constructed to exploit this fact. Hybridization of the antisense oligonucleotides of the invention with a nucleic acid encoding extracellular-signal-regulated kinase-6 can be detected by means known in the art.. Such means may include
15 conjugation of an enzyme to the oligonucleotide, radiolabelling of the oligonucleotide or any other suitable detection means. Kits using such detection means for detecting the level of extracellular-signal-regulated kinase-6 in a sample may also be prepared.

20 The present invention also includes pharmaceutical compositions and formulations which include the antisense compounds of the invention. The pharmaceutical compositions of the present invention may be administered in a number of ways depending upon whether local or systemic treatment is
25 desired and upon the area to be treated. Administration may be topical (including ophthalmic and to mucous membranes including vaginal and rectal delivery), pulmonary, e.g., by inhalation or insufflation of powders or aerosols, including by nebulizer; intratracheal, intranasal, epidermal and
30 transdermal), oral or parenteral. Parenteral administration includes intravenous, intraarterial, subcutaneous, intraperitoneal or intramuscular injection or infusion; or intracranial, e.g., intrathecal or intraventricular, administration. Oligonucleotides with at least one 2'-O-methoxyethyl modification are believed to be particularly
35 useful for oral administration.

ISPH-0728

-34-

PATENT

Pharmaceutical compositions and formulations for topical administration may include transdermal patches, ointments, lotions, creams, gels, drops, suppositories, sprays, liquids and powders. Conventional pharmaceutical carriers, aqueous, powder or oily bases, thickeners and the like may be necessary or desirable. Coated condoms, gloves and the like may also be useful. Preferred topical formulations include those in which the oligonucleotides of the invention are in admixture with a topical delivery agent such as lipids, liposomes, fatty acids, fatty acid esters, steroids, chelating agents and surfactants. Preferred lipids and liposomes include neutral (e.g. dioleoylphosphatidyl DOPE ethanolamine, dimyristoylphosphatidyl choline DMPC, distearoylphosphatidyl choline) negative (e.g. dimyristoylphosphatidyl glycerol DMPG) and cationic (e.g. dioleoyltetramethylaminopropyl DOTAP and dioleoylphosphatidyl ethanolamine DOTMA). Oligonucleotides of the invention may be encapsulated within liposomes or may form complexes thereto, in particular to cationic liposomes. Alternatively, oligonucleotides may be complexed to lipids, in particular to cationic lipids. Preferred fatty acids and esters include but are not limited arachidonic acid, oleic acid, eicosanoic acid, lauric acid, caprylic acid, capric acid, myristic acid, palmitic acid, stearic acid, linoleic acid, linolenic acid, dicaprate, tricaprate, monoolein, dilaurin, glyceryl 1-monocaprate, 1-dodecylazacycloheptan-2-one, an acylcarnitine, an acylcholine, or a C₁₋₁₀ alkyl ester (e.g. isopropylmyristate IPM), monoglyceride, diglyceride or pharmaceutically acceptable salt thereof. Topical formulations are described in detail in United States patent application 09/315,298 filed on May 20, 1999 which is incorporated herein by reference in its entirety.

Compositions and formulations for oral administration include powders or granules, microparticulates, nanoparticulates, suspensions or solutions in water or non-aqueous media, capsules, gel capsules, sachets, tablets or

ISPH-0728

-35-

PATENT

minitabets. Thickeners, flavoring agents, diluents, emulsifiers, dispersing aids or binders may be desirable. Preferred oral formulations are those in which oligonucleotides of the invention are administered in

5 conjunction with one or more penetration enhancers surfactants and chelators. Preferred surfactants include fatty acids and/or esters or salts thereof, bile acids and/or salts thereof. Preferred bile acids/salts include chenodeoxycholic acid (CDCA) and ursodeoxychenodeoxycholic

10 acid (UDCA), cholic acid, dehydrocholic acid, deoxycholic acid, glucolic acid, glycholic acid, glycodeoxycholic acid, taurocholic acid, taurodeoxycholic acid, sodium tauro-24,25-dihydro-fusidate and sodium glycodihydrofusidate. Preferred fatty acids include arachidonic acid, undecanoic acid, oleic

15 acid, lauric acid, caprylic acid, capric acid, myristic acid, palmitic acid, stearic acid, linoleic acid, linolenic acid, dicaprate, tricaprate, monoolein, dilaurin, glyceryl 1-monocaprate, 1-dodecylazacycloheptan-2-one, an acylcarnitine, an acylcholine, or a monoglyceride, a

20 diglyceride or a pharmaceutically acceptable salt thereof (e.g. sodium). Also preferred are combinations of penetration enhancers, for example, fatty acids/salts in combination with bile acids/salts. A particularly preferred combination is the sodium salt of lauric acid, capric acid

25 and UDCA. Further penetration enhancers include polyoxyethylene-9-lauryl ether, polyoxyethylene-20-cetyl ether. Oligonucleotides of the invention may be delivered orally, in granular form including sprayed dried particles, or complexed to form micro or nanoparticles. Oligonucleotide

30 complexing agents include poly-amino acids; polyimines; polyacrylates; polyalkylacrylates, polyoxethanes, polyalkylcyanoacrylates; cationized gelatins, albumins, starches, acrylates, polyethyleneglycols (PEG) and starches;

35 polyalkylcyanoacrylates; DEAE-derivatized polyimines, pollulans, celluloses and starches. Particularly preferred complexing agents include chitosan, N-trimethylchitosan,

ISPH-0728

-36-

PATENT

poly-L-lysine, polyhistidine, polyornithine, polyspermines, protamine, polyvinylpyridine, polythiodiethylamino-methylethylene P(TDAE), polyaminostyrene (e.g. p-amino), poly(methylcyanoacrylate), poly(ethylcyanoacrylate),
5 poly(butylcyanoacrylate), poly(isobutylcyanoacrylate), poly(isohexylcyanoacrylate), DEAE-methacrylate, DEAE-hexylacrylate, DEAE-acrylamide, DEAE-albumin and DEAE-dextran, polymethylacrylate, polyhexylacrylate, poly(D,L-lactic acid), poly(DL-lactic-co-glycolic acid (PLGA),
10 alginate, and polyethyleneglycol (PEG). Oral formulations for oligonucleotides and their preparation are described in detail in United States applications 08/886,829 (filed July 1, 1997), 09/108,673 (filed July 1, 1998), 09/256,515 (filed February 23, 1999), 09/082,624 (filed May 21, 1998) and
15 09/315,298 (filed May 20, 1999), each of which is incorporated herein by reference in their entirety.

Compositions and formulations for parenteral, intrathecal or intraventricular administration may include sterile aqueous solutions which may also contain buffers,
20 diluents and other suitable additives such as, but not limited to, penetration enhancers, carrier compounds and other pharmaceutically acceptable carriers or excipients.

Pharmaceutical compositions of the present invention include, but are not limited to, solutions, emulsions, and
25 liposome-containing formulations. These compositions may be generated from a variety of components that include, but are not limited to, preformed liquids, self-emulsifying solids and self-emulsifying semisolids.

The pharmaceutical formulations of the present
30 invention, which may conveniently be presented in unit dosage form, may be prepared according to conventional techniques well known in the pharmaceutical industry. Such techniques include the step of bringing into association the active ingredients with the pharmaceutical carrier(s) or
35 excipient(s). In general, the formulations are prepared by uniformly and intimately bringing into association the active ingredients with liquid carriers or finely divided

solid carriers or both, and then, if necessary, shaping the product.

The compositions of the present invention may be formulated into any of many possible dosage forms such as, but not limited to, tablets, capsules, gel capsules, liquid syrups, soft gels, suppositories, and enemas. The compositions of the present invention may also be formulated as suspensions in aqueous, non-aqueous or mixed media. Aqueous suspensions may further contain substances which increase the viscosity of the suspension including, for example, sodium carboxymethylcellulose, sorbitol and/or dextran. The suspension may also contain stabilizers.

In one embodiment of the present invention the pharmaceutical compositions may be formulated and used as foams. Pharmaceutical foams include formulations such as, but not limited to, emulsions, microemulsions, creams, jellies and liposomes. While basically similar in nature these formulations vary in the components and the consistency of the final product. The preparation of such compositions and formulations is generally known to those skilled in the pharmaceutical and formulation arts and may be applied to the formulation of the compositions of the present invention.

25 Emulsions .

The compositions of the present invention may be prepared and formulated as emulsions. Emulsions are typically heterogenous systems of one liquid dispersed in another in the form of droplets usually exceeding 0.1 μm in diameter (Idson, in *Pharmaceutical Dosage Forms*, Lieberman, Rieger and Banker (Eds.), 1988, Marcel Dekker, Inc., New York, N.Y., volume 1, p. 199; Rosoff, in *Pharmaceutical Dosage Forms*, Lieberman, Rieger and Banker (Eds.), 1988, Marcel Dekker, Inc., New York, N.Y., Volume 1, p. 245; Block in *Pharmaceutical Dosage Forms*, Lieberman, Rieger and Banker (Eds.), 1988, Marcel Dekker, Inc., New York, N.Y., volume 2,

p. 335; Higuchi et al., in *Remington's Pharmaceutical Sciences*, Mack Publishing Co., Easton, PA, 1985, p. 301).

Emulsions are often biphasic systems comprising two immiscible liquid phases intimately mixed and dispersed with each other. In general, emulsions may be of either the water-in-oil (w/o) or the oil-in-water (o/w) variety. When an aqueous phase is finely divided into and dispersed as minute droplets into a bulk oily phase, the resulting composition is called a water-in-oil (w/o) emulsion. Alternatively, when an oily phase is finely divided into and dispersed as minute droplets into a bulk aqueous phase, the resulting composition is called an oil-in-water (o/w) emulsion. Emulsions may contain additional components in addition to the dispersed phases, and the active drug which may be present as a solution in either the aqueous phase, oily phase or itself as a separate phase. Pharmaceutical excipients such as emulsifiers, stabilizers, dyes, and anti-oxidants may also be present in emulsions as needed. Pharmaceutical emulsions may also be multiple emulsions that are comprised of more than two phases such as, for example, in the case of oil-in-water-in-oil (o/w/o) and water-in-oil-in-water (w/o/w) emulsions. Such complex formulations often provide certain advantages that simple binary emulsions do not. Multiple emulsions in which individual oil droplets of an o/w emulsion enclose small water droplets constitute a w/o/w emulsion. Likewise a system of oil droplets enclosed in globules of water stabilized in an oily continuous phase provides an o/w/o emulsion.

Emulsions are characterized by little or no thermodynamic stability. Often, the dispersed or discontinuous phase of the emulsion is well dispersed into the external or continuous phase and maintained in this form through the means of emulsifiers or the viscosity of the formulation. Either of the phases of the emulsion may be a semisolid or a solid, as is the case of emulsion-style ointment bases and creams. Other means of stabilizing emulsions entail the use of emulsifiers that may be

ISPH-0728

-39-

PATENT

incorporated into either phase of the emulsion. Emulsifiers may broadly be classified into four categories: synthetic surfactants, naturally occurring emulsifiers, absorption bases, and finely dispersed solids (Idson, in *Pharmaceutical*

- 5 *Dosage Forms*, Lieberman, Rieger and Banker (Eds.), 1988, Marcel Dekker, Inc., New York, N.Y., volume 1, p. 199).

- Synthetic surfactants, also known as surface active agents, have found wide applicability in the formulation of emulsions and have been reviewed in the literature (Rieger, 10 in *Pharmaceutical Dosage Forms*, Lieberman, Rieger and Banker (Eds.), 1988, Marcel Dekker, Inc., New York, N.Y., volume 1, p. 285; Idson, in *Pharmaceutical Dosage Forms*, Lieberman, Rieger and Banker (Eds.), Marcel Dekker, Inc., New York, N.Y., 1988, volume 1, p. 199). Surfactants are typically 15 amphiphilic and comprise a hydrophilic and a hydrophobic portion. The ratio of the hydrophilic to the hydrophobic nature of the surfactant has been termed the hydrophile/lipophile balance (HLB) and is a valuable tool in categorizing and selecting surfactants in the preparation of 20 formulations. Surfactants may be classified into different classes based on the nature of the hydrophilic group: nonionic, anionic, cationic and amphoteric (Rieger, in *Pharmaceutical Dosage Forms*, Lieberman, Rieger and Banker (Eds.), 1988, Marcel Dekker, Inc., New York, N.Y., volume 25 1, p. 285).

- Naturally occurring emulsifiers used in emulsion formulations include lanolin, beeswax, phosphatides, lecithin and acacia. Absorption bases possess hydrophilic properties such that they can soak up water to form w/o 30 emulsions yet retain their semisolid consistencies, such as anhydrous lanolin and hydrophilic petrolatum. Finely divided solids have also been used as good emulsifiers especially in combination with surfactants and in viscous preparations. These include polar inorganic solids, such as 35 heavy metal hydroxides, nonswelling clays such as bentonite,

ISPH-0728

-40-

PATENT

attapulгите, hectorite, kaolin, montmorillonite, colloidal aluminum silicate and colloidal magnesium aluminum silicate, pigments and nonpolar solids such as carbon or glyceryl tristearate.

5 A large variety of non-emulsifying materials are also included in emulsion formulations and contribute to the properties of emulsions. These include fats, oils, waxes, fatty acids, fatty alcohols, fatty esters, humectants, hydrophilic colloids, preservatives and antioxidants (Block,
10 in *Pharmaceutical Dosage Forms*, Lieberman, Rieger and Banker (Eds.), 1988, Marcel Dekker, Inc., New York, N.Y., volume 1, p. 335; Idson, in *Pharmaceutical Dosage Forms*, Lieberman, Rieger and Banker (Eds.), 1988, Marcel Dekker, Inc., New York, N.Y., volume 1, p. 199).

15 Hydrophilic colloids or hydrocolloids include naturally occurring gums and synthetic polymers such as polysaccharides (for example, acacia, agar, alginic acid, carrageenan, guar gum, karaya gum, and tragacanth), cellulose derivatives (for example, carboxymethylcellulose
20 and carboxypropylcellulose), and synthetic polymers (for example, carbomers, cellulose ethers, and carboxyvinyl polymers). These disperse or swell in water to form colloidal solutions that stabilize emulsions by forming strong interfacial films around the dispersed-phase droplets
25 and by increasing the viscosity of the external phase.

 Since emulsions often contain a number of ingredients such as carbohydrates, proteins, sterols and phosphatides that may readily support the growth of microbes, these formulations often incorporate preservatives. Commonly used
30 preservatives included in emulsion formulations include methyl paraben, propyl paraben, quaternary ammonium salts, benzalkonium chloride, esters of p-hydroxybenzoic acid, and boric acid. Antioxidants are also commonly added to emulsion formulations to prevent deterioration of the
35 formulation. Antioxidants used may be free radical scavengers such as tocopherols, alkyl gallates, butylated

ISPH-0728

-41-

PATENT

hydroxyanisole, butylated hydroxytoluene, or reducing agents such as ascorbic acid and sodium metabisulfite, and antioxidant synergists such as citric acid, tartaric acid, and lecithin.

5 The application of emulsion formulations via dermatological, oral and parenteral routes and methods for their manufacture have been reviewed in the literature (Idson, in *Pharmaceutical Dosage Forms*, Lieberman, Rieger and Banker (Eds.), 1988, Marcel Dekker, Inc., New York, N.Y., volume 1, p. 199). Emulsion formulations for oral
10 delivery have been very widely used because of ease of formulation, as well as efficacy from an absorption and bioavailability standpoint (Rosoff, in *Pharmaceutical Dosage Forms*, Lieberman, Rieger and Banker (Eds.), 1988, Marcel
15 Dekker, Inc., New York, N.Y., volume 1, p. 245; Idson, in *Pharmaceutical Dosage Forms*, Lieberman, Rieger and Banker (Eds.), 1988, Marcel Dekker, Inc., New York, N.Y., volume 1, p. 199). Mineral-oil base laxatives, oil-soluble vitamins and high fat nutritive preparations are among the materials
20 that have commonly been administered orally as o/w emulsions.

In one embodiment of the present invention, the compositions of oligonucleotides and nucleic acids are formulated as microemulsions. A microemulsion may be
25 defined as a system of water, oil and amphiphile which is a single optically isotropic and thermodynamically stable liquid solution (Rosoff, in *Pharmaceutical Dosage Forms*, Lieberman, Rieger and Banker (Eds.), 1988, Marcel Dekker, Inc., New York, N.Y., volume 1, p. 245). Typically
30 microemulsions are systems that are prepared by first dispersing an oil in an aqueous surfactant solution and then adding a sufficient amount of a fourth component, generally an intermediate chain-length alcohol to form a transparent system. Therefore, microemulsions have also been described
35 as thermodynamically stable, isotropically clear dispersions

ISPH-0728

-42-

PATENT

of two immiscible liquids that are stabilized by interfacial films of surface-active molecules (Leung and Shah, in: *Controlled Release of Drugs: Polymers and Aggregate Systems*, Rosoff, M., Ed., 1989, VCH Publishers, New York, pages 185-215). Microemulsions commonly are prepared via a combination of three to five components that include oil, water, surfactant, cosurfactant and electrolyte. Whether the microemulsion is of the water-in-oil (w/o) or an oil-in-water (o/w) type is dependent on the properties of the oil and surfactant used and on the structure and geometric packing of the polar heads and hydrocarbon tails of the surfactant molecules (Schott, in *Remington's Pharmaceutical Sciences*, Mack Publishing Co., Easton, PA, 1985, p. 271).

The phenomenological approach utilizing phase diagrams has been extensively studied and has yielded a comprehensive knowledge, to one skilled in the art, of how to formulate microemulsions (Rosoff, in *Pharmaceutical Dosage Forms*, Lieberman, Rieger and Banker (Eds.), 1988, Marcel Dekker, Inc., New York, N.Y., volume 1, p. 245; Block, in *Pharmaceutical Dosage Forms*, Lieberman, Rieger and Banker (Eds.), 1988, Marcel Dekker, Inc., New York, N.Y., volume 1, p. 335). Compared to conventional emulsions, microemulsions offer the advantage of solubilizing water-insoluble drugs in a formulation of thermodynamically stable droplets that are formed spontaneously.

Surfactants used in the preparation of microemulsions include, but are not limited to, ionic surfactants, non-ionic surfactants, Brij 96, polyoxyethylene oleyl ethers, polyglycerol fatty acid esters, tetraglycerol monolaurate (ML310), tetraglycerol monooleate (MO310), hexaglycerol monooleate (PO310), hexaglycerol pentaoleate (PO500), decaglycerol monocaprate (MCA750), decaglycerol monooleate (MO750), decaglycerol sequioleate (SO750), decaglycerol decaoleate (DAO750), alone or in combination with cosurfactants. The cosurfactant, usually a short-chain

ISPH-0728

-43-

PATENT

alcohol such as ethanol, 1-propanol, and 1-butanol, serves to increase the interfacial fluidity by penetrating into the surfactant film and consequently creating a disordered film because of the void space generated among surfactant molecules. Microemulsions may, however, be prepared without the use of cosurfactants and alcohol-free self-emulsifying microemulsion systems are known in the art. The aqueous phase may typically be, but is not limited to, water, an aqueous solution of the drug, glycerol, PEG300, PEG400, polyglycerols, propylene glycols, and derivatives of ethylene glycol. The oil phase may include, but is not limited to, materials such as Captex 300, Captex 355, Capmul MCM, fatty acid esters, medium chain (C8-C12) mono, di, and tri-glycerides, polyoxyethylated glyceryl fatty acid esters, fatty alcohols, polyglycolized glycerides, saturated polyglycolized C8-C10 glycerides, vegetable oils and silicone oil.

Microemulsions are particularly of interest from the standpoint of drug solubilization and the enhanced absorption of drugs. Lipid based microemulsions (both o/w and w/o) have been proposed to enhance the oral bioavailability of drugs, including peptides (Constantinides et al., *Pharmaceutical Research*, 1994, 11, 1385-1390; Ritschel, *Meth. Find. Exp. Clin. Pharmacol.*, 1993, 13, 205). Microemulsions afford advantages of improved drug solubilization, protection of drug from enzymatic hydrolysis, possible enhancement of drug absorption due to surfactant-induced alterations in membrane fluidity and permeability, ease of preparation, ease of oral administration over solid dosage forms, improved clinical potency, and decreased toxicity (Constantinides et al., *Pharmaceutical Research*, 1994, 11, 1385; Ho et al., *J. Pharm. Sci.*, 1996, 85, 138-143). Often microemulsions may form spontaneously when their components are brought together at ambient temperature. This may be particularly advantageous when formulating thermolabile drugs, peptides

ISPH-0728

-44-

PATENT

or oligonucleotides. Microemulsions have also been effective in the transdermal delivery of active components in both cosmetic and pharmaceutical applications. It is expected that the microemulsion compositions and
5 formulations of the present invention will facilitate the increased systemic absorption of oligonucleotides and nucleic acids from the gastrointestinal tract, as well as improve the local cellular uptake of oligonucleotides and nucleic acids within the gastrointestinal tract, vagina,
10 buccal cavity and other areas of administration.

Microemulsions of the present invention may also contain additional components and additives such as sorbitan monostearate (Grill 3), Labrasol, and penetration enhancers to improve the properties of the formulation and to enhance
15 the absorption of the oligonucleotides and nucleic acids of the present invention. Penetration enhancers used in the microemulsions of the present invention may be classified as belonging to one of five broad categories - surfactants, fatty acids, bile salts, chelating agents, and non-chelating
20 non-surfactants (Lee et al., *Critical Reviews in Therapeutic Drug Carrier Systems*, 1991, p. 92). Each of these classes has been discussed above.

Liposomes

25 There are many organized surfactant structures besides microemulsions that have been studied and used for the formulation of drugs. These include monolayers, micelles, bilayers and vesicles. Vesicles, such as liposomes, have attracted great interest because of their specificity and
30 the duration of action they offer from the standpoint of drug delivery. As used in the present invention, the term "liposome" means a vesicle composed of amphiphilic lipids arranged in a spherical bilayer or bilayers.

Liposomes are unilamellar or multilamellar vesicles
35 which have a membrane formed from a lipophilic material and an aqueous interior. The aqueous portion contains the composition to be delivered. Cationic liposomes possess the

ISPH-0728

-45-

PATENT

advantage of being able to fuse to the cell wall. Non-cationic liposomes, although not able to fuse as efficiently with the cell wall, are taken up by macrophages *in vivo*.

5 In order to cross intact mammalian skin, lipid vesicles must pass through a series of fine pores, each with a diameter less than 50 nm, under the influence of a suitable transdermal gradient. Therefore, it is desirable to use a liposome which is highly deformable and able to pass through such fine pores.

10 Further advantages of liposomes include; liposomes obtained from natural phospholipids are biocompatible and biodegradable; liposomes can incorporate a wide range of water and lipid soluble drugs; liposomes can protect encapsulated drugs in their internal compartments from
15 metabolism and degradation (Rosoff, in *Pharmaceutical Dosage Forms*, Lieberman, Rieger and Banker (Eds.), 1988, Marcel Dekker, Inc., New York, N.Y., volume 1, p. 245). Important considerations in the preparation of liposome formulations are the lipid surface charge, vesicle size and the aqueous
20 volume of the liposomes.

Liposomes are useful for the transfer and delivery of active ingredients to the site of action. Because the liposomal membrane is structurally similar to biological membranes, when liposomes are applied to a tissue, the
25 liposomes start to merge with the cellular membranes and as the merging of the liposome and cell progresses, the liposomal contents are emptied into the cell where the active agent may act.

Liposomal formulations have been the focus of extensive
30 investigation as the mode of delivery for many drugs. There is growing evidence that for topical administration, liposomes present several advantages over other formulations. Such advantages include reduced side-effects related to high systemic absorption of the administered
35 drug, increased accumulation of the administered drug at the

ISPH-0728

-46-

PATENT

desired target, and the ability to administer a wide variety of drugs, both hydrophilic and hydrophobic, into the skin.

Several reports have detailed the ability of liposomes to deliver agents including high-molecular weight DNA into
5 the skin. Compounds including analgesics, antibodies, hormones and high-molecular weight DNAs have been administered to the skin. The majority of applications resulted in the targeting of the upper epidermis.

Liposomes fall into two broad classes. Cationic
10 liposomes are positively charged liposomes which interact with the negatively charged DNA molecules to form a stable complex. The positively charged DNA/liposome complex binds to the negatively charged cell surface and is internalized in an endosome. Due to the acidic pH within the endosome,
15 the liposomes are ruptured, releasing their contents into the cell cytoplasm (Wang et al., *Biochem. Biophys. Res. Commun.*, 1987, 147, 980-985).

Liposomes which are pH-sensitive or negatively-charged, entrap DNA rather than complex with it. Since both the DNA
20 and the lipid are similarly charged, repulsion rather than complex formation occurs. Nevertheless, some DNA is entrapped within the aqueous interior of these liposomes. pH-sensitive liposomes have been used to deliver DNA encoding the thymidine kinase gene to cell monolayers in
25 culture. Expression of the exogenous gene was detected in the target cells (Zhou et al., *Journal of Controlled Release*, 1992, 19, 269-274).

One major type of liposomal composition includes phospholipids other than naturally-derived
30 phosphatidylcholine. Neutral liposome compositions, for example, can be formed from dimyristoyl phosphatidylcholine (DMPC) or dipalmitoyl phosphatidylcholine (DPPC). Anionic liposome compositions generally are formed from dimyristoyl phosphatidylglycerol, while anionic fusogenic liposomes are
35 formed primarily from dioleoyl phosphatidylethanolamine (DOPE). Another type of liposomal composition is formed

ISPH-0728

-47-

PATENT

from phosphatidylcholine (PC) such as, for example, soybean PC, and egg PC. Another type is formed from mixtures of phospholipid and/or phosphatidylcholine and/or cholesterol.

Several studies have assessed the topical delivery of liposomal drug formulations to the skin. Application of liposomes containing interferon to guinea pig skin resulted in a reduction of skin herpes sores while delivery of interferon via other means (e.g. as a solution or as an emulsion) were ineffective (Weiner et al., *Journal of Drug Targeting*, 1992, 2, 405-410). Further, an additional study tested the efficacy of interferon administered as part of a liposomal formulation to the administration of interferon using an aqueous system, and concluded that the liposomal formulation was superior to aqueous administration (du Plessis et al., *Antiviral Research*, 1992, 18, 259-265).

Non-ionic liposomal systems have also been examined to determine their utility in the delivery of drugs to the skin, in particular systems comprising non-ionic surfactant and cholesterol. Non-ionic liposomal formulations comprising Novasome™ I (glyceryl dilaurate/cholesterol/polyoxyethylene-10-stearyl ether) and Novasome™ II (glyceryl distearate/cholesterol/polyoxyethylene-10-stearyl ether) were used to deliver cyclosporin-A into the dermis of mouse skin. Results indicated that such non-ionic liposomal systems were effective in facilitating the deposition of cyclosporin-A into different layers of the skin (Hu et al. *S.T.P. Pharma. Sci.*, 1994, 4, 6, 466).

Liposomes also include "sterically stabilized" liposomes, a term which, as used herein, refers to liposomes comprising one or more specialized lipids that, when incorporated into liposomes, result in enhanced circulation lifetimes relative to liposomes lacking such specialized lipids. Examples of sterically stabilized liposomes are those in which part of the vesicle-forming lipid portion of

ISPH-0728

-48-

PATENT

the liposome (A) comprises one or more glycolipids, such as monosialoganglioside G_{M1} , or (B) is derivatized with one or more hydrophilic polymers, such as a polyethylene glycol (PEG) moiety. While not wishing to be bound by any particular theory, it is thought in the art that, at least for sterically stabilized liposomes containing gangliosides, sphingomyelin, or PEG-derivatized lipids, the enhanced circulation half-life of these sterically stabilized liposomes derives from a reduced uptake into cells of the reticuloendothelial system (RES) (Allen et al., *FEBS Letters*, 1987, 223, 42; Wu et al., *Cancer Research*, 1993, 53, 3765). Various liposomes comprising one or more glycolipids are known in the art. Papahadjopoulos et al. (*Ann. N.Y. Acad. Sci.*, 1987, 507, 64) reported the ability of monosialoganglioside G_{M1} , galactocerebroside sulfate and phosphatidylinositol to improve blood half-lives of liposomes. These findings were expounded upon by Gabizon et al. (*Proc. Natl. Acad. Sci. U.S.A.*, 1988, 85, 6949). U.S. Patent No. 4,837,028 and WO 88/04924, both to Allen et al., disclose liposomes comprising (1) sphingomyelin and (2) the ganglioside G_{M1} or a galactocerebroside sulfate ester. U.S. Patent No. 5,543,152 (Webb et al.) discloses liposomes comprising sphingomyelin. Liposomes comprising 1,2-sn-dimyristoylphosphatidylcholine are disclosed in WO 97/13499 (Lim et al.).

Many liposomes comprising lipids derivatized with one or more hydrophilic polymers, and methods of preparation thereof, are known in the art. Sunamoto et al. (*Bull. Chem. Soc. Jpn.*, 1980, 53, 2778) described liposomes comprising a nonionic detergent, 2C₁₂15G, that contains a PEG moiety. Illum et al. (*FEBS Lett.*, 1984, 167, 79) noted that hydrophilic coating of polystyrene particles with polymeric glycols results in significantly enhanced blood half-lives. Synthetic phospholipids modified by the attachment of

ISPH-0728

-49-

PATENT

carboxylic groups of polyalkylene glycols (e.g., PEG) are described by Sears (U.S. Patent Nos. 4,426,330 and 4,534,899). Klibanov et al. (*FEBS Lett.*, 1990, 268, 235) described experiments demonstrating that liposomes
5 comprising phosphatidylethanolamine (PE) derivatized with PEG or PEG stearate have significant increases in blood circulation half-lives. Blume et al. (*Biochimica et Biophysica Acta*, 1990, 1029, 91) extended such observations
10 to other PEG-derivatized phospholipids, e.g., DSPE-PEG, formed from the combination of distearoylphosphatidylethanolamine (DSPE) and PEG. Liposomes having covalently bound PEG moieties on their external surface are described in European Patent No. EP 0 445 131 B1 and WO 90/04384 to Fisher. Liposome compositions
15 containing 1-20 mole percent of PE derivatized with PEG, and methods of use thereof, are described by Woodle et al. (U.S. Patent Nos. 5,013,556 and 5,356,633) and Martin et al. (U.S. Patent No. 5,213,804 and European Patent No. EP 0 496 813 B1). Liposomes comprising a number of other lipid-polymer
20 conjugates are disclosed in WO 91/05545 and U.S. Patent No. 5,225,212 (both to Martin et al.) and in WO 94/20073 (Zalipsky et al.) Liposomes comprising PEG-modified ceramide lipids are described in WO 96/10391 (Choi et al.). U.S. Patent Nos. 5,540,935 (Miyazaki et al.) and 5,556,948
25 (Tagawa et al.) describe PEG-containing liposomes that can be further derivatized with functional moieties on their surfaces.

A limited number of liposomes comprising nucleic acids are known in the art. WO 96/40062 to Thierry et al.
30 discloses methods for encapsulating high molecular weight nucleic acids in liposomes. U.S. Patent No. 5,264,221 to Tagawa et al. discloses protein-bonded liposomes and asserts that the contents of such liposomes may include an antisense RNA. U.S. Patent No. 5,665,710 to Rahman et al. describes

ISPH-0728

-50-

PATENT

certain methods of encapsulating oligodeoxynucleotides in liposomes. WO 97/04787 to Love et al. discloses liposomes comprising antisense oligonucleotides targeted to the raf gene.

5 Transfersomes are yet another type of liposomes, and are highly deformable lipid aggregates which are attractive candidates for drug delivery vehicles. Transfersomes may be described as lipid droplets which are so highly deformable that they are easily able to penetrate through pores which
10 are smaller than the droplet. Transfersomes are adaptable to the environment in which they are used, e.g. they are self-optimizing (adaptive to the shape of pores in the skin), self-repairing, frequently reach their targets without fragmenting, and often self-loading. To make
15 transfersomes it is possible to add surface edge-activators, usually surfactants, to a standard liposomal composition. Transfersomes have been used to deliver serum albumin to the skin. The transfersome-mediated delivery of serum albumin has been shown to be as effective as subcutaneous injection
20 of a solution containing serum albumin.

Surfactants find wide application in formulations such as emulsions (including microemulsions) and liposomes. The most common way of classifying and ranking the properties of the many different types of surfactants, both natural and
25 synthetic, is by the use of the hydrophile/lipophile balance (HLB). The nature of the hydrophilic group (also known as the "head") provides the most useful means for categorizing the different surfactants used in formulations (Rieger, in *Pharmaceutical Dosage Forms*, Marcel Dekker, Inc., New York,
30 NY, 1988, p. 285).

If the surfactant molecule is not ionized, it is classified as a nonionic surfactant. Nonionic surfactants find wide application in pharmaceutical and cosmetic products and are usable over a wide range of pH values. In
35 general their HLB values range from 2 to about 18 depending on their structure. Nonionic surfactants include nonionic

esters such as ethylene glycol esters, propylene glycol esters, glyceryl esters, polyglyceryl esters, sorbitan esters, sucrose esters, and ethoxylated esters. Nonionic alkanolamides and ethers such as fatty alcohol ethoxylates, propoxylated alcohols, and ethoxylated/propoxylated block polymers are also included in this class. The polyoxyethylene surfactants are the most popular members of the nonionic surfactant class.

If the surfactant molecule carries a negative charge when it is dissolved or dispersed in water, the surfactant is classified as anionic. Anionic surfactants include carboxylates such as soaps, acyl lactylates, acyl amides of amino acids, esters of sulfuric acid such as alkyl sulfates and ethoxylated alkyl sulfates, sulfonates such as alkyl benzene sulfonates, acyl isethionates, acyl taurates and sulfosuccinates, and phosphates. The most important members of the anionic surfactant class are the alkyl sulfates and the soaps.

If the surfactant molecule carries a positive charge when it is dissolved or dispersed in water, the surfactant is classified as cationic. Cationic surfactants include quaternary ammonium salts and ethoxylated amines. The quaternary ammonium salts are the most used members of this class.

If the surfactant molecule has the ability to carry either a positive or negative charge, the surfactant is classified as amphoteric. Amphoteric surfactants include acrylic acid derivatives, substituted alkylamides, N-alkylbetaines and phosphatides.

The use of surfactants in drug products, formulations and in emulsions has been reviewed (Rieger, in *Pharmaceutical Dosage Forms*, Marcel Dekker, Inc., New York, NY, 1988, p. 285).

Penetration Enhancers

In one embodiment, the present invention employs various penetration enhancers to effect the efficient

ISPH-0728

-52-

PATENT

delivery of nucleic acids, particularly oligonucleotides, to the skin of animals. Most drugs are present in solution in both ionized and nonionized forms. However, usually only lipid soluble or lipophilic drugs readily cross cell
5 membranes. It has been discovered that even non-lipophilic drugs may cross cell membranes if the membrane to be crossed is treated with a penetration enhancer. In addition to aiding the diffusion of non-lipophilic drugs across cell membranes, penetration enhancers also enhance the
10 permeability of lipophilic drugs.

Penetration enhancers may be classified as belonging to one of five broad categories, i.e., surfactants, fatty acids, bile salts, chelating agents, and non-chelating non-surfactants (Lee et al., *Critical Reviews in Therapeutic*
15 *Drug Carrier Systems*, 1991, p.92). Each of the above mentioned classes of penetration enhancers are described below in greater detail.

Surfactants: In connection with the present invention,
20 surfactants (or "surface-active agents") are chemical entities which, when dissolved in an aqueous solution, reduce the surface tension of the solution or the interfacial tension between the aqueous solution and another liquid, with the result that absorption of oligonucleotides
25 through the mucosa is enhanced. In addition to bile salts and fatty acids, these penetration enhancers include, for example, sodium lauryl sulfate, polyoxyethylene-9-lauryl ether and polyoxyethylene-20-cetyl ether) (Lee et al., *Critical Reviews in Therapeutic Drug Carrier Systems*, 1991,
30 p.92); and perfluorochemical emulsions, such as FC-43. Takahashi et al., *J. Pharm. Pharmacol.*, 1988, 40, 252).

Fatty acids: Various fatty acids and their derivatives which act as penetration enhancers include, for example, oleic acid, lauric acid, capric acid (n-decanoic acid),
35 myristic acid, palmitic acid, stearic acid, linoleic acid, linolenic acid, dicaprates, tricaprates, monoolein (1-

monooleoyl-rac-glycerol), dilaurin, caprylic acid, arachidonic acid, glycerol 1-monocaprinate, 1-dodecylazacycloheptan-2-one, acylcarnitines, acylcholines, C₁₋₁₀ alkyl esters thereof (e.g., methyl, isopropyl and t-butyl), and mono- and di-glycerides thereof (i.e., oleate, laurate, caprate, myristate, palmitate, stearate, linoleate, etc.) (Lee et al., *Critical Reviews in Therapeutic Drug Carrier Systems*, 1991, p.92; Muranishi, *Critical Reviews in Therapeutic Drug Carrier Systems*, 1990, 7, 1-33; El Hariri et al., *J. Pharm. Pharmacol.*, 1992, 44, 651-654).

Bile salts: The physiological role of bile includes the facilitation of dispersion and absorption of lipids and fat-soluble vitamins (Brunton, Chapter 38 in: Goodman & Gilman's *The Pharmacological Basis of Therapeutics*, 9th Ed., Hardman et al. Eds., McGraw-Hill, New York, 1996, pp. 934-935). Various natural bile salts, and their synthetic derivatives, act as penetration enhancers. Thus the term "bile salts" includes any of the naturally occurring components of bile as well as any of their synthetic derivatives. The bile salts of the invention include, for example, cholic acid (or its pharmaceutically acceptable sodium salt, sodium cholate), dehydrocholic acid (sodium dehydrocholate), deoxycholic acid (sodium deoxycholate), glucolic acid (sodium glucolate), glycholic acid (sodium glycocholate), glycodeoxycholic acid (sodium glycodeoxycholate), taurocholic acid (sodium taurocholate), taurodeoxycholic acid (sodium taurodeoxycholate), chenodeoxycholic acid (sodium chenodeoxycholate), ursodeoxycholic acid (UDCA), sodium tauro-24,25-dihydro-fusidate (STDHF), sodium glycodihydrofusidate and polyoxyethylene-9-lauryl ether (POE) (Lee et al., *Critical Reviews in Therapeutic Drug Carrier Systems*, 1991, page 92; Swinyard, Chapter 39 In: *Remington's Pharmaceutical Sciences*, 18th Ed., Gennaro, ed.,

ISPH-0728

-54-

PATENT

Mack Publishing Co., Easton, PA, 1990, pages 782-783;
Muranishi, *Critical Reviews in Therapeutic Drug Carrier
Systems*, 1990, 7, 1-33; Yamamoto et al., *J. Pharm. Exp.
Ther.*, 1992, 263, 25; Yamashita et al., *J. Pharm. Sci.*,
5 1990, 79, 579-583).

Chelating Agents: Chelating agents, as used in
connection with the present invention, can be defined as
compounds that remove metallic ions from solution by forming
10 complexes therewith, with the result that absorption of
oligonucleotides through the mucosa is enhanced. With
regards to their use as penetration enhancers in the present
invention, chelating agents have the added advantage of also
serving as DNase inhibitors, as most characterized DNA
15 nucleases require a divalent metal ion for catalysis and are
thus inhibited by chelating agents (Jarrett, *J. Chromatogr.*,
1993, 618, 315-339). Chelating agents of the invention
include but are not limited to disodium
ethylenediaminetetraacetate (EDTA), citric acid, salicylates
20 (e.g., sodium salicylate, 5-methoxysalicylate and
homovanilate), N-acyl derivatives of collagen, laureth-9 and
N-amino acyl derivatives of beta-diketones (enamines) (Lee et
al.; *Critical Reviews in Therapeutic Drug Carrier Systems*,
1991, page 92; Muranishi, *Critical Reviews in Therapeutic
25 Drug Carrier Systems*, 1990, 7, 1-33; Buur et al., *J. Control
Rel.*, 1990, 14, 43-51).

Non-chelating non-surfactants: As used herein, non-
chelating non-surfactant penetration enhancing compounds can
30 be defined as compounds that demonstrate insignificant
activity as chelating agents or as surfactants but that
nonetheless enhance absorption of oligonucleotides through
the alimentary mucosa (Muranishi, *Critical Reviews in
Therapeutic Drug Carrier Systems*, 1990, 7, 1-33). This

ISPH-0728

-55-

PATENT

class of penetration enhancers include, for example, unsaturated cyclic ureas, 1-alkyl- and 1-alkenylazacyclo-alkanone derivatives (Lee et al., *Critical Reviews in Therapeutic Drug Carrier Systems*, 1991, page 92); and non-steroidal anti-inflammatory agents such as diclofenac sodium, indomethacin and phenylbutazone (Yamashita et al., *J. Pharm. Pharmacol.*, 1987, 39, 621-626).

Agents that enhance uptake of oligonucleotides at the cellular level may also be added to the pharmaceutical and other compositions of the present invention. For example, cationic lipids, such as lipofectin (Junichi et al, U.S. Patent No. 5,705,188), cationic glycerol derivatives, and polycationic molecules, such as polylysine (Lollo et al., PCT Application WO 97/30731), are also known to enhance the cellular uptake of oligonucleotides.

Other agents may be utilized to enhance the penetration of the administered nucleic acids, including glycols such as ethylene glycol and propylene glycol, pyrrols such as 2-pyrrol, azones, and terpenes such as limonene and menthone.

Carriers

Certain compositions of the present invention also incorporate carrier compounds in the formulation. As used herein, "carrier compound" or "carrier" can refer to a nucleic acid, or analog thereof, which is inert (i.e., does not possess biological activity *per se*) but is recognized as a nucleic acid by *in vivo* processes that reduce the bioavailability of a nucleic acid having biological activity by, for example, degrading the biologically active nucleic acid or promoting its removal from circulation. The coadministration of a nucleic acid and a carrier compound, typically with an excess of the latter substance, can result in a substantial reduction of the amount of nucleic acid recovered in the liver, kidney or other extracirculatory reservoirs, presumably due to competition between the

ISPH-0728

-56-

PATENT

carrier compound and the nucleic acid for a common receptor. For example, the recovery of a partially phosphorothioate oligonucleotide in hepatic tissue can be reduced when it is coadministered with polyinosinic acid, dextran sulfate, polycytidic acid or 4-acetamido-4'-isothiocyano-stilbene-2,2'-disulfonic acid (Miyao et al., *Antisense Res. Dev.*, 1995, 5, 115-121; Takakura et al., *Antisense & Nucl. Acid Drug Dev.*, 1996, 6, 177-183).

10 Excipients

In contrast to a carrier compound, a "pharmaceutical carrier" or "excipient" is a pharmaceutically acceptable solvent, suspending agent or any other pharmacologically inert vehicle for delivering one or more nucleic acids to an animal. The excipient may be liquid or solid and is selected, with the planned manner of administration in mind, so as to provide for the desired bulk, consistency, etc., when combined with a nucleic acid and the other components of a given pharmaceutical composition. Typical pharmaceutical carriers include, but are not limited to, binding agents (e.g., pregelatinized maize starch, polyvinylpyrrolidone or hydroxypropyl methylcellulose, etc.); fillers (e.g., lactose and other sugars, microcrystalline cellulose, pectin, gelatin, calcium sulfate, ethyl cellulose, polyacrylates or calcium hydrogen phosphate, etc.); lubricants (e.g., magnesium stearate, talc, silica, colloidal silicon dioxide, stearic acid, metallic stearates, hydrogenated vegetable oils, corn starch, polyethylene glycols, sodium benzoate, sodium acetate, etc.); disintegrants (e.g., starch, sodium starch glycolate, etc.); and wetting agents (e.g., sodium lauryl sulphate, etc.).

Pharmaceutically acceptable organic or inorganic excipient suitable for non-parenteral administration which do not deleteriously react with nucleic acids can also be

ISPH-0728

-57-

PATENT

used to formulate the compositions of the present invention. Suitable pharmaceutically acceptable carriers include, but are not limited to, water, salt solutions, alcohols, polyethylene glycols, gelatin, lactose, amylose, magnesium
5 stearate, talc, silicic acid, viscous paraffin, hydroxymethylcellulose, polyvinylpyrrolidone and the like.

Formulations for topical administration of nucleic acids may include sterile and non-sterile aqueous solutions, non-aqueous solutions in common solvents such as alcohols,
10 or solutions of the nucleic acids in liquid or solid oil bases. The solutions may also contain buffers, diluents and other suitable additives. Pharmaceutically acceptable organic or inorganic excipients suitable for non-parenteral administration which do not deleteriously react with nucleic
15 acids can be used.

Suitable pharmaceutically acceptable excipients include, but are not limited to, water, salt solutions, alcohol, polyethylene glycols, gelatin, lactose, amylose, magnesium stearate, talc, silicic acid, viscous paraffin,
20 hydroxymethylcellulose, polyvinylpyrrolidone and the like.

Other Components

The compositions of the present invention may additionally contain other adjunct components conventionally
25 found in pharmaceutical compositions, at their art-established usage levels. Thus, for example, the compositions may contain additional, compatible, pharmaceutically-active materials such as, for example, antipruritics, astringents, local anesthetics or
30 anti-inflammatory agents, or may contain additional materials useful in physically formulating various dosage forms of the compositions of the present invention, such as dyes, flavoring agents, preservatives, antioxidants, opacifiers, thickening agents and stabilizers. However,
35 such materials, when added, should not unduly interfere with the biological activities of the components of the compositions of the present invention. The formulations can

ISPH-0728

-58-

PATENT

be sterilized and, if desired, mixed with auxiliary agents, e.g., lubricants, preservatives, stabilizers, wetting agents, emulsifiers, salts for influencing osmotic pressure, buffers, colorings, flavorings and/or aromatic substances
5 and the like which do not deleteriously interact with the nucleic acid(s) of the formulation.

Aqueous suspensions may contain substances which increase the viscosity of the suspension including, for example, sodium carboxymethylcellulose, sorbitol and/or
10 dextran. The suspension may also contain stabilizers.

Certain embodiments of the invention provide pharmaceutical compositions containing (a) one or more antisense compounds and (b) one or more other chemotherapeutic agents which function by a non-antisense
15 mechanism. Examples of such chemotherapeutic agents include but are not limited to daunorubicin, daunomycin, dactinomycin, doxorubicin, epirubicin, idarubicin, esorubicin, bleomycin, mafosfamide, ifosfamide, cytosine arabinoside, bis-chloroethylnitrosurea, busulfan, mitomycin
20 C, actinomycin D, mithramycin, prednisone, hydroxyprogesterone, testosterone, tamoxifen, dacarbazine, procarbazine, hexamethylmelamine, pentamethylmelamine, mitoxantrone, amsacrine, chlorambucil, methylcyclohexylnitrosurea, nitrogen mustards, melphalan,
25 cyclophosphamide, 6-mercaptopurine, 6-thioguanine, cytarabine, 5-azacytidine, hydroxyurea, deoxycoformycin, 4-hydroxyperoxycyclophosphoramide, 5-fluorouracil (5-FU), 5-fluorodeoxyuridine (5-FUdR), methotrexate (MTX), colchicine, taxol, vincristine, vinblastine, etoposide (VP-16),
30 trimetrexate, irinotecan, topotecan, gemcitabine, teniposide, cisplatin and diethylstilbestrol (DES). See, generally, *The Merck Manual of Diagnosis and Therapy*, 15th Ed. 1987, pp. 1206-1228, Berkow et al., eds., Rahway, N.J. When used with the compounds of the invention, such
35 chemotherapeutic agents may be used individually (e.g., 5-FU and oligonucleotide), sequentially (e.g., 5-FU and

ISPH-0728

-60-

PATENT

given once or more daily, weekly, monthly or yearly, or even once every 2 to 20 years. Persons of ordinary skill in the art can easily estimate repetition rates for dosing based on measured residence times and concentrations of the drug in
5 bodily fluids or tissues. Following successful treatment, it may be desirable to have the patient undergo maintenance therapy to prevent the recurrence of the disease state, wherein the oligonucleotide is administered in maintenance doses, ranging from 0.01 ug to 100 g per kg of body weight,
10 once or more daily, to once every 20 years.

While the present invention has been described with specificity in accordance with certain of its preferred embodiments, the following examples serve only to illustrate the invention and are not intended to limit the same.

15

EXAMPLES**Example 1****Nucleoside Phosphoramidites for Oligonucleotide Synthesis**20 **Deoxy and 2'-alkoxy amidites**

2'-Deoxy and 2'-methoxy beta-cyanoethyl-diisopropyl phosphoramidites were purchased from commercial sources (e.g. Chemgenes, Needham MA or Glen Research, Inc. Sterling VA). Other 2'-O-alkoxy substituted nucleoside amidites are
25 prepared as described in U.S. Patent 5,506,351, herein incorporated by reference. For oligonucleotides synthesized using 2'-alkoxy amidites, optimized synthesis cycles were developed that incorporate multiple steps coupling longer wait times relative to standard synthesis cycles.

30 The following abbreviations are used in the text: thin layer chromatography (TLC), melting point (MP), high pressure liquid chromatography (HPLC), Nuclear Magnetic Resonance (NMR), argon (Ar), methanol (MeOH), dichloromethane (CH₂Cl₂), triethylamine (TEA), dimethyl
35 formamide (DMF), ethyl acetate (EtOAc), dimethyl sulfoxide (DMSO), tetrahydrofuran (THF).

ISPH-0728

-61-

PATENT

Oligonucleotides containing 5-methyl-2'-deoxycytidine (5-Me-dC) nucleotides were synthesized according to published methods (Sanghvi, et. al., *Nucleic Acids Research*, 1993, 21, 3197-3203) using commercially available

- 5 phosphoramidites (Glen Research, Sterling VA or ChemGenes, Needham MA) or prepared as follows:

Preparation of 5'-O-Dimethoxytrityl-thymidine intermediate for 5-methyl dC amidite

- 10 To a 50 L glass reactor equipped with air stirrer and Ar gas line was added thymidine (1.00 kg, 4.13 mol) in anhydrous pyridine (6 L) at ambient temperature. Dimethoxytrityl (DMT) chloride (1.47 kg, 4.34 mol, 1.05 eq) was added as a solid in four portions over 1 h. After 30
- 15 min, TLC indicated approx. 95% product, 2% thymidine, 5% DMT reagent and by-products and 2 % 3',5'-bis DMT product (R_f in EtOAc 0.45, 0.05, 0.98, 0.95 respectively). Saturated sodium bicarbonate (4 L) and CH_2Cl_2 were added with stirring (pH of the aqueous layer 7.5). An additional 18 L of water
- 20 was added, the mixture was stirred, the phases were separated, and the organic layer was transferred to a second 50 L vessel. The aqueous layer was extracted with additional CH_2Cl_2 (2 x 2 L). The combined organic layer was washed with water (10 L) and then concentrated in a rotary
- 25 evaporator to approx. 3.6 kg total weight. This was redissolved in CH_2Cl_2 (3.5 L), added to the reactor followed by water (6 L) and hexanes (13 L). The mixture was vigorously stirred and seeded to give a fine white suspended solid starting at the interface. After stirring for 1 h,
- 30 the suspension was removed by suction through a 1/2" diameter teflon tube into a 20 L suction flask, poured onto a 25 cm Coors Buchner funnel, washed with water (2 x 3 L) and a mixture of hexanes- CH_2Cl_2 (4:1, 2x3 L) and allowed to air dry overnight in pans (1" deep). This was further dried
- 35 in a vacuum oven (75°C, 0.1 mm Hg, 48 h) to a constant weight of 2072 g (93%) of a white solid, (mp 122-124°C).

ISPH-0728

-62-

PATENT

TLC indicated a trace contamination of the bis DMT product. NMR spectroscopy also indicated that 1-2 mole percent pyridine and about 5 mole percent of hexanes was still present.

5

Preparation of 5'-O-Dimethoxytrityl-2'-deoxy-5-methylcytidine intermediate for 5-methyl-dC amidite

To a 50 L Schott glass-lined steel reactor equipped with an electric stirrer, reagent addition pump (connected to an addition funnel), heating/cooling system, internal thermometer and an Ar gas line was added 5'-O-dimethoxytrityl-thymidine (3.00 kg, 5.51 mol), anhydrous acetonitrile (25 L) and TEA (12.3 L, 88.4 mol, 16 eq). The mixture was chilled with stirring to -10°C internal temperature (external -20°C). Trimethylsilylchloride (2.1 L, 16.5 mol, 3.0 eq) was added over 30 minutes while maintaining the internal temperature below -5°C, followed by a wash of anhydrous acetonitrile (1 L). Note: the reaction is mildly exothermic and copious hydrochloric acid fumes form over the course of the addition. The reaction was allowed to warm to 0°C and the reaction progress was confirmed by TLC (EtOAc-hexanes 4:1; R_f 0.43 to 0.84 of starting material and silyl product, respectively). Upon completion, triazole (3.05 kg, 44 mol, 8.0 eq) was added the reaction was cooled to -20°C internal temperature (external -30°C). Phosphorous oxychloride (1035 mL, 11.1 mol, 2.01 eq) was added over 60 min so as to maintain the temperature between -20°C and -10°C during the strongly exothermic process, followed by a wash of anhydrous acetonitrile (1 L). The reaction was warmed to 0 °C and stirred for 1 h. TLC indicated a complete conversion to the triazole product (R_f 0.83 to 0.34 with the product spot glowing in long wavelength UV light). The reaction mixture was a peach-colored thick suspension, which turned darker red upon warming without apparent decomposition. The reaction was cooled to -15°C internal temperature and water (5 L) was slowly added at a rate to maintain the temperature below

ISPH-0728

-63-

PATENT

+10°C in order to quench the reaction and to form a homogenous solution. (Caution: this reaction is initially very strongly exothermic). Approximately one-half of the reaction volume (22 L) was transferred by air pump to another vessel, diluted with EtOAc (12 L) and extracted with water (2 x 8 L). The combined water layers were back-extracted with EtOAc (6 L). The water layer was discarded and the organic layers were concentrated in a 20 L rotary evaporator to an oily foam. The foam was coevaporated with anhydrous acetonitrile (4 L) to remove EtOAc. (note: dioxane may be used instead of anhydrous acetonitrile if dried to a hard foam). The second half of the reaction was treated in the same way. Each residue was dissolved in dioxane (3 L) and concentrated ammonium hydroxide (750 mL) was added. A homogenous solution formed in a few minutes and the reaction was allowed to stand overnight (although the reaction is complete within 1 h).

TLC indicated a complete reaction (product R_f 0.35 in EtOAc-MeOH 4:1). The reaction solution was concentrated on a rotary evaporator to a dense foam. Each foam was slowly redissolved in warm EtOAc (4 L; 50°C), combined in a 50 L glass reactor vessel, and extracted with water (2 x 4L) to remove the triazole by-product. The water was back-extracted with EtOAc (2 L). The organic layers were combined and concentrated to about 8 kg total weight, cooled to 0°C and seeded with crystalline product. After 24 hours, the first crop was collected on a 25 cm Coors Buchner funnel and washed repeatedly with EtOAc (3 x 3L) until a white powder was left and then washed with ethyl ether (2 x 3L). The solid was put in pans (1'' deep) and allowed to air dry overnight. The filtrate was concentrated to an oil, then redissolved in EtOAc (2 L), cooled and seeded as before. The second crop was collected and washed as before (with proportional solvents) and the filtrate was first extracted with water (2 x 1L) and then concentrated to an oil. The residue was dissolved in EtOAc (1 L) and yielded a third

ISPH-0728

-64-

PATENT

crop which was treated as above except that more washing was required to remove a yellow oily layer.

After air-drying, the three crops were dried in a vacuum oven (50°C, 0.1 mm Hg, 24 h) to a constant weight (1750, 600 and 200 g, respectively) and combined to afford 2550 g (85%) of a white crystalline product (MP 215-217°C) when TLC and NMR spectroscopy indicated purity. The mother liquor still contained mostly product (as determined by TLC) and a small amount of triazole (as determined by NMR spectroscopy), bis DMT product and unidentified minor impurities. If desired, the mother liquor can be purified by silica gel chromatography using a gradient of MeOH (0-25%) in EtOAc to further increase the yield.

15 Preparation of 5'-O-Dimethoxytrityl-2'-deoxy-N⁴-benzoyl-5-methylcytidine penultimate intermediate for 5-methyl dC amidite

Crystalline 5'-O-dimethoxytrityl-5-methyl-2'-deoxycytidine (2000 g, 3.68 mol) was dissolved in anhydrous DMF (6.0 kg) at ambient temperature in a 50 L glass reactor vessel equipped with an air stirrer and argon line. Benzoic anhydride (Chem Impex not Aldrich, 874 g, 3.86 mol, 1.05 eq) was added and the reaction was stirred at ambient temperature for 8 h. TLC (CH₂Cl₂-EtOAc; CH₂Cl₂-EtOAc 4:1; R_f 0.25) indicated approx. 92% complete reaction. An additional amount of benzoic anhydride (44 g, 0.19 mol) was added. After a total of 18 h, TLC indicated approx. 96% reaction completion. The solution was diluted with EtOAc (20 L), TEA (1020 mL, 7.36 mol, ca 2.0 eq) was added with stirring, and the mixture was extracted with water (15 L, then 2 x 10 L). The aqueous layer was removed (no back-extraction was needed) and the organic layer was concentrated in 2 x 20 L rotary evaporator flasks until a foam began to form. The residues were coevaporated with acetonitrile (1.5 L each) and dried (0.1 mm Hg, 25°C, 24 h) to 2520 g of a dense foam. High pressure liquid

ISPH-0728

-65-

PATENT

chromatography (HPLC) revealed a contamination of 6.3% of N4, 3'-O-dibenzoyl product, but very little other impurities.

The product was purified by Biotage column chromatography (5 kg Biotage) prepared with 65:35:1 hexanes-EtOAc-TEA (4L). The crude product (800 g), dissolved in CH₂Cl₂ (2 L), was applied to the column. The column was washed with the 65:35:1 solvent mixture (20 kg), then 20:80:1 solvent mixture (10 kg), then 99:1 EtOAc:TEA (17kg). The fractions containing the product were collected, and any fractions containing the product and impurities were retained to be resubjected to column chromatography. The column was re-equilibrated with the original 65:35:1 solvent mixture (17 kg). A second batch of crude product (840 g) was applied to the column as before. The column was washed with the following solvent gradients: 65:35:1 (9 kg), 55:45:1 (20 kg), 20:80:1 (10 kg), and 99:1 EtOAc:TEA (15 kg). The column was reequilibrated as above, and a third batch of the crude product (850 g) plus impure fractions recycled from the two previous columns (28 g) was purified following the procedure for the second batch. The fractions containing pure product combined and concentrated on a 20L rotary evaporator, co-evaporated with acetontirile (3 L) and dried (0.1 mm Hg, 48 h, 25°C) to a constant weight of 2023 g (85%) of white foam and 20 g of slightly contaminated product from the third run. HPLC indicated a purity of 99.8% with the balance as the diBenzoyl product.

[5'-O-(4,4'-Dimethoxytriphenylmethyl)-2'-deoxy-N⁴-benzoyl-5-methylcytidin-3'-O-yl]-2-cyanoethyl-N,N-diisopropylphosphoramidite (5-methyl dC amidite)

5'-O-(4,4'-Dimethoxytriphenylmethyl)-2'-deoxy-N⁴-benzoyl-5-methylcytidine (998 g, 1.5 mol) was dissolved in anhydrous DMF (2 L). The solution was co-evaporated with toluene (300 ml) at 50°C under reduced pressure, then cooled to room temperature and 2-cyanoethyl

ISPH-0728

-66-

PATENT

tetraisopropylphosphorodiamidite (680 g, 2.26 mol) and tetrazole (52.5 g, 0.75 mol) were added. The mixture was shaken until all tetrazole was dissolved, N-methylimidazole (15 ml) was added and the mixture was left at room temperature for 5 hours. TEA (300 ml) was added, the mixture was diluted with DMF (2.5 L) and water (600 ml), and extracted with hexane (3 x 3 L). The mixture was diluted with water (1.2 L) and extracted with a mixture of toluene (7.5 L) and hexane (6 L). The two layers were separated, the upper layer was washed with DMF-water (7:3 v/v, 3 x 2 L) and water (3 x 2 L), and the phases were separated. The organic layer was dried (Na_2SO_4), filtered and rotary evaporated. The residue was co-evaporated with acetonitrile (2 x 2 L) under reduced pressure and dried to a constant weight (25 °C, 0.1mm Hg, 40 h) to afford 1250 g an off-white foam solid (96%).

2'-Fluoro amidites

2'-Fluorodeoxyadenosine amidites

2'-fluoro oligonucleotides were synthesized as described previously [Kawasaki, et. al., *J. Med. Chem.*, 1993, 36, 831-841] and United States patent 5,670,633, herein incorporated by reference. The preparation of 2'-fluoropyrimidines containing a 5-methyl substitution are described in US Patent 5,861,493. Briefly, the protected nucleoside N6-benzoyl-2'-deoxy-2'-fluoroadenosine was synthesized utilizing commercially available 9-beta-D-arabinofuranosyladenine as starting material and whereby the 2'-alpha-fluoro atom is introduced by a $\text{S}_{\text{N}}2$ -displacement of a 2'-beta-triflate group. Thus N6-benzoyl-9-beta-D-arabinofuranosyladenine was selectively protected in moderate yield as the 3',5'-ditetrahydropyranyl (THP) intermediate. Deprotection of the THP and N6-benzoyl groups was accomplished using standard methodologies to obtain the 5'-dimethoxytrityl-(DMT) and 5'-DMT-3'-phosphoramidite intermediates..

2'-Fluorodeoxyguanosine

The synthesis of 2'-deoxy-2'-fluoroguanosine was accomplished using tetraisopropylidisiloxanyl (TPDS) protected 9-beta-D-arabinofuranosylguanine as starting material, and conversion to the intermediate isobutyryl-arabinofuranosylguanosine. Alternatively, isobutyryl-arabinofuranosylguanosine was prepared as described by Ross et al., (Nucleosides & Nucleosides, 16, 1645, 1997). Deprotection of the TPDS group was followed by protection of the hydroxyl group with THP to give isobutyryl di-THP protected arabinofuranosylguanine. Selective O-deacylation and triflation was followed by treatment of the crude product with fluoride, then deprotection of the THP groups. Standard methodologies were used to obtain the 5'-DMT- and 5'-DMT-3'-phosphoramidites.

2'-Fluorouridine

Synthesis of 2'-deoxy-2'-fluorouridine was accomplished by the modification of a literature procedure in which 2,2'-anhydro-1-beta-D-arabinofuranosyluracil was treated with 70% hydrogen fluoride-pyridine. Standard procedures were used to obtain the 5'-DMT and 5'-DMT-3'phosphoramidites.

2'-Fluorodeoxycytidine

2'-deoxy-2'-fluorocytidine was synthesized via amination of 2'-deoxy-2'-fluorouridine, followed by selective protection to give N4-benzoyl-2'-deoxy-2'-fluorocytidine. Standard procedures were used to obtain the 5'-DMT and 5'-DMT-3'phosphoramidites.

2'-O-(2-Methoxyethyl) modified amidites

2'-O-Methoxyethyl-substituted nucleoside amidites (otherwise known as MOE amidites) are prepared as follows, or alternatively, as per the methods of Martin, P., (Helvetica Chimica Acta, 1995, 78, 486-504).

ISPH-0728

-68-

PATENT

Preparation of 2'-O-(2-methoxyethyl)-5-methyluridine
intermediate

2,2'-Anhydro-5-methyl-uridine (2000 g, 8.32 mol),
tris(2-methoxyethyl)borate (2504 g, 10.60 mol), sodium
5 bicarbonate (60 g, 0.70 mol) and anhydrous 2-methoxyethanol
(5 L) were combined in a 12 L three necked flask and heated
to 130 °C (internal temp) at atmospheric pressure, under an
argon atmosphere with stirring for 21 h. TLC indicated a
complete reaction. The solvent was removed under reduced
10 pressure until a sticky gum formed (50-85°C bath temp and
100-11 mm Hg) and the residue was redissolved in water (3 L)
and heated to boiling for 30 min in order the hydrolyze the
borate esters. The water was removed under reduced pressure
until a foam began to form and then the process was
15 repeated. HPLC indicated about 77% product, 15% dimer (5'
of product attached to 2' of starting material) and unknown
derivatives, and the balance was a single unresolved early
eluting peak.

The gum was redissolved in brine (3 L), and the flask
20 was rinsed with additional brine (3 L). The combined
aqueous solutions were extracted with chloroform (20 L) in a
heavier-than continuous extractor for 70 h. The chloroform
layer was concentrated by rotary evaporation in a 20 L flask
to a sticky foam (2400 g). This was coevaporated with MeOH
25 (400 mL) and EtOAc (8 L) at 75°C and 0.65 atm until the foam
dissolved at which point the vacuum was lowered to about 0.5
atm. After 2.5 L of distillate was collected a precipitate
began to form and the flask was removed from the rotary
evaporator and stirred until the suspension reached ambient
30 temperature. EtOAc (2 L) was added and the slurry was
filtered on a 25 cm table top Buchner funnel and the product
was washed with EtOAc (3 x 2 L). The bright white solid was
air dried in pans for 24 h then further dried in a vacuum
oven (50°C, 0.1 mm Hg, 24 h) to afford 1649 g of a white
35 crystalline solid (mp 115.5-116.5°C).

The brine layer in the 20 L continuous extractor was
further extracted for 72 h with recycled chloroform. The

ISPH-0728

-69-

PATENT

chloroform was concentrated to 120 g of oil and this was combined with the mother liquor from the above filtration (225 g), dissolved in brine (250 mL) and extracted once with chloroform (250 mL). The brine solution was continuously
5 extracted and the product was crystallized as described above to afford an additional 178 g of crystalline product containing about 2% of thymine. The combined yield was 1827 g (69.4%). HPLC indicated about 99.5% purity with the balance being the dimer.

10

Preparation of 5'-O-DMT-2'-O-(2-methoxyethyl)-5-methyluridine penultimate intermediate

In a 50 L glass-lined steel reactor, 2'-O-(2-methoxyethyl)-5-methyl-uridine (MOE-T, 1500 g, 4.738 mol),
15 lutidine (1015 g, 9.476 mol) were dissolved in anhydrous acetonitrile (15 L). The solution was stirred rapidly and chilled to -10°C (internal temperature). Dimethoxytriphenylmethyl chloride (1765.7 g, 5.21 mol) was added as a solid in one portion. The reaction was allowed
20 to warm to -2°C over 1 h. (Note: The reaction was monitored closely by TLC (EtOAc) to determine when to stop the reaction so as to not generate the undesired bis-DMT substituted side product). The reaction was allowed to warm from -2 to 3°C over 25 min. then quenched by adding MeOH
25 (300 mL) followed after 10 min by toluene (16 L) and water (16 L). The solution was transferred to a clear 50 L vessel with a bottom outlet, vigorously stirred for 1 minute, and the layers separated. The aqueous layer was removed and the organic layer was washed successively with 10% aqueous
30 citric acid (8 L) and water (12 L). The product was then extracted into the aqueous phase by washing the toluene solution with aqueous sodium hydroxide (0.5N, 16 L and 8 L). The combined aqueous layer was overlaid with toluene (12 L) and solid citric acid (8 moles, 1270 g) was added with
35 vigorous stirring to lower the pH of the aqueous layer to 5.5 and extract the product into the toluene. The organic

ISPH-0728

-70-

PATENT

layer was washed with water (10 L) and TLC of the organic layer indicated a trace of DMT-O-Me, bis DMT and dimer DMT.

The toluene solution was applied to a silica gel column (6 L sintered glass funnel containing approx. 2 kg of silica gel slurried with toluene (2 L) and TEA (25 mL)) and the fractions were eluted with toluene (12 L) and EtOAc (3 x 4 L) using vacuum applied to a filter flask placed below the column. The first EtOAc fraction containing both the desired product and impurities were resubjected to column chromatography as above. The clean fractions were combined, rotary evaporated to a foam, coevaporated with acetonitrile (6 L) and dried in a vacuum oven (0.1 mm Hg, 40 h, 40°C) to afford 2850 g of a white crisp foam. NMR spectroscopy indicated a 0.25 mole % remainder of acetonitrile (calculates to be approx. 47 g) to give a true dry weight of 2803 g (96%). HPLC indicated that the product was 99.41% pure, with the remainder being 0.06 DMT-O-Me, 0.10 unknown, 0.44 bis DMT, and no detectable dimer DMT or 3'-O-DMT.

20 **Preparation of [5'-O-(4,4'-Dimethoxytriphenylmethyl)-2'-O-(2-methoxyethyl)-5-methyluridin-3'-O-yl]-2-cyanoethyl-N,N-diisopropylphosphoramidite (MOE T amidite)**

5'-O-(4,4'-Dimethoxytriphenylmethyl)-2'-O-(2-methoxyethyl)-5-methyluridine (1237 g, 2.0 mol) was dissolved in anhydrous DMF (2.5 L). The solution was co-evaporated with toluene (200 ml) at 50°C under reduced pressure, then cooled to room temperature and 2-cyanoethyl tetraisopropylphosphorodiamidite (900 g, 3.0 mol) and tetrazole (70 g, 1.0 mol) were added. The mixture was shaken until all tetrazole was dissolved, N-methylimidazole (20 ml) was added and the solution was left at room temperature for 5 hours. TEA (300 ml) was added, the mixture was diluted with DMF (3.5 L) and water (600 ml) and extracted with hexane (3 x 3L). The mixture was diluted with water (1.6 L) and extracted with the mixture of toluene (12 L) and hexanes (9 L). The upper layer was washed with DMF-

ISPH-0728

-71-

PATENT

water (7:3 v/v, 3x3 L) and water (3x3 L). The organic layer was dried (Na_2SO_4), filtered and evaporated. The residue was co-evaporated with acetonitrile (2 x 2 L) under reduced pressure and dried in a vacuum oven (25°C, 0.1mm Hg, 40 h) to afford 1526 g of an off-white foamy solid (95%).

Preparation of 5'-O-Dimethoxytrityl-2'-O-(2-methoxyethyl)-5-methylcytidine intermediate

To a 50 L Schott glass-lined steel reactor equipped with an electric stirrer, reagent addition pump (connected to an addition funnel), heating/cooling system, internal thermometer and argon gas line was added 5'-O-dimethoxytrityl-2'-O-(2-methoxyethyl)-5-methyl-uridine (2.616 kg, 4.23 mol, purified by base extraction only and no scrub column), anhydrous acetonitrile (20 L), and TEA (9.5 L, 67.7 mol, 16 eq). The mixture was chilled with stirring to -10°C internal temperature (external -20°C). Trimethylsilylchloride (1.60 L, 12.7 mol, 3.0 eq) was added over 30 min. while maintaining the internal temperature below -5°C, followed by a wash of anhydrous acetonitrile (1 L). (Note: the reaction is mildly exothermic and copious hydrochloric acid fumes form over the course of the addition). The reaction was allowed to warm to 0°C and the reaction progress was confirmed by TLC (EtOAc, R_f 0.68 and 0.87 for starting material and silyl product, respectively). Upon completion, triazole (2.34 kg, 33.8 mol, 8.0 eq) was added the reaction was cooled to -20°C internal temperature (external -30°C). Phosphorous oxychloride (793 mL, 8.51 mol, 2.01 eq) was added slowly over 60 min so as to maintain the temperature between -20°C and -10°C (note: strongly exothermic), followed by a wash of anhydrous acetonitrile (1 L). The reaction was warmed to 0°C and stirred for 1 h, at which point it was an off-white thick suspension. TLC indicated a complete conversion to the triazole product (EtOAc, R_f 0.87 to 0.75 with the product spot glowing in long wavelength UV light). The reaction was cooled to -15°C and water (5 L) was slowly added at a rate to maintain the

ISPH-0728

-72-

PATENT

temperature below +10°C in order to quench the reaction and to form a homogenous solution. (Caution: this reaction is initially very strongly exothermic). Approximately one-half of the reaction volume (22 L) was transferred by air pump to another vessel, diluted with EtOAc (12 L) and extracted with water (2 x 8 L). The second half of the reaction was treated in the same way. The combined aqueous layers were back-extracted with EtOAc (8 L). The organic layers were combined and concentrated in a 20 L rotary evaporator to an oily foam. The foam was coevaporated with anhydrous acetonitrile (4 L) to remove EtOAc. (note: dioxane may be used instead of anhydrous acetonitrile if dried to a hard foam). The residue was dissolved in dioxane (2 L) and concentrated ammonium hydroxide (750 mL) was added. A homogenous solution formed in a few minutes and the reaction was allowed to stand overnight.

TLC indicated a complete reaction (CH_2Cl_2 -acetone-MeOH, 20:5:3, R_f 0.51). The reaction solution was concentrated on a rotary evaporator to a dense foam and slowly redissolved in warm CH_2Cl_2 (4 L, 40°C) and transferred to a 20 L glass extraction vessel equipped with a air-powered stirrer. The organic layer was extracted with water (2 x 6 L) to remove the triazole by-product. (Note: In the first extraction an emulsion formed which took about 2 h to resolve). The water layer was back-extracted with CH_2Cl_2 (2 x 2 L), which in turn was washed with water (3 L). The combined organic layer was concentrated in 2 x 20 L flasks to a gum and then recrystallized from EtOAc seeded with crystalline product. After sitting overnight, the first crop was collected on a 25 cm Coors Buchner funnel and washed repeatedly with EtOAc until a white free-flowing powder was left (about 3 x 3 L). The filtrate was concentrated to an oil recrystallized from EtOAc, and collected as above. The solid was air-dried in pans for 48 h, then further dried in a vacuum oven (50°C, 0.1mm Hg, 17 h) to afford 2248 g of a bright white, dense solid (86%). An HPLC analysis indicated both crops to be

ISPH-0728

-73-

PATENT

99.4% pure and NMR spectroscopy indicated only a faint trace of EtOAc remained.

Preparation of 5'-O-dimethoxytrityl-2'-O-(2-methoxyethyl)-

5 N4-benzoyl-5-methyl-cytidine penultimate intermediate:

Crystalline 5'-O-dimethoxytrityl-2'-O-(2-methoxyethyl)-5-methyl-cytidine (1000 g, 1.62 mol) was suspended in anhydrous DMF (3 kg) at ambient temperature and stirred under an Ar atmosphere. Benzoic anhydride (439.3 g, 1.94 mol) was added in one portion. The solution clarified after 5 hours and was stirred for 16 h. HPLC indicated 0.45% starting material remained (as well as 0.32% N4, 3'-O-bis Benzoyl). An additional amount of benzoic anhydride (6.0 g, 0.0265 mol) was added and after 17 h, HPLC indicated no starting material was present. TEA (450 mL, 3.24 mol) and toluene (6 L) were added with stirring for 1 minute. The solution was washed with water (4 x 4 L), and brine (2 x 4 L). The organic layer was partially evaporated on a 20 L rotary evaporator to remove 4 L of toluene and traces of water. HPLC indicated that the bis benzoyl side product was present as a 6% impurity. The residue was diluted with toluene (7 L) and anhydrous DMSO (200 mL, 2.82 mol) and sodium hydride (60% in oil, 70 g, 1.75 mol) was added in one portion with stirring at ambient temperature over 1 h. The reaction was quenched by slowly adding then washing with aqueous citric acid (10%, 100 mL over 10 min, then 2 x 4 L), followed by aqueous sodium bicarbonate (2%, 2 L), water (2 x 4 L) and brine (4 L). The organic layer was concentrated on a 20 L rotary evaporator to about 2 L total volume. The residue was purified by silica gel column chromatography (6 L Buchner funnel containing 1.5 kg of silica gel wetted with a solution of EtOAc-hexanes-TEA(70:29:1)). The product was eluted with the same solvent (30 L) followed by straight EtOAc (6 L). The fractions containing the product were combined, concentrated on a rotary evaporator to a foam and then dried in a vacuum oven (50°C, 0.2 mm Hg, 8 h) to afford

ISPH-0728

-74-

PATENT

1155 g of a crisp, white foam (98%). HPLC indicated a purity of >99.7%.

Preparation of [5'-O-(4,4'-Dimethoxytriphenylmethyl)-
5 2'-O-(2-methoxyethyl)-N⁴-benzoyl-5-methylcytidin-3'-O-yl]-2-
cyanoethyl-N,N-diisopropylphosphoramidite (MOE 5-Me-C
amidite)

5'-O-(4,4'-Dimethoxytriphenylmethyl)-2'-O-(2-
methoxyethyl)-N⁴-benzoyl-5-methylcytidine (1082 g, 1.5 mol)
10 was dissolved in anhydrous DMF (2 L) and co-evaporated with
toluene (300 ml) at 50 °C under reduced pressure. The mixture
was cooled to room temperature and 2-cyanoethyl
tetraisopropylphosphorodiamidite (680 g, 2.26 mol) and
tetrazole (52.5 g, 0.75 mol) were added. The mixture was
15 shaken until all tetrazole was dissolved, N-methylimidazole
(30 ml) was added, and the mixture was left at room
temperature for 5 hours. TEA (300 ml) was added, the
mixture was diluted with DMF (1 L) and water (400 ml) and
extracted with hexane (3 x 3 L). The mixture was diluted
20 with water (1.2 L) and extracted with a mixture of toluene
(9 L) and hexanes (6 L). The two layers were separated and
the upper layer was washed with DMF-water (60:40 v/v, 3 x 3
L) and water (3 x 2 L). The organic layer was dried
(Na₂SO₄), filtered and evaporated. The residue was co-
25 evaporated with acetonitrile (2 x 2 L) under reduced
pressure and dried in a vacuum oven (25 °C, 0.1mm Hg, 40 h)
to afford 1336 g of an off-white foam (97%).

Preparation of [5'-O-(4,4'-Dimethoxytriphenylmethyl)-
30 2'-O-(2-methoxyethyl)-N⁶-benzoyl-adenosin-3'-O-yl]-2-
cyanoethyl-N,N-diisopropylphosphoramidite (MOE A amidite)

5'-O-(4,4'-Dimethoxytriphenylmethyl)-2'-O-(2-
methoxyethyl)-N⁶-benzoyl-adenosine (purchased from Reliable
Biopharmaceutical, St. Lois, MO), 1098 g, 1.5 mol) was
35 dissolved in anhydrous DMF (3 L) and co-evaporated with

ISPH-0728

-75-

PATENT

toluene (300 ml) at 50 °C. The mixture was cooled to room temperature and 2-cyanoethyl tetraisopropylphosphorodiamidite (680 g, 2.26 mol) and tetrazole (78.8 g, 1.24 mol) were added. The mixture was
5 shaken until all tetrazole was dissolved, N-methylimidazole (30 ml) was added, and mixture was left at room temperature for 5 hours. TEA (300 ml) was added, the mixture was diluted with DMF (1 L) and water (400 ml) and extracted with hexanes (3 x 3 L). The mixture was diluted with water (1.4
10 L) and extracted with the mixture of toluene (9 L) and hexanes (6 L). The two layers were separated and the upper layer was washed with DMF-water (60:40, v/v, 3 x 3 L) and water (3 x 2 L). The organic layer was dried (Na₂SO₄), filtered and evaporated to a sticky foam. The residue was
15 co-evaporated with acetonitrile (2.5 L) under reduced pressure and dried in a vacuum oven (25 °C, 0.1mm Hg, 40 h) to afford 1350 g of an off-white foam solid (96%).

Preparation of [5'-O-(4,4'-Dimethoxytriphenylmethyl)-
20 2'-O-(2-methoxyethyl)-N⁴-isobutyrylguanosin-3'-O-yl]-2-cyanoethyl-N,N-diisopropylphosphoramidite (MOE G amidite)
5'-O-(4,4'-Dimethoxytriphenylmethyl)-2'-O-(2-methoxyethyl)-N⁴-isobutyrylguanosine (purchased from Reliable Biopharmaceutical, St. Louis, MO, 1426 g, 2.0 mol) was
25 dissolved in anhydrous DMF (2 L). The solution was co-evaporated with toluene (200 ml) at 50 °C, cooled to room temperature and 2-cyanoethyl tetraisopropylphosphorodiamidite (900 g, 3.0 mol) and tetrazole (68 g, 0.97 mol) were added. The mixture was
30 shaken until all tetrazole was dissolved, N-methylimidazole (30 ml) was added, and the mixture was left at room temperature for 5 hours. TEA (300 ml) was added, the mixture was diluted with DMF (2 L) and water (600 ml) and extracted with hexanes (3 x 3 L). The mixture was diluted
35 with water (2 L) and extracted with a mixture of toluene (10 L) and hexanes (5 L). The two layers were separated and the

ISPH-0728

-76-

PATENT

upper layer was washed with DMF-water (60:40, v/v, 3x3 L). EtOAc (4 L) was added and the solution was washed with water (3 x 4 L). The organic layer was dried (Na_2SO_4), filtered and evaporated to approx. 4 kg. Hexane (4 L) was added, the mixture was shaken for 10 min, and the supernatant liquid was decanted. The residue was co-evaporated with acetonitrile (2 x 2 L) under reduced pressure and dried in a vacuum oven (25 °C, 0.1mm Hg, 40 h) to afford 1660 g of an off-white foamy solid (91%).

10

2'-O-(Aminooxyethyl) nucleoside amidites and 2'-O-(dimethylaminooxyethyl) nucleoside amidites

2'-(Dimethylaminooxyethoxy) nucleoside amidites

2'-(Dimethylaminooxyethoxy) nucleoside amidites (also known in the art as 2'-O-(dimethylaminooxyethyl) nucleoside amidites) are prepared as described in the following paragraphs. Adenosine, cytidine and guanosine nucleoside amidites are prepared similarly to the thymidine (5-methyluridine) except the exocyclic amines are protected with a benzoyl moiety in the case of adenosine and cytidine and with isobutyryl in the case of guanosine.

5'-O-tert-Butyldiphenylsilyl-O²-2'-anhydro-5-methyluridine

O²-2'-anhydro-5-methyluridine (Pro. Bio. Sint., Varese, Italy, 100.0g, 0.416 mmol), dimethylaminopyridine (0.66g, 0.013eq, 0.0054mmol) were dissolved in dry pyridine (500 ml) at ambient temperature under an argon atmosphere and with mechanical stirring. tert-Butyldiphenylchlorosilane (125.8g, 119.0mL, 1.1eq, 0.458mmol) was added in one portion. The reaction was stirred for 16 h at ambient temperature. TLC (R_f 0.22, EtOAc) indicated a complete reaction. The solution was concentrated under reduced pressure to a thick oil. This was partitioned between CH_2Cl_2 (1 L) and saturated sodium bicarbonate (2 x 1 L) and brine (1 L). The organic layer was dried over sodium sulfate,

ISPH-0728

-77-

PATENT

filtered, and concentrated under reduced pressure to a thick oil. The oil was dissolved in a 1:1 mixture of EtOAc and ethyl ether (600mL) and cooling the solution to -10°C afforded a white crystalline solid which was collected by
5 filtration, washed with ethyl ether (3 x2 00 mL) and dried (40°C, 1mm Hg, 24 h) to afford 149g of white solid (74.8%). TLC and NMR spectroscopy were consistent with pure product.

10 5'-O-tert-Butyldiphenylsilyl-2'-O-(2-hydroxyethyl)-5-methyluridine

In the fume hood, ethylene glycol (350 mL, excess) was added cautiously with manual stirring to a 2 L stainless steel pressure reactor containing borane in tetrahydrofuran (1.0 M, 2.0 eq, 622 mL). (Caution : evolves hydrogen gas).
15 5'-O-tert-Butyldiphenylsilyl-O²-2'-anhydro-5-methyluridine (149 g, 0.311 mol) and sodium bicarbonate (0.074 g, 0.003 eq) were added with manual stirring. The reactor was sealed and heated in an oil bath until an internal temperature of 160 °C was reached and then maintained for 16 h (pressure <
20 100 psig). The reaction vessel was cooled to ambient temperature and opened. TLC (EtOAc, R_f 0.67 for desired product and R_f 0.82 for ara-T side product) indicated about 70% conversion to the product. The solution was concentrated under reduced pressure (10 to 1mm Hg) in a warm
25 water bath (40-100°C) with the more extreme conditions used to remove the ethylene glycol. (Alternatively, once the THF has evaporated the solution can be diluted with water and the product extracted into EtOAc). The residue was purified by column chromatography (2kg silica gel, EtOAc-hexanes
30 gradient 1:1 to 4:1). The appropriate fractions were combined, evaporated and dried to afford 84 g of a white crisp foam (50%), contaminated starting material (17.4g, 12% recovery) and pure reusable starting material (20g, 13% recovery). TLC and NMR spectroscopy were consistent with
35 99% pure product.

ISPH-0728

-78-

PATENT

2'-O-([2-phthalimidoxy)ethyl]-5'-t-butylidiphenylsilyl-
5-methyluridine

5'-O-tert-Butylidiphenylsilyl-2'-O-(2-hydroxyethyl)-5-methyluridine (20g, 36.98mmol) was mixed with
5 triphenylphosphine (11.63g, 44.36mmol) and N-hydroxyphthalimide (7.24g, 44.36mmol) and dried over P₂O₅ under high vacuum for two days at 40°C. The reaction mixture was flushed with argon and dissolved in dry THF (369.8mL, Aldrich, sure seal bottle). Diethyl-azodicarboxylate
10 (6.98mL, 44.36mmol) was added dropwise to the reaction mixture with the rate of addition maintained such that the resulting deep red coloration is just discharged before adding the next drop. The reaction mixture was stirred for 4 hrs., after which time TLC (EtOAc:hexane, 60:40) indicated
15 that the reaction was complete. The solvent was evaporated in vacuo and the residue purified by flash column chromatography (eluted with 60:40 EtOAc:hexane), to yield 2'-O-([2-phthalimidoxy)ethyl]-5'-t-butylidiphenylsilyl-5-methyluridine as white foam (21.819 g, 86%) upon rotary
20 evaporation.

5'-O-tert-butylidiphenylsilyl-2'-O-[(2-formadoximinooxy)ethyl]-5-methyluridine

2'-O-([2-phthalimidoxy)ethyl]-5'-t-butylidiphenylsilyl-
25 5-methyluridine (3.1g, 4.5mmol) was dissolved in dry CH₂Cl₂ (4.5mL) and methylhydrazine (300mL, 4.64mmol) was added dropwise at -10°C to 0°C. After 1 h the mixture was filtered, the filtrate washed with ice cold CH₂Cl₂, and the combined organic phase was washed with water and brine and
30 dried (anhydrous Na₂SO₄). The solution was filtered and evaporated to afford 2'-O-(aminooxyethyl) thymidine, which was then dissolved in MeOH (67.5mL). Formaldehyde (20% aqueous solution, w/w, 1.1 eq.) was added and the resulting mixture was stirred for 1 h. The solvent was removed under
35 vacuum and the residue was purified by column chromatography

ISPH-0728

-79-

PATENT

to yield 5'-O-tert-butyldiphenylsilyl-2'-O-[(2-formadoximinooxy) ethyl]-5-methyluridine as white foam (1.95 g, 78%) upon rotary evaporation.

- 5 5'-O-tert-Butyldiphenylsilyl-2'-O-[N,N
 dimethylaminooxyethyl]-5-methyluridine
 5'-O-tert-butyldiphenylsilyl-2'-O-[(2-
formadoximinooxy)ethyl]-5-methyluridine (1.77g, 3.12mmol)
was dissolved in a solution of 1M pyridinium p-
10 toluenesulfonate (PPTS) in dry MeOH (30.6mL) and cooled to
10°C under inert atmosphere. Sodium cyanoborohydride (0.39g,
6.13mmol) was added and the reaction mixture was stirred.
After 10 minutes the reaction was warmed to room temperature
and stirred for 2 h. while the progress of the reaction was
15 monitored by TLC (5% MeOH in CH₂Cl₂). Aqueous NaHCO₃
solution (5%, 10mL) was added and the product was extracted
with EtOAc (2 x 20 mL). The organic phase was dried over
anhydrous Na₂SO₄, filtered, and evaporated to dryness. This
entire procedure was repeated with the resulting residue,
20 with the exception that formaldehyde (20% w/w, 30 mL, 3.37
mol) was added upon dissolution of the residue in the
PPTS/MeOH solution. After the extraction and evaporation,
the residue was purified by flash column chromatography and
(eluted with 5% MeOH in CH₂Cl₂) to afford 5'-O-tert-
25 butyldiphenylsilyl-2'-O-[N,N-dimethylaminooxyethyl]-5-
methyluridine as a white foam (14.6g, 80%) upon rotary
evaporation.

- 2'-O-(dimethylaminooxyethyl)-5-methyluridine
30 Triethylamine trihydrofluoride (3.91mL, 24.0mmol) was
dissolved in dry THF and TEA (1.67mL, 12mmol, dry, stored
over KOH) and added to 5'-O-tert-butyldiphenylsilyl-2'-O-
[N,N-dimethylaminooxyethyl]-5-methyluridine (1.40g,
2.4mmol). The reaction was stirred at room temperature for
35 24 hrs and monitored by TLC (5% MeOH in CH₂Cl₂). The solvent

ISPH-0728

-80-

PATENT

was removed under vacuum and the residue purified by flash column chromatography (eluted with 10% MeOH in CH_2Cl_2) to afford 2'-O-(dimethylaminoxyethyl)-5-methyluridine (766mg, 92.5%) upon rotary evaporation of the solvent.

5

5'-O-DMT-2'-O-(dimethylaminoxyethyl)-5-methyluridine 2'-O-(dimethylaminoxyethyl)-5-methyluridine (750 mg, 2.17 mmol) was dried over P_2O_5 under high vacuum overnight at 40°C, co-evaporated with anhydrous pyridine (20 mL), and dissolved in pyridine (11 mL) under argon atmosphere. 4-dimethylaminopyridine (26.5 mg, 2.60 mmol) and 4,4'-dimethoxytrityl chloride (880 mg, 2.60 mmol) were added to the pyridine solution and the reaction mixture was stirred at room temperature until all of the starting material had reacted. Pyridine was removed under vacuum and the residue was purified by column chromatography (eluted with 10% MeOH in CH_2Cl_2 containing a few drops of pyridine) to yield 5'-O-DMT-2'-O-(dimethylamino-oxyethyl)-5-methyluridine (1.13g, 80%) upon rotary evaporation.

20

5'-O-DMT-2'-O-(2-N,N-dimethylaminoxyethyl)-5-methyluridine-3'-[(2-cyanoethyl)-N,N-diisopropylphosphoramidite]

5'-O-DMT-2'-O-(dimethylaminoxyethyl)-5-methyluridine (1.08 g, 1.67 mmol) was co-evaporated with toluene (20 mL), N,N-diisopropylamine tetrazonide (0.29 g, 1.67 mmol) was added and the mixture was dried over P_2O_5 under high vacuum overnight at 40°C. This was dissolved in anhydrous acetonitrile (8.4 mL) and 2-cyanoethyl-N,N,N¹,N¹-tetraisopropylphosphoramidite (2.12 mL, 6.08 mmol) was added. The reaction mixture was stirred at ambient temperature for 4 h under inert atmosphere. The progress of the reaction was monitored by TLC (hexane:EtOAc 1:1). The solvent was evaporated, then the residue was dissolved in EtOAc (70mL) and washed with 5% aqueous NaHCO_3 (40mL). The EtOAc layer was dried over anhydrous Na_2SO_4 , filtered, and

35

ISPH-0728

-81-

PATENT

concentrated. The residue obtained was purified by column chromatography (EtOAc as eluent) to afford 5'-O-DMT-2'-O-(2-N,N-dimethylaminooxyethyl)-5-methyluridine-3'-[(2-cyanoethyl)-N,N-diisopropylphosphoramidite] as a foam
5 (1.04g, 74.9%) upon rotary evaporation.

2'-(Aminooxyethoxy) nucleoside amidites

2'-(Aminooxyethoxy) nucleoside amidites (also known in the art as 2'-O-(aminooxyethyl) nucleoside amidites) are
10 prepared as described in the following paragraphs. Adenosine, cytidine and thymidine nucleoside amidites are prepared similarly.

N2-isobutyryl-6-O-diphenylcarbamoyl-2'-O-(2-ethylacetyl)-5'-O-(4,4'-dimethoxytrityl)guanosine-3'-[(2-cyanoethyl)-N,N-diisopropylphosphoramidite]
15

The 2'-O-aminooxyethyl guanosine analog may be obtained by selective 2'-O-alkylation of diaminopurine riboside. Multigram quantities of diaminopurine riboside may be
20 purchased from Schering AG (Berlin) to provide 2'-O-(2-ethylacetyl) diaminopurine riboside along with a minor amount of the 3'-O-isomer. 2'-O-(2-ethylacetyl) diaminopurine riboside may be resolved and converted to 2'-O-(2-ethylacetyl)guanosine by treatment with adenosine
25 deaminase. (McGee, D. P. C., Cook, P. D., Guinosso, C. J., WO 94/02501 A1 940203.) Standard protection procedures should afford 2'-O-(2-ethylacetyl)-5'-O-(4,4'-dimethoxytrityl)guanosine and 2-N-isobutyryl-6-O-diphenylcarbamoyl-2'-O-(2-ethylacetyl)-5'-O-(4,4'-
30 dimethoxytrityl)guanosine which may be reduced to provide 2-N-isobutyryl-6-O-diphenylcarbamoyl-2'-O-(2-hydroxyethyl)-5'-O-(4,4'-dimethoxytrityl)guanosine. As before the hydroxyl group may be displaced by N-hydroxyphthalimide via a Mitsunobu reaction, and the protected nucleoside may be
35 phosphitylated as usual to yield 2-N-isobutyryl-6-O-diphenylcarbamoyl-2'-O-([2-phthalamidoxy]ethyl)-5'-O-(4,4'-

ISPH-0728

-82-

PATENT

dimethoxytrityl)guanosine-3'-[(2-cyanoethyl)-N,N-diisopropylphosphoramidite].

2'-dimethylaminoethoxyethoxy (2'-DMAEOE) nucleoside amidites

5 2'-dimethylaminoethoxyethoxy nucleoside amidites (also known in the art as 2'-O-dimethylaminoethoxyethyl, i.e., 2'-O-CH₂-O-CH₂-N(CH₂)₂, or 2'-DMAEOE nucleoside amidites) are prepared as follows. Other nucleoside amidites are prepared similarly.

10

2'-O-[2(2-N,N-dimethylaminoethoxy)ethyl]-5-methyl uridine

2[2-(Dimethylamino)ethoxy]ethanol (Aldrich, 6.66 g, 50 mmol) was slowly added to a solution of borane in tetrahydrofuran (1 M, 10 mL, 10 mmol) with stirring in a 100 mL
15 bomb. (Caution: Hydrogen gas evolves as the solid dissolves). O²-,2'-anhydro-5-methyluridine (1.2 g, 5 mmol), and sodium bicarbonate (2.5 mg) were added and the bomb was sealed, placed in an oil bath and heated to 155°C for 26 h. then cooled to room temperature. The crude solution was
20 concentrated, the residue was diluted with water (200 mL) and extracted with hexanes (200 mL). The product was extracted from the aqueous layer with EtOAc (3 x 200 mL) and the combined organic layers were washed once with water, dried over anhydrous sodium sulfate, filtered and
25 concentrated. The residue was purified by silica gel column chromatography (eluted with 5:100:2 MeOH/CH₂Cl₂/TEA) as the eluent. The appropriate fractions were combined and evaporated to afford the product as a white solid.

30 **5'-O-dimethoxytrityl-2'-O-[2(2-N,N-dimethylaminoethoxy)ethyl]-5-methyl uridine**

To 0.5 g (1.3 mmol) of 2'-O-[2(2-N,N-dimethylaminoethoxy)ethyl]-5-methyl uridine in anhydrous pyridine (8 mL), was added TEA (0.36 mL) and dimethoxytrityl chloride
35 (DMT-Cl, 0.87 g, 2 eq.) and the reaction was stirred for 1 h. The reaction mixture was poured into water (200 mL) and

ISPH-0728

-83-

PATENT

extracted with CH_2Cl_2 (2 x 200 mL). The combined CH_2Cl_2 layers were washed with saturated NaHCO_3 solution, followed by saturated NaCl solution, dried over anhydrous sodium sulfate, filtered and evaporated. The residue was purified
5 by silica gel column chromatography (eluted with 5:100:1 $\text{MeOH}/\text{CH}_2\text{Cl}_2/\text{TEA}$) to afford the product.

5'-O-Dimethoxytrityl-2'-O-[2(2-N,N-dimethylaminoethoxy)ethyl]-5-methyl uridine-3'-O-
10 (cyanoethyl-N,N-diisopropyl)phosphoramidite
Diisopropylaminotetrazolide (0.6 g) and 2-cyanoethoxy-N,N-diisopropyl phosphoramidite (1.1 mL, 2 eq.) were added to a solution of 5'-O-dimethoxytrityl-2'-O-[2(2-N,N-dimethylaminoethoxy)ethyl]-5-methyluridine (2.17 g, 3 mmol)
15 dissolved in CH_2Cl_2 (20 mL) under an atmosphere of argon. The reaction mixture was stirred overnight and the solvent evaporated. The resulting residue was purified by silica gel column chromatography with EtOAc as the eluent to afford the title compound.

20

Example 2

Oligonucleotide synthesis

Unsubstituted and substituted phosphodiester (P=O) oligonucleotides are synthesized on an automated DNA
25 synthesizer (Applied Biosystems model 394) using standard phosphoramidite chemistry with oxidation by iodine.

Phosphorothioates (P=S) are synthesized similar to phosphodiester oligonucleotides with the following exceptions: thiation was effected by utilizing a 10% w/v
30 solution of 3H-1,2-benzodithiole-3-one 1,1-dioxide in acetonitrile for the oxidation of the phosphite linkages. The thiation reaction step time was increased to 180 sec and preceded by the normal capping step. After cleavage from the CPG column and deblocking in concentrated ammonium
35 hydroxide at 55°C (12-16 hr), the oligonucleotides were recovered by precipitating with >3 volumes of ethanol from a

ISPH-0728

-84-

PATENT

1 M NH₄OAc solution. Phosphinate oligonucleotides are prepared as described in U.S. Patent 5,508,270, herein incorporated by reference.

Alkyl phosphonate oligonucleotides are prepared as described in U.S. Patent 4,469,863, herein incorporated by reference.

3'-Deoxy-3'-methylene phosphonate oligonucleotides are prepared as described in U.S. Patents 5,610,289 or 5,625,050, herein incorporated by reference.

Phosphoramidite oligonucleotides are prepared as described in U.S. Patent, 5,256,775 or U.S. Patent 5,366,878, herein incorporated by reference.

Alkylphosphonothioate oligonucleotides are prepared as described in published PCT applications PCT/US94/00902 and PCT/US93/06976 (published as WO 94/17093 and WO 94/02499, respectively), herein incorporated by reference.

3'-Deoxy-3'-amino phosphoramidate oligonucleotides are prepared as described in U.S. Patent 5,476,925, herein incorporated by reference.

Phosphotriester oligonucleotides are prepared as described in U.S. Patent 5,023,243, herein incorporated by reference.

Borano phosphate oligonucleotides are prepared as described in U.S. Patents 5,130,302 and 5,177,198, both herein incorporated by reference.

Example 3

Oligonucleoside Synthesis

Methylenemethylimino linked oligonucleosides, also identified as MMI linked oligonucleosides, methylenedimethylhydrazo linked oligonucleosides, also identified as MDH linked oligonucleosides, and methylenecarbonylamino linked oligonucleosides, also identified as amide-3 linked oligonucleosides, and methyleneaminocarbonyl linked oligonucleosides, also identified as amide-4 linked oligonucleosides, as well as mixed backbone compounds having, for instance, alternating MMI and P=O or P=S linkages are

ISPH-0728

-85-

PATENT

prepared as described in U.S. Patents 5,378,825, 5,386,023, 5,489,677, 5,602,240 and 5,610,289, all of which are herein incorporated by reference.

Formacetal and thioformacetal linked oligonucleosides
5 are prepared as described in U.S. Patents 5,264,562 and 5,264,564, herein incorporated by reference.

Ethylene oxide linked oligonucleosides are prepared as described in U.S. Patent 5,223,618, herein incorporated by reference.

10

Example 4

PNA Synthesis

Peptide nucleic acids (PNAs) are prepared in accordance with any of the various procedures referred to in Peptide
15 Nucleic Acids (PNA): Synthesis, Properties and Potential Applications, *Bioorganic & Medicinal Chemistry*, 1996, 4, 5-23. They may also be prepared in accordance with U.S. Patents 5,539,082, 5,700,922, and 5,719,262, herein incorporated by reference.

20

Example 5

Synthesis of Chimeric Oligonucleotides

Chimeric oligonucleotides, oligonucleosides or mixed oligonucleotides/oligonucleosides of the invention can be of
25 several different types. These include a first type wherein the "gap" segment of linked nucleosides is positioned between 5' and 3' "wing" segments of linked nucleosides and a second "open end" type wherein the "gap" segment is located at either the 3' or the 5' terminus of the
30 oligomeric compound. Oligonucleotides of the first type are also known in the art as "gapmers" or gapped oligonucleotides. Oligonucleotides of the second type are also known in the art as "hemimers" or "wingmers".

ISPH-0728

-86-

PATENT

[2'-O-Me]--[2'-deoxy]--[2'-O-Me] Chimeric**Phosphorothioate Oligonucleotides**

Chimeric oligonucleotides having 2'-O-alkyl phosphorothioate and 2'-deoxy phosphorothioate oligonucleotide segments are synthesized using an Applied Biosystems automated DNA synthesizer Model 394, as above. Oligonucleotides are synthesized using the automated synthesizer and 2'-deoxy-5'-dimethoxytrityl-3'-O-phosphoramidite for the DNA portion and 5'-dimethoxytrityl-2'-O-methyl-3'-O-phosphoramidite for 5' and 3' wings. The standard synthesis cycle is modified by incorporating coupling steps with increased reaction times for the 5'-dimethoxytrityl-2'-O-methyl-3'-O-phosphoramidite. The fully protected oligonucleotide is cleaved from the support and deprotected in concentrated ammonia (NH₄OH) for 12-16 hr at 55°C. The deprotected oligo is then recovered by an appropriate method (precipitation, column chromatography, volume reduced *in vacuo* and analyzed spectrophotometrically for yield and for purity by capillary electrophoresis and by mass spectrometry.

[2'-O-(2-Methoxyethyl)]--[2'-deoxy]--[2'-O-**(Methoxyethyl)] Chimeric Phosphorothioate****Oligonucleotides**

[2'-O-(2-methoxyethyl)]--[2'-deoxy]--[2'-O-(methoxyethyl)] chimeric phosphorothioate oligonucleotides were prepared as per the procedure above for the 2'-O-methyl chimeric oligonucleotide, with the substitution of 2'-O-(methoxyethyl) amidites for the 2'-O-methyl amidites.

[2'-O-(2-Methoxyethyl) Phosphodiester]--[2'-deoxy**Phosphorothioate]--[2'-O-(2-Methoxyethyl)****Phosphodiester] Chimeric Oligonucleotides**

[2'-O-(2-methoxyethyl phosphodiester)]--[2'-deoxy phosphorothioate]--[2'-O-(methoxyethyl) phosphodiester]

ISPH-0728

-87-

PATENT

chimeric oligonucleotides are prepared as per the above procedure for the 2'-O-methyl chimeric oligonucleotide with the substitution of 2'-O-(methoxyethyl) amidites for the 2'-O-methyl amidites, oxidation with iodine to generate the phosphodiester internucleotide linkages within the wing portions of the chimeric structures and sulfurization utilizing 3,4-dihydro-2H-benzothio-1,2-dioxole-3-one 1,1-dioxide (Beaucage Reagent) to generate the phosphorothioate internucleotide linkages for the center gap.

Other chimeric oligonucleotides, chimeric oligonucleosides and mixed chimeric oligonucleotides/oligonucleosides are synthesized according to United States patent 5,623,065, herein incorporated by reference.

Example 6

Oligonucleotide Isolation

After cleavage from the controlled pore glass solid support and deblocking in concentrated ammonium hydroxide at 55°C for 12-16 hours, the oligonucleotides or oligonucleosides are recovered by precipitation out of 1 M NH_4OAc with >3 volumes of ethanol. Synthesized oligonucleotides were analyzed by electrospray mass spectroscopy (molecular weight determination) and by capillary gel electrophoresis and judged to be at least 70% full length material. The relative amounts of phosphorothioate and phosphodiester linkages obtained in the synthesis was determined by the ratio of correct molecular weight relative to the -16 amu product (+/-32 +/-48). For some studies oligonucleotides were purified by HPLC, as described by Chiang et al., *J. Biol. Chem.* 1991, 266, 18162-18171. Results obtained with HPLC-purified material were similar to those obtained with non-HPLC purified material.

ISPH-0728

-88-

PATENT

Example 7**Oligonucleotide Synthesis - 96 Well Plate Format**

Oligonucleotides were synthesized via solid phase P(III) phosphoramidite chemistry on an automated synthesizer capable of assembling 96 sequences simultaneously in a 96-well format. Phosphodiester internucleotide linkages were afforded by oxidation with aqueous iodine. Phosphorothioate internucleotide linkages were generated by sulfurization utilizing 3,4-dihydro-2H-benzothiole-3-one 1,1-dioxide (Beaucage Reagent) in anhydrous acetonitrile. Standard base-protected beta-cyanoethyl-diisopropyl phosphoramidites were purchased from commercial vendors (e.g. PE-Applied Biosystems, Foster City, CA, or Pharmacia, Piscataway, NJ). Non-standard nucleosides are synthesized as per standard or patented methods. They are utilized as base protected beta-cyanoethyl-diisopropyl phosphoramidites.

Oligonucleotides were cleaved from support and deprotected with concentrated NH_4OH at elevated temperature (55-60°C) for 12-16 hours and the released product then dried in vacuo. The dried product was then re-suspended in sterile water to afford a master plate from which all analytical and test plate samples are then diluted utilizing robotic pipettors.

Example 8**Oligonucleotide Analysis - 96-Well Plate Format**

The concentration of oligonucleotide in each well was assessed by dilution of samples and UV absorption spectroscopy. The full-length integrity of the individual products was evaluated by capillary electrophoresis (CE) in either the 96-well format (Beckman P/ACE™ MDQ) or, for individually prepared samples, on a commercial CE apparatus (e.g., Beckman P/ACE™ 5000, ABI 270). Base and backbone composition was confirmed by mass analysis of the compounds utilizing electrospray-mass spectroscopy. All assay test

ISPH-0728

-89-

PATENT

plates were diluted from the master plate using single and multi-channel robotic pipettors. Plates were judged to be acceptable if at least 85% of the compounds on the plate were at least 85% full length.

5

Example 9**Cell culture and oligonucleotide treatment**

The effect of antisense compounds on target nucleic acid expression can be tested in any of a variety of cell types provided that the target nucleic acid is present at measurable levels. This can be routinely determined using, for example, PCR or Northern blot analysis. The following cell types are provided for illustrative purposes, but other cell types can be routinely used, provided that the target is expressed in the cell type chosen. This can be readily determined by methods routine in the art, for example Northern blot analysis, ribonuclease protection assays, or RT-PCR.

20 **T-24 cells:**

The human transitional cell bladder carcinoma cell line T-24 was obtained from the American Type Culture Collection (ATCC) (Manassas, VA). T-24 cells were routinely cultured in complete McCoy's 5A basal media (Invitrogen Corporation, Carlsbad, CA) supplemented with 10% fetal calf serum (Invitrogen Corporation, Carlsbad, CA), penicillin 100 units per mL, and streptomycin 100 micrograms per mL (Invitrogen Corporation, Carlsbad, CA). Cells were routinely passaged by trypsinization and dilution when they reached 90% confluence. Cells were seeded into 96-well plates (Falcon-Primaria #3872) at a density of 7000 cells/well for use in RT-PCR analysis.

For Northern blotting or other analysis, cells may be seeded onto 100 mm or other standard tissue culture plates and treated similarly, using appropriate volumes of medium and oligonucleotide.

35

ISPH-0728

-90-

PATENT

A549 cells:

The human lung carcinoma cell line A549 was obtained from the American Type Culture Collection (ATCC) (Manassas, VA). A549 cells were routinely cultured in DMEM basal media (Invitrogen Corporation, Carlsbad, CA) supplemented with 10% fetal calf serum (Invitrogen Corporation, Carlsbad, CA), penicillin 100 units per mL, and streptomycin 100 micrograms per mL (Invitrogen Corporation, Carlsbad, CA). Cells were routinely passaged by trypsinization and dilution when they reached 90% confluence.

NHDF cells:

Human neonatal dermal fibroblast (NHDF) were obtained from the Clonetics Corporation (Walkersville, MD). NHDFs were routinely maintained in Fibroblast Growth Medium (Clonetics Corporation, Walkersville, MD) supplemented as recommended by the supplier. Cells were maintained for up to 10 passages as recommended by the supplier.

HEK cells:

Human embryonic keratinocytes (HEK) were obtained from the Clonetics Corporation (Walkersville, MD). HEKs were routinely maintained in Keratinocyte Growth Medium (Clonetics Corporation, Walkersville, MD) formulated as recommended by the supplier. Cells were routinely maintained for up to 10 passages as recommended by the supplier.

Treatment with antisense compounds:

When cells reached 70% confluency, they were treated with oligonucleotide. For cells grown in 96-well plates, wells were washed once with 100 μ L OPTI-MEMTM-1 reduced-serum medium (Invitrogen Corporation, Carlsbad, CA) and then treated with 130 μ L of OPTI-MEMTM-1 containing 3.75 μ g/mL LIPOFECTINTM (Invitrogen Corporation, Carlsbad, CA) and the desired concentration of oligonucleotide. After 4-7 hours

ISPH-0728

-91-

PATENT

of treatment, the medium was replaced with fresh medium. Cells were harvested 16-24 hours after oligonucleotide treatment.

The concentration of oligonucleotide used varies from
5 cell line to cell line. To determine the optimal
oligonucleotide concentration for a particular cell line,
the cells are treated with a positive control
oligonucleotide at a range of concentrations. For human
cells the positive control oligonucleotide is selected from
10 either ISIS 13920 (TCCGTCATCGCTCCTCAGGG, SEQ ID NO: 1) which
is targeted to human H-ras, or ISIS 18078,
(GTGCGCGCGAGCCCGAAATC, SEQ ID NO: 2) which is targeted to
human Jun-N-terminal kinase-2 (JNK2). Both controls are 2'-
O-methoxyethyl gapmers (2'-O-methoxyethyls shown in bold)
15 with a phosphorothioate backbone. For mouse or rat cells
the positive control oligonucleotide is ISIS 15770,
ATGCATTCTGCCCCCAAGGA, SEQ ID NO: 3, a 2'-O-methoxyethyl
gapmer (2'-O-methoxyethyls shown in bold) with a
phosphorothioate backbone which is targeted to both mouse
20 and rat c-raf. The concentration of positive control
oligonucleotide that results in 80% inhibition of c-Ha-ras
(for ISIS 13920) or c-raf (for ISIS 15770) mRNA is then
utilized as the screening concentration for new
oligonucleotides in subsequent experiments for that cell
25 line. If 80% inhibition is not achieved, the lowest
concentration of positive control oligonucleotide that
results in 60% inhibition of H-ras or c-raf mRNA is then
utilized as the oligonucleotide screening concentration in
subsequent experiments for that cell line. If 60%
30 inhibition is not achieved, that particular cell line is
deemed as unsuitable for oligonucleotide transfection
experiments.

Example 10**Analysis of oligonucleotide inhibition of extracellular-signal-regulated kinase-6 expression**

Antisense modulation of extracellular-signal-regulated kinase-6 expression can be assayed in a variety of ways known in the art. For example, extracellular-signal-regulated kinase-6 mRNA levels can be quantitated by, e.g., Northern blot analysis, competitive polymerase chain reaction (PCR), or real-time PCR (RT-PCR). Real-time quantitative PCR is presently preferred. RNA analysis can be performed on total cellular RNA or poly(A)+ mRNA. The preferred method of RNA analysis of the present invention is the use of total cellular RNA as described in other examples herein. Methods of RNA isolation are taught in, for example, Ausubel, F.M. et al., *Current Protocols in Molecular Biology*, Volume 1, pp. 4.1.1-4.2.9 and 4.5.1-4.5.3, John Wiley & Sons, Inc., 1993. Northern blot analysis is routine in the art and is taught in, for example, Ausubel, F.M. et al., *Current Protocols in Molecular Biology*, Volume 1, pp. 4.2.1-4.2.9, John Wiley & Sons, Inc., 1996. Real-time quantitative (PCR) can be conveniently accomplished using the commercially available ABI PRISM™ 7700 Sequence Detection System, available from PE-Applied Biosystems, Foster City, CA and used according to manufacturer's instructions.

Protein levels of extracellular-signal-regulated kinase-6 can be quantitated in a variety of ways well known in the art, such as immunoprecipitation, Western blot analysis (immunoblotting), ELISA or fluorescence-activated cell sorting (FACS). Antibodies directed to extracellular-signal-regulated kinase-6 can be identified and obtained from a variety of sources, such as the MSRS catalog of antibodies (Aerie Corporation, Birmingham, MI), or can be prepared via conventional antibody generation methods. Methods for preparation of polyclonal antisera are taught

ISPH-0728

-93-

PATENT

in, for example, Ausubel, F.M. et al., (*Current Protocols in Molecular Biology*, Volume 2, pp. 11.12.1-11.12.9, John Wiley & Sons, Inc., 1997). Preparation of monoclonal antibodies is taught in, for example, Ausubel, F.M. et al., (*Current*
5 *Protocols in Molecular Biology*, Volume 2, pp. 11.4.1-11.11.5, John Wiley & Sons, Inc., 1997).

Immunoprecipitation methods are standard in the art and can be found at, for example, Ausubel, F.M. et al., (*Current Protocols in Molecular Biology*, Volume 2, pp. 10.16.1-
10 *10.16.11*, John Wiley & Sons, Inc., 1998). Western blot (immunoblot) analysis is standard in the art and can be found at, for example, Ausubel, F.M. et al., (*Current Protocols in Molecular Biology*, Volume 2, pp. 10.8.1-
10.8.21, John Wiley & Sons, Inc., 1997). Enzyme-linked
15 immunosorbent assays (ELISA) are standard in the art and can be found at, for example, Ausubel, F.M. et al., (*Current Protocols in Molecular Biology*, Volume 2, pp. 11.2.1-11.2.22, John Wiley & Sons, Inc., 1991).

20 Example 11

Poly(A)+ mRNA isolation

Poly(A)+ mRNA was isolated according to Miura et al., (*Clin. Chem.*, 1996, 42, 1758-1764). Other methods for poly(A)+ mRNA isolation are taught in, for example, Ausubel,
25 F.M. et al., (*Current Protocols in Molecular Biology*, Volume 1, pp. 4.5.1-4.5.3, John Wiley & Sons, Inc., 1993). Briefly, for cells grown on 96-well plates, growth medium was removed from the cells and each well was washed with 200 μ L cold PBS. 60 μ L lysis buffer (10 mM Tris-HCl, pH 7.6, 1
30 mM EDTA, 0.5 M NaCl, 0.5% NP-40, 20 mM vanadyl-ribonucleoside complex) was added to each well, the plate was gently agitated and then incubated at room temperature

for five minutes. 55 μ L of lysate was transferred to Oligo
d(T) coated 96-well plates (AGCT Inc., Irvine CA). Plates
were incubated for 60 minutes at room temperature, washed 3
times with 200 μ L of wash buffer (10 mM Tris-HCl pH 7.6, 1
5 mM EDTA, 0.3 M NaCl). After the final wash, the plate was
blotted on paper towels to remove excess wash buffer and
then air-dried for 5 minutes. 60 μ L of elution buffer (5 mM
Tris-HCl pH 7.6), preheated to 70°C, was added to each well,
the plate was incubated on a 90° hot plate for 5 minutes,
10 and the eluate was then transferred to a fresh 96-well
plate.

Cells grown on 100 mm or other standard plates may be
treated similarly, using appropriate volumes of all
solutions.

15

Example 12

Total RNA Isolation

Total RNA was isolated using an RNEASY 96™ kit and
buffers purchased from Qiagen Inc. (Valencia, CA) following
20 the manufacturer's recommended procedures. Briefly, for
cells grown on 96-well plates, growth medium was removed
from the cells and each well was washed with 200 μ L cold
PBS. 150 μ L Buffer RLT was added to each well and the plate
vigorously agitated for 20 seconds. 150 μ L of 70% ethanol
25 was then added to each well and the contents mixed by
pipetting three times up and down. The samples were then
transferred to the RNEASY 96™ well plate attached to a
QIAVAC™ manifold fitted with a waste collection tray and
attached to a vacuum source. Vacuum was applied for 1
30 minute. 500 μ L of Buffer RW1 was added to each well of the
RNEASY 96™ plate and incubated for 15 minutes and the vacuum
was again applied for 1 minute. An additional 500 μ L of
Buffer RW1 was added to each well of the RNEASY 96™ plate

ISPH-0728

-95-

PATENT

and the vacuum was applied for 2 minutes. 1 mL of Buffer RPE was then added to each well of the RNEASY 96™ plate and the vacuum applied for a period of 90 seconds. The Buffer RPE wash was then repeated and the vacuum was applied for an additional 3 minutes. The plate was then removed from the QIAVAC™ manifold and blotted dry on paper towels. The plate was then re-attached to the QIAVAC™ manifold fitted with a collection tube rack containing 1.2 mL collection tubes. RNA was then eluted by pipetting 170 µL water into each well, incubating 1 minute, and then applying the vacuum for 3 minutes.

The repetitive pipetting and elution steps may be automated using a QIAGEN Bio-Robot 9604 (Qiagen, Inc., Valencia CA). Essentially, after lysing of the cells on the culture plate, the plate is transferred to the robot deck where the pipetting, DNase treatment and elution steps are carried out.

Example 13

Real-time Quantitative PCR Analysis of extracellular-signal-regulated kinase-6 mRNA Levels

Quantitation of extracellular-signal-regulated kinase-6 mRNA levels was determined by real-time quantitative PCR using the ABI PRISM™ 7700 Sequence Detection System (PE-Applied Biosystems, Foster City, CA) according to manufacturer's instructions. This is a closed-tube, non-gel-based, fluorescence detection system which allows high-throughput quantitation of polymerase chain reaction (PCR) products in real-time. As opposed to standard PCR in which amplification products are quantitated after the PCR is completed, products in real-time quantitative PCR are quantitated as they accumulate. This is accomplished by including in the PCR reaction an oligonucleotide probe that anneals specifically between the forward and reverse PCR primers, and contains two fluorescent dyes. A reporter dye

ISPH-0728

-96-

PATENT

(e.g., FAM or JOE, obtained from either PE-Applied Biosystems, Foster City, CA, Operon Technologies Inc., Alameda, CA or Integrated DNA Technologies Inc., Coralville, IA) is attached to the 5' end of the probe and a quencher dye (e.g., TAMRA, obtained from either PE-Applied Biosystems, Foster City, CA, Operon Technologies Inc., Alameda, CA or Integrated DNA Technologies Inc., Coralville, IA) is attached to the 3' end of the probe. When the probe and dyes are intact, reporter dye emission is quenched by the proximity of the 3' quencher dye. During amplification, annealing of the probe to the target sequence creates a substrate that can be cleaved by the 5'-exonuclease activity of Taq polymerase. During the extension phase of the PCR amplification cycle, cleavage of the probe by Taq polymerase releases the reporter dye from the remainder of the probe (and hence from the quencher moiety) and a sequence-specific fluorescent signal is generated. With each cycle, additional reporter dye molecules are cleaved from their respective probes, and the fluorescence intensity is monitored at regular intervals by laser optics built into the ABI PRISM™ 7700 Sequence Detection System. In each assay, a series of parallel reactions containing serial dilutions of mRNA from untreated control samples generates a standard curve that is used to quantitate the percent inhibition after antisense oligonucleotide treatment of test samples.

Prior to quantitative PCR analysis, primer-probe sets specific to the target gene being measured are evaluated for their ability to be "multiplexed" with a GAPDH amplification reaction. In multiplexing, both the target gene and the internal standard gene GAPDH are amplified concurrently in a single sample. In this analysis, mRNA isolated from untreated cells is serially diluted. Each dilution is amplified in the presence of primer-probe sets specific for GAPDH only, target gene only ("single-plexing"), or both (multiplexing). Following PCR amplification, standard curves of GAPDH and target mRNA signal as a function of

ISPH-0728

-97-

PATENT

dilution are generated from both the single-plexed and multiplexed samples. If both the slope and correlation coefficient of the GAPDH and target signals generated from the multiplexed samples fall within 10% of their
5 corresponding values generated from the single-plexed samples, the primer-probe set specific for that target is deemed multiplexable. Other methods of PCR are also known in the art.

10 PCR reagents were obtained from Invitrogen Corporation, (Carlsbad, CA). RT-PCR reactions were carried out by adding 20 μ L PCR cocktail (2.5x PCR buffer (-MgCl₂), 6.6 mM MgCl₂, 375 μ M each of dATP, dCTP, dGTP and dTTP, 375 nM each of forward primer and reverse primer, 125 nM of probe, 4 Units RNase inhibitor, 1.25 Units PLATINUM[®] Taq, 5 Units MuLV
15 reverse transcriptase, and 2.5x ROX dye) to 96-well plates containing 30 μ L total RNA solution. The RT reaction was carried out by incubation for 30 minutes at 48°C. Following a 10 minute incubation at 95°C to activate the PLATINUM[®] Taq, 40 cycles of a two-step PCR protocol were carried out: 95°C
20 for 15 seconds (denaturation) followed by 60°C for 1.5 minutes (annealing/extension).

Gene target quantities obtained by real time RT-PCR are normalized using either the expression level of GAPDH, a gene whose expression is constant, or by quantifying total
25 RNA using RiboGreen[™] (Molecular Probes, Inc. Eugene, OR). GAPDH expression is quantified by real time RT-PCR, by being run simultaneously with the target, multiplexing, or separately. Total RNA is quantified using RiboGreen[™] RNA quantification reagent from Molecular Probes. Methods of
30 RNA quantification by RiboGreen[™] are taught in Jones, L.J., et al, (Analytical Biochemistry, 1998, 265, 368-374).

In this assay, 170 μ L of RiboGreen[™] working reagent (RiboGreen[™] reagent diluted 1:350 in 10mM Tris-HCl, 1 mM EDTA, pH 7.5) is pipetted into a 96-well plate containing 30
35 μ L purified, cellular RNA. The plate is read in a CytoFluor

ISPH-0728

-98-

PATENT

4000 (PE Applied Biosystems) with excitation at 480nm and emission at 520nm.

Probes and primers to human extracellular-signal-regulated kinase-6 were designed to hybridize to a human
5 extracellular-signal-regulated kinase-6 sequence, using published sequence information (GenBank accession number X79483.1, incorporated herein as SEQ ID NO:4). For human extracellular-signal-regulated kinase-6 the PCR primers were:
10 forward primer: CTCGTTGCCACCTTGACCTT (SEQ ID NO: 5)
reverse primer: TGGAACCCGGGCGTCT (SEQ ID NO: 6) and the PCR probe was: FAM-TTGCATCCCAAGGCATCCATCAGA-TAMRA (SEQ ID NO: 7) where FAM is the fluorescent dye and TAMRA is the quencher dye. For human GAPDH the PCR primers were:
15 forward primer: GAAGGTGAAGGTCGGAGTC (SEQ ID NO:8)
reverse primer: GAAGATGGTGATGGGATTTC (SEQ ID NO:9) and the PCR probe was: 5' JOE-CAAGCTTCCCCGTTCTCAGCC- TAMRA 3' (SEQ ID NO: 10) where JOE is the fluorescent reporter dye and TAMRA is the quencher dye.

20

Example 14

Northern blot analysis of extracellular-signal-regulated kinase-6 mRNA levels

Eighteen hours after antisense treatment, cell
25 monolayers were washed twice with cold PBS and lysed in 1 mL RNAZOL™ (TEL-TEST "B" Inc., Friendswood, TX). Total RNA was prepared following manufacturer's recommended protocols. Twenty micrograms of total RNA was fractionated by electrophoresis through 1.2% agarose gels containing 1.1%
30 formaldehyde using a MOPS buffer system (AMRESCO, Inc. Solon, OH). RNA was transferred from the gel to HYBOND™-N+ nylon membranes (Amersham Pharmacia Biotech, Piscataway, NJ) by overnight capillary transfer using a Northern/Southern Transfer buffer system (TEL-TEST "B" Inc., Friendswood, TX).
35 RNA transfer was confirmed by UV visualization. Membranes were fixed by UV cross-linking using a STRATALINKER™ UV

ISPH-0728

-99-

PATENT

Crosslinker 2400 (Stratagene, Inc, La Jolla, CA) and then probed using QUICKHYB™ hybridization solution (Stratagene, La Jolla, CA) using manufacturer's recommendations for stringent conditions.

- 5 To detect human extracellular-signal-regulated kinase-6, a human extracellular-signal-regulated kinase-6 specific probe was prepared by PCR using the forward primer CTCGTTGCCACCTTGACCTT (SEQ ID NO: 5) and the reverse primer TGGAACCCGGGCGTCT (SEQ ID NO: 6). To normalize for
10 variations in loading and transfer efficiency membranes were stripped and probed for human glyceraldehyde-3-phosphate dehydrogenase (GAPDH) RNA (Clontech, Palo Alto, CA).

- Hybridized membranes were visualized and quantitated using a PHOSPHORIMAGER™ and IMAGEQUANT™ Software V3.3
15 (Molecular Dynamics, Sunnyvale, CA). Data was normalized to GAPDH levels in untreated controls.

Example 15

- Antisense inhibition of human extracellular-signal-regulated
20 kinase-6 expression by chimeric phosphorothioate oligonucleotides having 2'-MOE wings and a deoxy gap

- In accordance with the present invention, a series of oligonucleotides were designed to target different regions of the human extracellular-signal-regulated kinase-6 RNA, using published sequences (GenBank accession number
25 X79483.1, incorporated herein as SEQ ID NO: 4). The oligonucleotides are shown in Table 1. "Target site" indicates the first (5'-most) nucleotide number on the particular target sequence to which the oligonucleotide
30 binds. All compounds in Table 1 are chimeric oligonucleotides ("gapmers") 20 nucleotides in length, composed of a central "gap" region consisting of ten 2'-deoxynucleotides, which is flanked on both sides (5' and 3' directions) by five-nucleotide "wings". The wings are
35 composed of 2'-methoxyethyl (2'-MOE)nucleotides. The internucleoside (backbone) linkages are phosphorothioate

ISPH-0728

-100-

PATENT

(P=S) throughout the oligonucleotide. All cytidine residues are 5-methylcytidines. The compounds were analyzed for their effect on human extracellular-signal-regulated kinase-6 mRNA levels by quantitative real-time PCR as described in other examples herein. Data are averages from two experiments in which T-24 cells were treated with the antisense oligonucleotides of the present invention. The positive control for each datapoint is identified in the table by sequence ID number. The positive control for each datapoint is identified in the table by sequence ID number. If present, "N.D." indicates "no data".

Table 1

Inhibition of human extracellular-signal-regulated kinase-6 mRNA levels by chimeric phosphorothioate oligonucleotides having 2'-MOE wings and a deoxy gap

ISIS #	REGION	TARGET SEQ ID NO	TARGET SITE	SEQUENCE	% INHIB	SEQ ID NO	CONTROL SEQ ID NO
157011	Coding	4	432	ccttcatcatctggtacacg	6	11	2
157012	Coding	4	724	tccttcagctggtccagggtg	55	12	2
157013	3'UTR	4	1412	ccaccagctctgagggtttct	63	13	2
157014	Start Codon	4	25	ggagagctcatggcaggccc	8	14	2
157015	Coding	4	263	gtggcgcgatgtgcttgagca	48	15	2
157016	Coding	4	433	cccttcatcatctggtacac	9	16	2
157017	Coding	4	314	atccagggtctcatcaggag	48	17	2
157018	Stop Codon	4	1136	ccggagcccagagatcttc	78	18	2
157019	3'UTR	4	1474	ctgtccttcctctgcatggc	0	19	2
157020	Coding	4	410	gaactggatccggtcctcgc	55	20	2
157021	Coding	4	534	ggccgaagtccaggatcttc	61	21	2
157022	3'UTR	4	1499	tgagttggtgccctgctccc	45	22	2
157023	3'UTR	4	1232	tctgatggatgcottgggat	85	23	2
157024	Coding	4	427	atcatctggtacacgaggaa	56	24	2
157025	Coding	4	394	tcgcctagcttctcatgttt	46	25	2
157026	Coding	4	837	aggcaaatccttcttctcc	39	26	2
157027	3'UTR	4	1235	tgctctgatggatgccttgg	38	27	2
157028	3'UTR	4	1612	gctacaaaagggtctatttc	52	28	2
157029	Coding	4	545	ctgcctggccaggccgaagt	33	29	2
157030	Coding	4	933	aaagaaactgcctgcagtc	0	30	2
157031	3'UTR	4	1435	gaggccaaggctgatctgga	23	31	2
157032	Coding	4	419	gtacacgagggaactggatcc	56	32	2
157033	Coding	4	338	caccaggtaaaagtccgtga	25	33	2
157034	Coding	4	1015	tcaaagtagtcaaaggagtc	0	34	2

ISPH-0728

-101-

PATENT

157035	Coding	4	197	gggccgatacagcttcttga	46	35	2
157036	3'UTR	4	1420	ctggagccccaccagctctg	61	36	2
157037	Coding	4	769	cgctgcacaaactcagccgg	59	37	2
157038	Coding	4	807	ggcccttcattgtagttcttg	36	38	2
157039	Coding	4	1002	aggagtcatacttcttg	54	39	2
157040	3'UTR	4	1421	tctggagccccaccagctct	30	40	2
157041	3'UTR	4	1509	gggatgtccctgagttggtg	52	41	2
157042	3'UTR	4	1544	ggtgcaggaaggtccactga	64	42	2
157043	Coding	4	380	atgtttcatgagcttgccca	54	43	2
157044	Coding	4	443	atacctcagcccttcattca	26	44	2
157045	Coding	4	369	gcttgcccaggtcggtgcc	62	45	2
157046	3'UTR	4	1198	aggtcaaggtggcaacgaga	75	46	2
157047	Coding	4	798	tgtagttcttggcctcatcg	56	47	2

As shown in Table 1, SEQ ID NOS 12, 13, 15, 17, 18, 20, 21, 22, 23, 24, 25, 28, 32, 35, 36, 37, 39, 41, 42, 43, 45, 46 and 47 demonstrated at least 40% inhibition of human
 5 extracellular-signal-regulated kinase-6 expression in this assay and are therefore preferred. The target sites to which these preferred sequences are complementary are herein referred to as "preferred target regions" and are therefore preferred sites for targeting by compounds of the present
 10 invention. These preferred target regions are shown in Table 2. The sequences represent the reverse complement of the preferred antisense compounds shown in Table 1. "Target site" indicates the first (5'-most) nucleotide number of the corresponding target nucleic acid. Also shown in Table 2 is
 15 the species in which each of the preferred target regions was found.

Table 2

Sequence and position of preferred target regions identified
 20 in extracellular-signal-regulated kinase-6.

SITE ID	TARGET SEQ ID NO	TARGET SITE	SEQUENCE	REV COMP OF SEQ ID	ACTIVE IN	SEQ ID NO
72512	4	724	cacctggaccagctgaagga	12	<i>H. sapiens</i>	48
72513	4	1412	agaaacctcagagctggtgg	13	<i>H. sapiens</i>	49
72515	4	263	tgctcaagcacatgcgccac	15	<i>H. sapiens</i>	50
72517	4	314	ctcctgatgagaccctggat	17	<i>H. sapiens</i>	51
72518	4	1136	gaagatctctgggctccggg	18	<i>H. sapiens</i>	52
72520	4	410	gcgaggaccggatccagttc	20	<i>H. sapiens</i>	53
72521	4	534	gaagatcctggacttcggcc	21	<i>H. sapiens</i>	54

72522	4	1499	gggagcagggcaccaactca	22	<i>H. sapiens</i>	55
72523	4	1232	atcccaaggcatccatcaga	23	<i>H. sapiens</i>	56
72524	4	427	ttcctcgtgtaccagatgat	24	<i>H. sapiens</i>	57
72525	4	394	aaacatgagaagctagggcga	25	<i>H. sapiens</i>	58
72528	4	1612	gaaatagaccctttttagc	28	<i>H. sapiens</i>	59
72532	4	419	ggatccagttcctcgtgtac	32	<i>H. sapiens</i>	60
72535	4	197	tcaagaagctgtatcggccc	35	<i>H. sapiens</i>	61
72536	4	1420	cagagctggtggggctccag	36	<i>H. sapiens</i>	62
72537	4	769	cgggctgagtttgtgcagcg	37	<i>H. sapiens</i>	63
72539	4	1002	ccagaagtatgatgactcct	39	<i>H. sapiens</i>	64
72541	4	1509	caccaactcagggacatccc	41	<i>H. sapiens</i>	65
72542	4	1544	tcagtggaccttcctgcacc	42	<i>H. sapiens</i>	66
72543	4	380	tgggcaagctcatgaaacat	43	<i>H. sapiens</i>	67
72545	4	369	gggcaccgacctgggcaagc	45	<i>H. sapiens</i>	68
72546	4	1198	tctcgttgccaccttgacct	46	<i>H. sapiens</i>	69
72547	4	798	cgatgaggccaagaactaca	47	<i>H. sapiens</i>	70

As these "preferred target regions" have been found by experimentation to be open to, and accessible for, hybridization with the antisense compounds of the present invention, one of skill in the art will recognize or be able to ascertain, using no more than routine experimentation, further embodiments of the invention that encompass other compounds that specifically hybridize to these sites and consequently inhibit the expression of extracellular-signal-regulated kinase-6.

Example 16

Western blot analysis of extracellular-signal-regulated kinase-6 protein levels

Western blot analysis (immunoblot analysis) is carried out using standard methods. Cells are harvested 16-20 h after oligonucleotide treatment, washed once with PBS, suspended in Laemmli buffer (100 ul/well), boiled for 5 minutes and loaded on a 16% SDS-PAGE gel. Gels are run for 1.5 hours at 150 V, and transferred to membrane for western blotting. Appropriate primary antibody directed to extracellular-signal-regulated kinase-6 is used, with a radiolabeled or fluorescently labeled secondary antibody directed against the primary antibody species. Bands are visualized using a PHOSPHORIMAGER™ (Molecular Dynamics, Sunnyvale CA).

Example 17**Treatment of angiogenic disease: melanoma**

In an in vivo test, Meth-A sarcoma and melanoma cells (1.times.10.sup.6) are inoculated subcutaneously in 0.1 ml
5 saline in the same position of the dorsal skin of C3H mice (n=20). On the same day, the mice receive orally either extracellular-signal-regulated kinase-6 inhibitor, at 100 mg per kg in body weight, suspended in 300 uL of olive oil (n=10) or 300 uL olive oil alone (n=10). This treatment is
10 carried out every day and the diameter of the tumors is monitored every second day. On day 12 the mice are sacrificed and the tumor weights are measured.

Meth-A sarcoma tumor growth in mice treated with extracellular-signal-regulated kinase-6 inhibitor is slower
15 than in control mice. The weight (grams) of both the Meth-A sarcoma and melanoma tumors on day 12 is measured, and the mice treated with extracellular-signal-regulated kinase-6 inhibitor have lower tumor mass. In a small number of control and 2-methoxyestradiol mice, the dorsal skin,
20 together with the tumor, are excised and the angiogenesis within the subcutaneous fascia in the control and treated mice is visualized with indian ink. Apart from their marginally lower weight, the treated mice exhibit no apparent signs of toxicity and are all alive after 12 days
25 of daily treatment.

Extracellular-signal-regulated kinase-6 inhibitor thus has potent pharmacological properties which may be applied in the treatment angiogenic diseases, including solid tumors.

ISPH-0728

-104-

PATENT

Example 18**Methods of inhibiting angiogenesis**

Angiogenesis is the growth of new blood vessels (veins & arteries) by endothelial cells. This process is important
5 in the development of a number of human diseases, and is believed to be particularly important in regulating the growth of solid tumors. Without new vessel formation it is believed that tumors will not grow beyond a few millimeters in size. In addition to their use as anti-cancer agents,
10 inhibitors of angiogenesis have potential for the treatment of diabetic retinopathy, cardiovascular disease, rheumatoid arthritis and psoriasis.

During the process of angiogenesis, endothelial cells perform several distinct functions, including the
15 degradation of the extracellular matrix (ECM), migration, proliferation and the formation of tube-like structures. Various genes may regulate some of these processes in primary human umbilical vein endothelial cells (HUVECs). The extracellular-signal-regulated kinase-6 inhibitor
20 employed in this assay is an antisense oligomer ISIS No. 157018 (SEQ ID NO: 18); and the control (or negative control) employed in this assay is the mixed sequence 20-mer negative oligonucleotide control, ISIS 29848, NNNNNNNNNNNNNNNNNNNNNN (where N is A, T, C or G), incorporated
25 herein as SEQ ID NO: 71.

(A) Matrix MetalloProteinase (MMP) Activity Assay

During angiogenesis, endothelial cells need to be able to degrade the extracellular matrix so they can migrate and
30 form new vessels. Endothelial cells secrete matrix metalloproteinases (MMPs) in order to accomplish this degradation. MMPs are a family of zinc-dependent endopeptidases that fall into eight distinct classes: five

ISPH-0728

-105-

PATENT

are secreted and three are membrane-type MMPs (MT-MMPs). MMPs exert these effects by cleaving a diverse group of substrates, which include not only structural components of the extracellular matrix, but also growth-factor-binding
5 proteins, growth-factor precursors, receptor tyrosine kinases, cell-adhesion molecules and other proteinases. In this assay the activity of MMPs secreted into the media above antisense oligonucleotide-treated HUVECs is measured.

MMP activity in the media above HUVECs is measured
10 using the EnzChek Gelatinase/Collagenase Assay Kit (Molecular Probes, Eugene, OR). HUVECs are plated at 3000 cells/well in 96-well plates. One day later, cells are transfected with antisense oligonucleotides according to standard published procedures (Monia et al., (1993) J Biol
15 Chem. 1993 Jul 5;268(19):14514-22) with 75nM oligonucleotide in lipofectin (Gibco, Grand Island, NY). Antisense oligonucleotides are tested in triplicate on each 96-well plate, except for positive and negative antisense controls, which are measured up to six times per plate. Twenty hours
20 post-transfection, MMP production is stimulated by the addition of recombinant human vascular endothelial growth factor (VEGF). Fifty hours post-transfection, a p-aminophenylmercuric acetate (APMA; Sigma-Aldrich, St. Louis, MO) solution is added to each well of a Corning-Costar 96-
25 well clear bottom plate (VWR International, Brisbane, CA). The APMA solution is used to promote cleavage of inactive MMP precursor proteins (Nagase et al., (1991) Biomed Biochim Acta, 50(4-6):749-54). Media above the HUVECs is then transferred to the wells. After 30 minutes, the quenched,
30 fluorogenic MMP cleavage substrate is added, and baseline fluorescence is read immediately at 485nm excitation/530nm emission. Following an overnight incubation at 37°C in the dark, plates are read again to determine the amount of

ISPH-0728

-106-

PATENT

fluorescence, which corresponds to MMP activity. Total protein from HUVEC lysates is used to normalize the readings, and MMP activities \pm standard deviation are expressed relative to transfectant-only controls.

5

(B) Endothelial Tube Formation Assay

Angiogenesis is stimulated by numerous factors that promote interaction of endothelial cells with each other and with extracellular matrix molecules, resulting in the formation of capillary tubes. This morphogenic process is necessary for the delivery of oxygen to nearby tissues and plays an essential role in embryonic development, wound healing, and tumor growth. Moreover, this process can be reproduced in tissue culture by the formation of tube-like structures by endothelial cells. There are several different variations of the assay that use different matrices, such as collagen I [Kanayasu, 1991], Matrigel [Yamagishi, 1997] and fibrin [Bach, 1998] as growth substrates for the cells. In this assay, HUVECs are plated on a matrix derived from the Engelbreth-Holm-Swarm mouse tumor, which is very similar to Matrigel [Kleinman, 1986; Madri, 1986]. Untreated HUVECs form tube-like structures when grown on this substrate. Loss of tube formation *in-vitro* has been correlated with the inhibition of angiogenesis *in-vivo* (Carmeliet et al., (2000) Nature 407:249-257; and Zhang et al., (2002) Cancer Research 62:2034-42), which supports the use of *in-vitro* tube formation as an endpoint for angiogenesis.

The Tube Formation Assay is performed using an *In-vitro* Angiogenesis Assay Kit (Chemicon International, Temecula, CA), or growth factor reduced Matrigel (BD Biosciences, Bedford, MA). Cells are plated and transfected with extracellular-signal-regulated kinase-6 inhibitors

ISPH-0728

-107-

PATENT

(antisense oligonucleotides) as described for the MMP activity assay, except cells are plated at 4000 cells/well. Fifty hours post-transfection, cells are transferred to 96-well plates coated with ECMatrix™ (Chemicon International) or growth factor depleted matrigel. Under these conditions, untreated HUVECs form tube-like structures. After an overnight incubation at 37° C, treated and untreated cells are inspected by light microscopy. Individual wells are assigned discrete scores from 1 to 5 depending on the extent of tube formation. A score of 1 refers to a well with no tube formation while a score of 5 is given to wells where all cells are forming an extensive tubular network.

As calculated from the assigned discrete scores, cells treated with extracellular-signal-regulated kinase-6 inhibitors had tube formation score reduction of about 50% as compared to lipid-treated cells. Thus, it is shown that transforming growth factor beta 3 inhibitors can inhibit angiogenesis.

(C) RNA Expression Levels of Angiogenic Genes

Endothelial cells must regulate the expression of many genes in order to perform the functions necessary for angiogenesis. This gene regulation has been the subject of intense scrutiny, and many genes have been identified as being important for the angiogenic phenotype. The expression levels of four genes, previously identified as being highly expressed in angiogenic endothelial cells, is measured here (Integrin beta 3, endoglin/CD105, TEM5 and MMP-14/MT-MMP1).

Integrin beta 3 is part of a family of heterodimeric transmembrane receptors that consist of alpha and beta subunits. Each subunit recognizes a unique set of ECM ligands, thereby allowing cells to transmit angiogenic

ISPH-0728

-108-

PATENT

signals from the extracellular matrix. Integrin beta 3 is prominently expressed on proliferating vascular endothelial cells, and it plays roles in allowing new blood vessels to form at tumor sites as well as allowing the epithelial cells of breast tumors to spread. Blockage of Integrin alpha 3 with monoclonal antibodies or low molecular weight antagonists inhibits blood vessel formation in a variety of in-vivo models, including tumor angiogenesis and neovascularization during oxygen-induced retinopathy.

10 Endoglin is a Transforming Growth Factor receptor-associated protein highly expressed on endothelial cells, and present on some leukemia cells and minor subsets of bone marrow cells. Its expression is upregulated in endothelial cells of angiogenic tissues and is therefore used as a prognostic indicator in various tumors. Endoglin functions as an ancillary receptor influencing binding of the Transforming Growth Factor beta (TGF-beta) family of ligands to signaling receptors, thus mediating cell survival. Mutations of the endoglin gene result in a genetic disease of the vasculature- Hereditary Haemorrhagic Telangiectasia (HHT), which is characterized by bleeding from malformed blood vessels. Defective signaling by different TGF-beta ligands and receptors is thought to be involved.

25 Tumor endothelial marker 5 (TEM5) is a putative 7-pass transmembrane protein (GPCR) for which EST sequence but no other information is available. The mRNA transcript, designated KIAA1531, encodes one of many tumor endothelium markers (TEMs) that display elevated expression (greater than 10-fold) during tumor angiogenesis. TEM5 is coordinately expressed with other TEMs on tumor endothelium in humans and mice.

MMP-14, a membrane-type MMP (MT-MMP) covalently linked to the cell membrane, is involved in matrix detachment and

ISPH-0728

-109-

PATENT

migration. MMP-14 is thought to promote tumor angiogenesis; antibodies directed against the catalytic domain of MMP-14 block endothelial-cell migration, invasion and capillary tube formation *in-vitro*. MMP-14 can degrade the fibrin matrix that surrounds newly formed vessels potentially allowing the endothelial cells to invade further into the tumor tissue. MMP-14 null mice have impaired angiogenesis during development, further demonstrating the role of MMP-14 in angiogenesis.

10 Cells are plated and transfected as described for the MMP activity assay. Twenty hours post-transfection, cells are stimulated with recombinant human VEGF. Total RNA is harvested 52 hours post-transfection, and the amount of total RNA from each sample is determined using a Ribogreen Assay (Molecular Probes, Eugene, OR). Real-time PCR is performed on the total RNA using primer/probe sets for four Angiogenic Hallmark Genes: integrin beta 3, endoglin, Tumor endothelial marker 5 (TEM5) and Matrix Metalloproteinase 14 (MMP14/MT1-MMP). Expression levels for each gene are normalized to total RNA, and values are expressed relative to controls.

20 Cells treated with extracellular-signal-regulated kinase-6 inhibitors had integrin beta 3 mRNA reduced to 50% of the control.

25

What is claimed is:

1. A compound 8 to 80 nucleobases in length targeted to a nucleic acid molecule encoding extracellular-signal-regulated kinase-6, wherein said compound specifically hybridizes with said nucleic acid molecule encoding extracellular-signal-regulated kinase-6 and inhibits the expression of extracellular-signal-regulated kinase-6.
2. The compound of claim 1 which is an antisense oligonucleotide.
3. The compound of claim 2 wherein the antisense oligonucleotide comprises at least one modified internucleoside linkage.
4. The compound of claim 3 wherein the modified internucleoside linkage is a phosphorothioate linkage.
5. The compound of claim 2 wherein the antisense oligonucleotide comprises at least one modified sugar moiety.
6. The compound of claim 5 wherein the modified sugar moiety is a 2'-O-methoxyethyl sugar moiety.
7. The compound of claim 2 wherein the antisense oligonucleotide comprises at least one modified nucleobase.
8. The compound of claim 7 wherein the modified nucleobase is a 5-methylcytosine.
9. The compound of claim 2 wherein the antisense oligonucleotide is a chimeric oligonucleotide.
10. A compound 8 to 80 nucleobases in length which specifically hybridizes with at least an 8-nucleobase portion of a preferred target region on a nucleic acid molecule encoding extracellular-signal-regulated kinase-6.
11. A composition comprising the compound of claim 1 and a pharmaceutically acceptable carrier or diluent.
12. The composition of claim 11 further comprising a colloidal dispersion system.
13. The composition of claim 11 wherein the compound is an antisense oligonucleotide.
14. A method of inhibiting the expression of extracellular-signal-regulated kinase-6 in cells or tissues

ISPH-0728

-111-

PATENT

comprising contacting said cells or tissues with the compound of claim 1 so that expression of extracellular-signal-regulated kinase-6 is inhibited.

15. A method of treating an animal having a disease or condition associated with extracellular-signal-regulated kinase-6 comprising administering to said animal a therapeutically or prophylactically effective amount of the compound of claim 1 so that expression of extracellular-signal-regulated kinase-6 is inhibited.

16. The method of claim 15 wherein the disease or condition is a hyperproliferative disorder.

17. The method of claim 16 wherein the hyperproliferative disorder is cancer.

18. The method of claim 15 wherein the disease or condition is an inflammatory disorder.

19. The method of claim 15 wherein the disease or condition is a neurodegenerative disorder.

20. The method of claim 19 wherein the neurodegenerative disorder is Alzheimer's disease.

21. A method for inhibiting angiogenesis in a mammal, the method comprises administering to the mammal a therapeutically effective amount of the compound of claim 1, whereby angiogenesis is inhibited.

22. The method of claim 21 wherein the compound prevents degradation of extracellular matrix for new blood vessel formation.

23. The method of claim 21 wherein the compound prevents tubular formation of blood vessels.

24. A method for preventing degradation of an extracellular matrix comprising administering to cells or tissues the compound of claim 1.

25. A method for preventing tubular formation of blood vessels comprising administering to cells or tissues the compound of claim 1.

ISPH-0728

-112-

PATENT

26. A method for treating an angiogenic disease in a mammal comprising administering to said mammal the compound of claim 1.

ISPH-0728

-113-

PATENT

ABSTRACT

Compounds, compositions and methods are provided for modulating the expression of extracellular-signal-regulated
5 kinase-6. The compositions comprise oligonucleotides, targeted to nucleic acid encoding extracellular-signal-regulated kinase-6. Methods of using these compounds for modulation of extracellular-signal-regulated kinase-6
expression and for diagnosis and treatment of disease
10 associated with expression extracellular-signal-regulated kinase-6 are provided.

Docket No.
ISPH-0728

Declaration and Power of Attorney For Patent Application

English Language Declaration

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name,

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled

EXTRACELLULAR-SIGNAL-REGULATED KINASE-6 INHIBITORS FOR INHIBITING ANGIOGENESIS

the specification of which

(check one)

☒ is attached hereto.

☐ was filed on _____ as United States Application No. or PCT International Application Number _____ and was amended on _____

(if applicable)

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose to the United States Patent and Trademark Office all information known to me to be material to patentability as defined in Title 37, Code of Federal Regulations, Section 1.56.

I hereby claim foreign priority benefits under Title 35, United States Code, Section 119(a)-(d) or Section 365(b) of any foreign application(s) for patent or inventor's certificate, or Section 365(a) of any PCT International application which designated at least one country other than the United States, listed below and have also identified below, by checking the box, any foreign application for patent or inventor's certificate or PCT International application having a filing date before that of the application on which priority is claimed.

Prior Foreign Application(s)

Priority Not Claimed

_____ (Number)	_____ (Country)	_____ (Day/Month/Year Filed)	<input type="checkbox"/>
_____ (Number)	_____ (Country)	_____ (Day/Month/Year Filed)	<input type="checkbox"/>
_____ (Number)	_____ (Country)	_____ (Day/Month/Year Filed)	<input type="checkbox"/>

I hereby claim the benefit under 35 U.S.C. Section 119(e) of any United States provisional application(s) listed below:

_____	_____
(Application Serial No.)	(Filing Date)
_____	_____
(Application Serial No.)	(Filing Date)
_____	_____
(Application Serial No.)	(Filing Date)

I hereby claim the benefit under 35 U. S. C. Section 120 of any United States application(s), or Section 365(c) of any PCT International application designating the United States, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT International application in the manner provided by the first paragraph of 35 U.S.C. Section 112, I acknowledge the duty to disclose to the United States Patent and Trademark Office all information known to me to be material to patentability as defined in Title 37, C. F. R., Section 1.56 which became available between the filing date of the prior application and the national or PCT International filing date of this application:

10/174,465	June 17, 2002	Pending
_____	_____	_____
(Application Serial No.)	(Filing Date)	(Status)
		(patented, pending, abandoned)
_____	_____	_____
(Application Serial No.)	(Filing Date)	(Status)
		(patented, pending, abandoned)
_____	_____	_____
(Application Serial No.)	(Filing Date)	(Status)
		(patented, pending, abandoned)

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

POWER OF ATTORNEY: As a named inventor, I hereby appoint the following attorney(s) and/or agent(s) to prosecute this application and transact all business in the Patent and Trademark Office connected therewith. *(list name and registration number)*

PATENT TRADEMARK OFFICE



32862

Send Correspondence to: **Jane Massey Licata**
Licata & Tyrrell P.C.
66 E. Main Street
Marlton, NJ 08053

Direct Telephone Calls to: *(name and telephone number)*
Jane Massey Licata, Tel: 856-810-1515

Full name of sole or first inventor Eric G. Marcusson	
Sole or first inventor's signature	Date
Residence San Diego, CA	
Citizenship United States	
Post Office Address 6369 Caminito de Pastel	
San Diego, CA 92111	

Full name of second inventor, if any C. Frank Bennett	
Second inventor's signature	Date
Residence Carlsbad, CA	
Citizenship United States	
Post Office Address 1347 Cassins Street	
Carlsbad, CA 92009	

Full name of third inventor, if any Kenneth W. Dobie	
Third inventor's signature	Date
Residence Del Mar, CA	
Citizenship United Kingdom	
Post Office Address 703 Stratford Court, #4	
Del Mar, CA 92014	

Full name of fourth inventor, if any	
Fourth inventor's signature	Date
Residence	
Citizenship	
Post Office Address	

Full name of fifth inventor, if any	
Fifth inventor's signature	Date
Residence	
Citizenship	
Post Office Address	

Full name of sixth inventor, if any	
Sixth inventor's signature	Date
Residence	
Citizenship	
Post Office Address	

SEQUENCE LISTING

<110> Eric G. Marcusson
C. Frank Bennett
Kenneth W. Dobie

<120> EXTRACELLULAR-SIGNAL-REGULATED KINASE-6 INHIBITORS FOR INHIBITING
ANGIOGENESIS

<130> ISPH-0728

<140> 10/174,465

<141> 2002-06-17

<160> 71

<210> 1
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 1
tccgtcatcg.ctcctcaggg 20

<210> 2
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 2
gtgcgcgcga gcccgaaatc 20

<210> 3
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 3
atgcattctg cccccaagga 20

<210> 4
<211> 1670
<212> DNA
<213> H. sapiens

2

<220>

<221> CDS

<222> (34)...(1137)

<400> 4

```

ggctctgcgg ggtgggcagc tcccgggcct gcc atg agc tct ccg ccg ccc acc      54
                               Met Ser Ser Pro Pro Thr
                               1           5

cgc agt ggc ttt tac cgc cag gag gtg acc aag acg gcc tgg gag gtg      102
Arg Ser Gly Phe Tyr Arg Gln Glu Val Thr Lys Thr Ala Trp Glu Val
          10           15           20

cgc gcc gtg tac cgg gac ctg cag ccc gtg ggc tcg ggc gcc tac ggc      150
Arg Ala Val Tyr Arg Asp Leu Gln Pro Val Gly Ser Gly Ala Tyr Gly
          25           30           35

gcg gtg tgc tcg gcc gtg gac ggc cgc acc ggc gct aag gtt gcc atc      198
Ala Val Cys Ser Ala Val Asp Gly Arg Thr Gly Ala Lys Val Ala Ile
          40           45           50           55

aag aag ctg tat cgg ccc ttc cag tcc gag ctg ttc gcc aag ctc gcc      246
Lys Lys Leu Tyr Arg Pro Phe Gln Ser Glu Leu Phe Ala Lys Leu Ala
          60           65           70

tac cgc gag ctg cgc ctg ctc aag cac atg cgc cac gag aac gtg atc      294
Tyr Arg Glu Leu Arg Leu Leu Lys His Met Arg His Glu Asn Val Ile
          75           80           85

ggg ctg ctg gac gta ttc act cct gat gag acc ctg gat gac ttc acg      342
Gly Leu Leu Asp Val Phe Thr Pro Asp Glu Thr Leu Asp Phe Thr
          90           95           100

gac ttt tac ctg gtg atg ccg ttc atg ggc acc gac ctg ggc aag ctc      390
Asp Phe Tyr Leu Val Met Pro Phe Met Gly Thr Asp Leu Gly Lys Leu
          105           110           115

atg aaa cat gag aag cta ggc gag gac cgg atc cag ttc ctc gtg tac      438
Met Lys His Glu Lys Leu Gly Glu Asp Arg Ile Gln Phe Leu Val Tyr
          120           125           130           135

cag atg atg aag ggg ctg agg tat atc cac gct gcc ggc atc atc cac      486
Gln Met Met Lys Gly Leu Arg Tyr Ile His Ala Ala Gly Ile Ile His
          140           145           150

aga gac ctg aag ccc ggc aac ctg gct gtg aac gaa gac tgt gag ctg      534
Arg Asp Leu Lys Pro Gly Asn Leu Ala Val Asn Glu Asp Cys Glu Leu
          155           160           165

aag atc ctg gac ttc ggc ctg gcc agg cag gca gac agt gag atg act      582
Lys Ile Leu Asp Phe Gly Leu Ala Arg Gln Ala Asp Ser Glu Met Thr
          170           175           180

ggg tac gtg gtg acc cgg tgg tac cgg gct ccc gag gtc atc ttg aat      630
Gly Tyr Val Val Thr Arg Trp Tyr Arg Ala Pro Glu Val Ile Leu Asn
          185           190           195

tgg atc gcg tac acg cag acg gtg gac atc tgg tct gtg ggc tgc atc      678
Trp Ile Ala Tyr Thr Gln Thr Val Asp Ile Trp Ser Val Gly Cys Ile
          200           205           210           215

```

atg gcg gag atg atc aca ggc aag acg ctg ttc aag ggc agc gac cac	726
Met Ala Glu Met Ile Thr Gly Lys Thr Leu Phe Lys Gly Ser Asp His	
220 225 230	
ctg gac cag ctg aag gag atc atg aag gtg acg ggg acg cct ccg gct	774
Leu Asp Gln Leu Lys Glu Ile Met Lys Val Thr Gly Thr Pro Pro Ala	
235 240 245	
gag ttt gtg cag cgg ctg cag agc gat gag gcc aag aac tac atg aag	822
Glu Phe Val Gln Arg Leu Gln Ser Asp Glu Ala Lys Asn Tyr Met Lys	
250 255 260	
ggc ctc ccc gaa ttg gag aag aag gat ttt gcc tct atc ctg acc aat	870
Gly Leu Pro Glu Leu Glu Lys Lys Asp Phe Ala Ser Ile Leu Thr Asn	
265 270 275	
gca agc cct ctg gct gtg aac ctc ctg gag aag atg ctg gtg ctg gac	918
Ala Ser Pro Leu Ala Val Asn Leu Leu Glu Lys Met Leu Val Leu Asp	
280 285 290 295	
gcg gac atc agg ttg act gca ggc gag ttt ctt tcc cat ccc tac ttc	966
Ala Asp Ile Arg Leu Thr Ala Gly Glu Phe Leu Ser His Pro Tyr Phe	
300 305 310	
gag tcc ctg cac gac acg gaa gat gag ccc cag gtc cag aag tat gat	1014
Glu Ser Leu His Asp Thr Glu Asp Glu Pro Gln Val Gln Lys Tyr Asp	
315 320 325	
gac tcc ttt gac tac ttt gac cgc aca ctg gat gaa tgg aag cgt gtt	1062
Asp Ser Phe Asp Tyr Phe Asp Arg Thr Leu Asp Glu Trp Lys Arg Val	
330 335 340	
act tac aaa gag gtg ctc agc ttc aag cct ccc cgg cag ctg ggg gcc	1110
Thr Tyr Lys Glu Val Leu Ser Phe Lys Pro Pro Arg Gln Leu Gly Ala	
345 350 355	
agg gtc tcc aag gag acg cct ctg tga agatctctgg gctccggggg	1157
Arg Val Ser Lys Glu Thr Pro Leu	
360 365	
ggcagtgagg accaccttca ccttccacct gagaggggac tctcgttgcc accttgacct	1217
tggtctggggc ttgcatccca aggcattccat cagagcagac gcccggttc catggacct	1277
cctccccact gccatgcctc tgctcttttg cgcccatcat ggaggagcac ctgaactttc	1337
tggacaagac ctctggccga cctggggatg gcctctgac cctggagcag tggaaacacaa	1397
aaaaaatac tctcagaaac ctgagagctg gtggggctcc agatcagcct tggcctctga	1457
gccctgcctg ctctgggcca tgcagaggaa ggacagaggg tgggagcagg gcaccaactc	1517
agggacatcc cctctccttg gcgacgtcag tggaccttcc tgcaccccca gcctggaatg	1577
taaatcagct gtgtggtgcc cgcgtggctg gaaggaaata gacccttttg tagctccaaa	1637
aaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaa	1670

4

<210> 5
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> PCR Primer

<400> 5
ctcgttgcca ccttgacctt

20

<210> 6
<211> 16
<212> DNA
<213> Artificial Sequence

<220>
<223> PCR Primer

<400> 6
tggaaccg cggtct

16

<210> 7
<211> 24
<212> DNA
<213> Artificial Sequence

<220>
<223> PCR Probe

<400> 7
ttgcatccca aggcattcat caga

24

<210> 8
<211> 19
<212> DNA
<213> Artificial Sequence

<220>

<223> PCR Primer

<400> 8
gaaggtgaag gtcggagtc

19

<210> 9
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> PCR Primer

<400> 9
gaagatggtg atgggatttc

20

<210> 10
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> PCR Probe

<400> 10
caagcttccc gttctcagcc

20

<210> 11
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 11
ccttcacat ctggtacacg

20

<210> 12
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 12
tccttcagct ggtccaggtg

20

<210> 13
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 13
ccaccagctc tgaggtttct

20

<210> 14
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 14
ggagagctca tggcaggccc

20

<210> 15
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 15
gtggcgcatg tgcttgagca

20

<210> 16
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 16
cccttcatca tctggtacac

20

<210> 17
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 17
atccagggtc tcatcaggag

20

<210> 18
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 18
cccggagccc agagatcttc

20

<210> 19
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 19
ctgtccttcc tctgcatggc

20

<210> 20
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 20
gaactggatc cggtcctcgc

20

<210> 21
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 21
ggccgaagtc caggatcttc

20

<210> 22
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 22
tgagttgggtg ccctgctccc

20

<210> 23
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 23
tctgatggat gccttgggat

20

<210> 24
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 24
atcatctggt acacgaggaa

20

<210> 25
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 25
tcgcctagct tctcatgttt 20

<210> 26
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 26
aggcaaaatc cttcttctcc 20

<210> 27
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 27
tgctctgatg gatgccttgg 20

<210> 28
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 28
gctacaaaag ggtctatttc 20

<210> 29
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 29
ctgcctggcc aggccgaagt 20

<210> 30
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 30
aaagaaactc gcctgcagtc

20

<210> 31
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 31
gaggccaagg ctgatctgga

20

<210> 32
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 32
gtacacgagg aactggatcc

20

<210> 33
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 33
caccaggtaa aagtccgtga

20

<210> 34
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 34
tcaaagtagt caaaggagtc

20

10

<210> 35
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 35
gggccgatac agcttcttga 20

<210> 36
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 36
ctggagcccc accagctctg 20

<210> 37
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 37
cgctgcacaa actcagccgg 20

<210> 38
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 38
ggcccttcac gtagttcttg 20

<210> 39
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 39
aggagtcac atacttctgg 20

11

<210> 40
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 40
tctggagccc caccagctct 20

<210> 41
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 41
gggatgtccc tgagttggtg 20

<210> 42
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 42
ggtgcaggaa ggtccactga 20

<210> 43
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 43
atgtttcatg agcttgccca 20

<210> 44
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 44
atacctcagc cccttcatca 20

12

<210> 45
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 45
gcttgcccag gtcggtgccc 20

<210> 46
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 46
aggtcaaggt ggcaacgaga 20

<210> 47
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 47
tgtagttctt ggcctcatcg 20

<210> 48
<211> 20
<212> DNA
<213> H. sapiens

<400> 48
cacctggacc agctgaagga 20

<210> 49
<211> 20
<212> DNA
<213> H. sapiens

<400> 49
agaaacctca gagctggtgg 20

<210> 50
<211> 20
<212> DNA
<213> H. sapiens

13

<400> 50
tgctcaagca catgcgccac 20

<210> 51
<211> 20
<212> DNA
<213> H. sapiens

<400> 51
ctcctgatga gaccctggat 20

<210> 52
<211> 20
<212> DNA
<213> H. sapiens

<400> 52
gaagatctct gggctccggg 20

<210> 53
<211> 20
<212> DNA
<213> H. sapiens

<400> 53
gcgaggaccg gatccagttc 20

<210> 54
<211> 20
<212> DNA
<213> H. sapiens

<400> 54
gaagatcctg gacttcggcc 20

<210> 55
<211> 20
<212> DNA
<213> H. sapiens

<400> 55
gggagcaggg caccaactca 20

<210> 56
<211> 20
<212> DNA
<213> H. sapiens

<400> 56
atcccaaggc atccatcaga 20

<210> 57
<211> 20

14

<212> DNA
<213> H. sapiens

<400> 57
ttcctcgtgt accagatgat 20

<210> 58
<211> 20
<212> DNA
<213> H. sapiens

<400> 58
aaacatgaga agctaggcga 20

<210> 59
<211> 20
<212> DNA
<213> H. sapiens

<400> 59
gaaatagacc cttttgtagc 20

<210> 60
<211> 20
<212> DNA
<213> H. sapiens

<400> 60
ggatccagtt cctcgtgtac 20

<210> 61
<211> 20
<212> DNA
<213> H. sapiens

<400> 61
tcaagaagct gtatcgccc 20

<210> 62
<211> 20
<212> DNA
<213> H. sapiens

<400> 62
cagagctggt ggggctccag 20

<210> 63
<211> 20
<212> DNA
<213> H. sapiens

<400> 63
ccggctgagt ttgtgcagcg 20

15

<210> 64
<211> 20
<212> DNA
<213> H. sapiens

<400> 64
ccagaagtat gatgactcct

20

<210> 65
<211> 20
<212> DNA
<213> H. sapiens

<400> 65
caccaactca gggacatccc

20

<210> 66
<211> 20
<212> DNA
<213> H. sapiens

<400> 66
tcagtggacc ttcctgcacc

20

<210> 67
<211> 20
<212> DNA
<213> H. sapiens

<400> 67
tgggcaagct catgaaacat

20

<210> 68
<211> 20
<212> DNA
<213> H. sapiens

<400> 68
gggcaccgac ctgggcaagc

20

<210> 69
<211> 20
<212> DNA
<213> H. sapiens

<400> 69
tctcgttgcc accttgacct

20

<210> 70
<211> 20
<212> DNA
<213> H. sapiens

16

<400> 70
cgatgaggcc aagaactaca

20

<210> 71
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<221> misc_feature
<222> 1-20
<223> n = A,T,C or G

<400> 71
nnnnnnnnnn nnnnnnnnnn

20

17

PATENT COOPERATION TREATY

PCT

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

(PCT Article 36 and Rule 70)

REC'D 10 FEB 2005

WIPO

PCT

Applicant's or agent's file reference PST-0055WO	FOR FURTHER ACTION See Notification of Transmittal of International Preliminary Examination Report (Form PCT/IPEA/416)	
International application No. PCT/US03/16214	International filing date (day/month/year) 16 June 2003 (16.06.2003)	Priority date (day/month/year) 17 June 2002 (17.06.2002)
International Patent Classification (IPC) or national classification and IPC IPC(7): C12Q 1/68; A01N 43/04; C07H 21/04; A61K 31/07 and US Cl.: 435/6, 91.1, 325, 375; 514/44; 536/24.5, 23.1, 24.3, 24.33		
Applicant ISIS PHARMACEUTICALS INC.		
<p>1. This international preliminary examination report has been prepared by this International Preliminary Examining Authority and is transmitted to the applicant according to Article 36.</p> <p>2. This REPORT consists of a total of <u>6</u> sheets, including this cover sheet.</p> <p><input type="checkbox"/> This report is also accompanied by ANNEXES, i.e., sheets of the description, claims and/or drawings which have been amended and are the basis for this report and/or sheets containing rectifications made before this Authority (see Rule 70.16 and Section 607 of the Administrative Instructions under the PCT).</p> <p>These annexes consist of a total of ___ sheets.</p> <p>3. This report contains indications relating to the following items:</p> <p>I <input checked="" type="checkbox"/> Basis of the report</p> <p>II <input type="checkbox"/> Priority</p> <p>III <input type="checkbox"/> Non-establishment of report with regard to novelty, inventive step and industrial applicability</p> <p>IV <input type="checkbox"/> Lack of unity of invention</p> <p>V <input checked="" type="checkbox"/> Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement</p> <p>VI <input type="checkbox"/> Certain documents cited</p> <p>VII <input type="checkbox"/> Certain defects in the international application</p> <p>VIII <input type="checkbox"/> Certain observations on the international application</p>		
Date of submission of the demand 30 December 2003 (30.12.2003)	Date of completion of this report 14 January 2005 (14.01.2005)	
Name and mailing address of the IPEA/US Mail Stop PCT, Attn: IPEA/US Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450 Facsimile No. (703) 305-3230	Authorized officer Terra C. Gibbs <i>T. Roberts for</i> Telephone No. (571) 272-1600	

Form PCT/IPEA/409 (cover sheet)(July 1998)

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

International application No.

PCT/US03/16214

I. Basis of the report

1. With regard to the elements of the international application:*

- ☒ the international application as originally filed.
- ☒ the description:
pages 1-127 as originally filed
pages NONE, filed with the demand
pages NONE, filed with the letter of _____.
- ☒ the claims:
pages 128-136, as originally filed
pages NONE, as amended (together with any statement) under Article 19
pages NONE, filed with the demand
pages NONE, filed with the letter of _____.
- ☐ the drawings:
pages NONE, as originally filed
pages NONE, filed with the demand
pages NONE, filed with the letter of _____.
- ☒ the sequence listing part of the description:
pages 1-88, as originally filed
pages NONE, filed with the demand
pages NONE, filed with the letter of _____.

2. With regard to the language, all the elements marked above were available or furnished to this Authority in the language in which the international application was filed, unless otherwise indicated under this item.

These elements were available or furnished to this Authority in the following language _____ which is:

- ☐ the language of a translation furnished for the purposes of international search (under Rule 23.1(b)).
- ☐ the language of publication of the international application (under Rule 48.3(b)).
- ☐ the language of the translation furnished for the purposes of international preliminary examination (under Rules 55.2 and/or 55.3).

3. With regard to any nucleotide and/or amino acid sequence disclosed in the international application, the international preliminary examination was carried out on the basis of the sequence listing:

- ☒ contained in the international application in printed form.
- ☒ filed together with the international application in computer readable form.
- ☐ furnished subsequently to this Authority in written form.
- ☐ furnished subsequently to this Authority in computer readable form.
- ☐ The statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the international application as filed has been furnished.
- ☐ The statement that the information recorded in computer readable form is identical to the written sequence listing has been furnished.

4. ☐ The amendments have resulted in the cancellation of:

- ☐ the description, pages NONE
- ☐ the claims, Nos. NONE
- ☐ the drawings, sheets/fig NONE

5. ☐ This report has been established as if (some of) the amendments had not been made, since they have been considered to go beyond the disclosure as filed, as indicated in the Supplemental Box (Rule 70.2(c)).**

* Replacement sheets which have been furnished to the receiving Office in response to an invitation under Article 14 are referred to in this report as "originally filed" and are not annexed to this report since they do not contain amendments (Rules 70.16 and 70.17).

** Any replacement sheet containing such amendments must be referred to under item 1 and annexed to this report.

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

International application No.
PCT/US03/16214**V. Reasoned statement under Rule 66.2(a)(ii) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement****1. STATEMENT**

Novelty (N)	Claims <u>28-48, and 50-65</u>	YES
	Claims <u>1-27 and 49</u>	NO
Inventive Step (IS)	Claims <u>28-48, and 50-65</u>	YES
	Claims <u>1-27 and 49</u>	NO
Industrial Applicability (IA)	Claims <u>1-65</u>	YES
	Claims <u>NONE</u>	NO

2. CITATIONS AND EXPLANATIONS

Please See Continuation Sheet

Supplemental Box

(To be used when the space in any of the preceding boxes is not sufficient)

V. 2. Citations and Explanations:

Claims 1-65 meet industrial applicability as defined by PCT Article 33(4), and thus have industrial applicability because the subject matter claimed can be made or used in industry.

Claims 28-48 and 50-65 meets the criteria set out in PCT Article 33(2)-(3), because the prior art does not teach or fairly suggest a method of treating a human having a disease or condition associated with Extracellular-signal-regulated kinase-6 using antisense compounds encoding Extracellular-signal-regulated kinase-6.

Claims 1-27 and 49 lack novelty under PCT Article 33(2) as being anticipated by Mercola, D. [U.S. 2002/0107218 A1].

Mercola, D. discloses compositions containing an antisense SAPK3 (also known as extracellular-signal-regulated kinase-6) nucleic acid molecule and a carrier that is acceptable for administration. Mercola, D. further disclose and claim an antisense nucleic molecule is a polymer of above twelve to fifty nucleotides, generally about fifteen to thirty-five nucleotides and usually about twenty to twenty-five nucleotides (see page 4 [0031], claims 1-4 and 11-14). Mercola, D. further discloses antisense molecules containing internucleoside linkages, phosphorothioate bonds and chimeric backbones are useful in the invention (see page 5 [0037] [0039] and [0040]). Mercola, D. further discloses a chemically synthesized antisense nucleic acid molecule can be introduced into a cell (see page 5 [0041]). Mercola, D. further disclose and claim a "SAPK inhibitory agent" can be an antisense SAPK... a SAPK inhibitory agent can be formulated as a pharmaceutical composition, which contains the agent and a pharmaceutically acceptable carrier (see page 7 [0054] and claims 21-24).

Claims 1-27 and 49 lack an inventive step under PCT Article 33(3) as being obvious Mercola, D. [U.S. 2002/0107218 A1], Dinev et al. (EMBO Reports, 2001 Vol. 2:829-834) and Lechner et al. [U.S. Patent No. 6,030,822] in further view of Baracchini et al. [U.S. Patent No. 5,801,154] and Fritz et al. (Journal of Colloid and Interface Science, 1997 Vol. 195:272-288).

Mercola, D. discloses compositions containing an antisense SAPK3 (also known as extracellular-signal-regulated kinase-6) nucleic acid molecule and a carrier that is acceptable for administration. Mercola, D. further disclose and claim an antisense nucleic molecule is a polymer of above twelve to fifty nucleotides, generally about fifteen to thirty-five nucleotides and usually about twenty to twenty-five nucleotides (see page 4 [0031], claims 1-4 and 11-14). Mercola, D. further discloses antisense molecules containing internucleoside linkages, phosphorothioate bonds and chimeric backbones are useful in the invention (see page 5 [0037] [0039] and [0040]). Mercola, D. further discloses a chemically synthesized antisense nucleic acid molecule can be introduced into a cell (see page 5 [0041]). Mercola, D. further disclose and claim a "SAPK inhibitory agent" can be an antisense SAPK... a SAPK inhibitory agent can be formulated as a pharmaceutical composition, which contains the agent and a pharmaceutically acceptable carrier (see

Supplemental Box

(To be used when the space in any of the preceding boxes is not sufficient)

page 7 [0054] and claims 21-24).

Dinev et al. teach ERK5 (also known as extracellular-signal-regulated kinase-6) is required for differentiation of muscle cells (see Abstract). Dinev et al. further teach ERK5 endogenous protein is inhibited and myogenic differentiation is blocked when ERK5 expression is inhibited by an undisclosed ERK5 antisense nucleic acid (see Figures 4A and 4B, respectively).

Lechner et al. disclose oligoribonucleotides, including antisense RNA and DNA molecules and ribozymes that function to inhibit translation of one or more components of ERK5 (see column 23, lines 19-66). Lechner et al. generally disclose antisense ERK5 nucleic acid constructs. The ERK5 nucleic acid disclosure of Lechner et al. is almost 100% homologous to SEQ ID NO: 4 of the instant invention (see Lechner et al. SEQ ID NO:2). Lechner et al. further disclose various modifications to the DNA molecule may be introduced as a means of increasing intracellular stability and half-life... possible modifications include the use of phosphorothioate or 2'-O-methyl linkages (see column 24, lines 1-9). Lechner et al. further disclose the use of pharmaceutically acceptable carriers to formulate the compounds disclosed for the practice of dosages suitable for systemic administration (see column 27, lines 11-24).

Mercola, D., Dinev et al. and Lechner et al. do not teach wherein the sugar moiety is a 2'-O-methoxyethyl sugar moiety; wherein the modified nucleobase is a 5-methylcytosine; and a pharmaceutically acceptable carrier or diluent, further comprising a colloidal dispersion system.

Baracchini et al. teach modified or substituted oligonucleotides are often preferred over native forms because of desirable properties such as enhanced cellular uptake, enhanced affinity for nucleic acid target and increased stability in the presence of nucleases. Baracchini et al. further teach antisense oligonucleotides with at least one modified sugar moiety and a modified 2'-O-methoxyethyl sugar moieties (see Table I)... with modified nucleobases, such as 5-methylcytosine (see column 7, lines 15-25).

Fritz et al. teach a composition comprising an antisense oligonucleotide and a pharmaceutically acceptable carrier or diluent comprising a colloidal dispersion system. Fritz et al. further teach that oligonucleotides, in combination with steric stabilizers, exhibit high colloidal stability with low toxic side effects as required for biological experiments in cell culture and *in vivo* (see page 287, last paragraph).

It would have been *prima facie* obvious to one of ordinary skill in the art to target and inhibit the expression of extracellular-signal-regulated kinase-6 because the prior art has taught antisense oligonucleotides targeting extracellular-signal-regulated kinase-6 mRNA can inhibit extracellular-signal-regulated kinase-6 expression (see Dinev et al. and Mercola, D.). One of ordinary skill in the art would have been motivated to inhibit the expression of extracellular-signal-regulated kinase-6 since the prior art has taught that extracellular-signal-regulated kinase-6 is critical for myogenic differentiation (Dinev et al.) and inhibiting extracellular-signal-regulated kinase-6 can inhibit a stress activated protein pathway (Mercola, D.). One of ordinary skill in the art would have expected success in making a compound 8 to 80 nucleobases in length targeted to a nucleic acid molecule encoding extracellular-signal-regulated kinase-6 since the prior art has taught extracellular-signal-regulated kinase-6 nucleic acids (Lechner et al.) and the prior art has taught antisense nucleic acids targeting extracellular-signal-regulated kinase-6 (see Mercola, D. and Dinev et al.). One of ordinary skill in the art would have been motivated to modify antisense oligonucleotides targeting extracellular-signal-regulated kinase-6 because the prior art has taught the desirability of such oligonucleotides are often preferred over native forms because of enhanced cellular uptake, enhanced affinity for nucleic acid target, increased stability in the presence of nucleases and the exhibition of high colloidal stability with low toxic side effects as required for biological experiments (Baracchini et al. and Fritz et al.).

Therefore, the invention as a whole would have been *prima facie* obvious to one of ordinary skill in the art at the time the invention was made.

Claims 1-27 and 49 lack novelty under PCT Article 33(2) as being anticipated by Monia et al. [U.S. Patent No. 6,140,124]. Monia et al. ('124) disclose a modified antisense oligonucleotide targeted to p38 mitogen activated protein kinase with the following sequence: 5'-caggccacag accagatgtc-3' (see SEQ ID NO:75). This antisense oligonucleotide is reverse complementary to bases 655-674 of SEQ ID NO:4 of the instant invention. It is noted that the reverse complementarity between the antisense oligonucleotide targeted to p38 mitogen activated protein kinase disclosed by Monia et al. and nucleobases 655-674 of SEQ ID NO:4 is not contiguous. However, the antisense oligonucleotide targeted to p38 mitogen activated protein kinase disclosed by Monia et al. exhibits 95% local similarity to nucleobases 655-674 of SEQ ID NO:4 of the instant invention, as it contains only one mismatch. Given this high degree of similarity, the antisense oligonucleotide targeted to p38 mitogen activated protein kinase disclosed by Monia et al. meets the structural limitations of the claimed invention and would be expected to "specifically hybridize" to a nucleic acid encoding extracellular-signal-regulated kinase-6 since the instant specification at page 13, lines 16-19 teaches, "it is understood in the art that the sequence of an antisense compound need not be 100% complementary to that of its target nucleic acid to be specifically hybridizable." Accordingly, the antisense oligonucleotide disclosed by Monia et al. would specifically hybridize to bases 655-674 of extracellular-signal-regulated kinase-6 (SEQ ID NO:4) as claimed.

Claims 1-27 and 49 lack novelty under PCT Article 33(2) as being anticipated by Bennett et al. [U.S. Patent No. 6,656,732]. Bennett et al. ('732) disclose a modified antisense oligonucleotide targeted to src-c with the following sequence: 5'-ggccaaccca aagtcggcca-3' (see SEQ ID NO:163). This antisense oligonucleotide is reverse complementary to bases 1351-1370 of the 3' untranslated region of SEQ ID NO:4 of the instant invention. It is noted that the reverse complementarity between the antisense oligonucleotide targeted to src-c disclosed by Bennett et al. and nucleobases 1351-1370 of the 3' untranslated region of SEQ ID NO:4 is not contiguous. However, the antisense oligonucleotide targeted to src-c disclosed by Bennett et al. exhibits 85% local similarity to

INTERNATIONAL PRELIMINARY EXAMINATION REPORTInternational application No.
PCT/US03/16214**Supplemental Box**

(To be used when the space in any of the preceding boxes is not sufficient)

nucleobases 1351-1370 of SEQ ID NO:4 of the instant invention, as it contains only three mismatches (see attached sequence alignment). Given this high degree of similarity, the antisense oligonucleotide targeted to src-c disclosed by Bennett et al. meets the structural limitations of the claimed invention and would be expected to "specifically hybridize" to 20 consecutive nucleobases within the 3' untranslated region of a nucleic acid encoding extracellular-signal-regulated kinase-6 since the instant specification at page 13, lines 16-19 teaches, "it is understood in the art that the sequence of an antisense compound need not be 100% complementary to that of its target nucleic acid to be specifically hybridizable." Accordingly, the antisense oligonucleotide disclosed by Bennett et al. would specifically hybridize with 20 consecutive nucleobases within nucleobases 1351-1370 of the 3' untranslated region of extracellular-signal-regulated kinase-6 (SEQ ID NO:4) as claimed.

----- NEW CITATIONS -----

US 6,140,124 A (MONIA et al.) 31 October 2000 (31.10.2000), see SEQ ID NOs: 75 and 85.
US 6,656,732 B1 (BENNETT et al.) 02 December 2003 (02.12.2003), see SEQ ID NO. 163.